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ABSTRACT 
Industrial, agricultural, and pharmaceutical requirements drive the development of a 
plethora of new chemical entities each year, many of which -for example drugs, 
pesticides, and food additives- have to be assessed for potential human health hazard. 
The current benchmark for risk assessement is the lifetime rodent bioassay which is 
expensive, time-consuming, laborious, requires the sacrifice of numerous animals, and 
is often irrelevant to humans. Hence alternative strategies to the rodent lifetime 
bioassay for prediction of chemical carcinogens are being pursued, especially for the 
liver which is an organ frequently affected by exogenous chemicals due to its 
detoxifying and metabolic roles. Numerous studies in recent years support the 
important role of microRNAs in cancer development, including hepatocellular 
carcinoma. The principal hypothesis of this project was that hepatic microRNA 
signatures can contribute to the earlier prediction of chemical hepatocarcinogens. 
Examination of livers from male Fischer rats treated with six chemical 
hepatocarcinogens, with diverse mode of actions for 90 days revealed that all the 
tested hepatocarcinogens affected the liver miRNAome from that early stage. 
Interestingly, a small set of microRNAs were identified whose expression was 
frequently deregulated by the hepatocarcinogens. Bioinformatic analysis indicates that 
these microRNAs can regulate pathways which are important in hepatocellular 
carcinoma. A more detailed investigation of one of those hepatocarcinogens, 
phenobarbital, showed that its effects on liver microRNAs were both dose and time 
dependent, with a progressive induction of specific microRNA clusters.Thus this 
study was the first to investigate in depth the effects of chemical hepatocarcinogens 
on the liver miRNAome and supports the potential usefulness of hepatic microRNA 
signatures in risk assessment. 
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1.1 Mechanisms of carcinogenesis 
1.1.1 Carcinogenesis is a multi-step, progressive process 
The term cancer describes more than 100 types of the disease with distinct cellular 
origins, symptoms, prognosis, and treatments. Nevertheless, all cancer cells are 
fundamentally different in their cellular physiology from normal cells.  Hanahan and 
Weinberg initially identified six key hallmarks which are common to cancer cells 
(Hanahan & Weinberg, 2000, Hanahan & Weinberg, 2011): 
 
 (1) Self-sufficiency in growth signals.  All normal cells require stimulation by extra-
cellular growth factors to initiate cell division. A necessary step for carcinogenesis is 
the acquired ability of pre-malignant and malignant cells to undergo abnormal, 
excessive proliferation in the absence of the appropriate mitogenic signals.  
 
(2) Insensitivity to anti-growth signals. Tissues abound with anti-proliferative 
signals which maintain tissue homeostasis by suppressing proliferation. Incipient 
cancer cells acquire the ability to proliferate even in the presence of such growth-
suppressive signals. 
 
(3) Evasion of apoptosis.  Apoptosis is the instigation of a program of cell death in a 
cell, when given the appropriate internal or external stimuli. Cancer cells are 
characterized by a resistance to the external and internal stimuli which normally 
stimulate apoptosis. 
 
(4) Limitless replicative potential. Normal cells can only replicate a limited number 
of times before reaching the Hayflick limit and entering a state of senescence. The 
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appearance of tumours requires the acquisition by cancer cells of the ability for 
unlimited replication.   
 
(5) Sustained angiogenesis. As tumours grow in size existing capillaries are not 
sufficient to supply the oxygen and nutrients needed by the growing tumour. In 
response to this problem cells within lesions of abnormal growth acquire the ability to 
trigger angiogenesis, thus increasing the supply of required substances.  
 
(6) Tissue invasion and metastasis. Aberrantly proliferating cells may not be 
harmful so long as they are contained. These are benign tumours. Eventually a 
fraction of the benign tumours will progress to become invasive (malignant) cancers 
which possess the ability to invade adjacent tissues. Invasive cancer cells can 
eventually become metastatic and invade other organs through the lymphatic system. 
 
Besides these six essential hallmarks, two other acquired biological capabilities of 
cancer cells that may be essential for the development of tumours are the abilities to 
evade the immune system and to limit their metabolism to glycolysis (Hanahan & 
Weinberg, 2011). 
 
Given the detrimental effects of cancers, long-lived animals such as mammals possess 
multiple safeguards to prevent their occurrence. Therefore no single factor can cause 
cancer. Rather, the development of all cancers requires multiple independent events 
(Hanahan & Weinberg, 2001, Vogelstein & Kinzler, 2004). Simultaneous occurrence 
of these multiple changes needed for the transformation of a specific cell from a 
normal to a transformed state is too improbable to occur. Instead cancers probably 
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originate in a process comparable to Darwinian evolution, whereby cancer cells 
gradually develop from a single original cell in a series of distinct steps (Figure 1.1).  
 
Figure 1.1 Clonal evolution of cancer cells 
Cancer initiation
Clonal expansion
Normal cells
Cancer progression
Benign cancer
Invasive (malignant) cancer
Months-years
in rodents
Decades in 
humans
Cancer progression
 
Fig. 1.1 Cancer is initiated after acquisition by a cell (usually an epithelial type) of a selective 
advantage (Cancer initiation). This pre-cancerous cell then undergoes clonal expansion. 
During cancer progression the initiated cell is transformed to a benign and then a malignant 
cancer cell through repeated acquisition of new traits followed by clonal expansion. The 
tumour is heterogeneous made up from subclones originating from the parental cancer cell. 
The process can take years in rodents and decades in humans.  
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Initiation of cancer occurs with the acquisition by a replication-competent cell of a 
selective advantage compared to normal cells e.g. an increased rate of cell division. 
Consequently clones of this altered cell will outcompete normal cells and become 
more abundant in their resident tissue. Progression of the initiated cell to more 
cancerous states occurs through repetitive rounds of this evolutionary process: 
acquisition by descendants of the original cell of new selective advantages followed 
by clonal expansion. Eventually this iterative process results in the generation of full-
blown malignant cancer (Nowell, 1976).  Multiple facts support this multi-step model 
of carcinogenesis. First, within tissues lesions represent intermediate steps from 
normal to pre-malignant to invasive cancers. Second, mathematical models of cancer 
incidence throughout a human lifetime suggest that at least 4-7 events are required for 
cancer development. Third, transformation of cells in vitro to a cancer state requires 
altered activity of multiple genes. Fourth, germline mutations cause a predisposition 
to cancer, not definite cancer appearance. Fifth, transgenic mouse models also support 
the requirement for multiple steps before the appearance of tumours (Hanahan & 
Weinberg, 2000).  
Cancer initiation and progression is driven by deregulation of cancer genes. Most 
mammalian genes are irrelevant for cancer. Cancer genes are the small subset of 
animal genes which drive tumour formation and growth. So far about 400 cancer 
genes have been identified (Stratton et al., 2009, Futreal et al., 2004). In normal cells 
most of these cancer genes are part of the normal cellular regulatory networks 
controlling cell division, apoptosis, and homeostasis(Hanahan & Weinberg, 2000). 
Cancer genes are classified into two categories based on the functional effects of their 
deregulation: oncogenes and tumour-suppressor genes. Oncogenes are inappropriately 
activated in cancers in order to facilitate tumour growth. Usually inappropriate 
Chapter 1 
 - 28 - 
 
activation of a single allele of an oncogene is sufficient to confer a selective 
advantage to a cell. For example activated Ras may stimulate cell proliferation while 
activated MDM2 inhibits cell death of tumour cells (Croce, 2008). Conversely for 
tumour-suppressors genes it is the loss of their activity which contributes to the 
progression of the disease. For tumour-suppressor genes it is normally required that 
both alleles are inactivated in a cancer cell for the effect to be observable. Two 
tumour suppressor genes that are frequently inactivated in tumours are p53 and 
retinoblastoma (Rb). Loss of P53 makes cancer cells more resistant to apoptosis while 
loss of Rb allows cells to be more resistant to anti-growth signals (Sherr, 2004).  
Ultimately cancer genes contribute to tumour development via the cellular pathways, 
which they control. Inappropriate activation of oncogenes and/or loss of tumour-
suppressor genes results in deregulation of key pathways and acquisition of the 
cellular traits essential to cancer development. Several such pathways have been 
demonstrated to be implicated with cancer, including the Rb, P53, PI3K, APC, HIF1, 
Gli, and Smad pathways (Vogelstein & Kinzler, 2004). Since cellular pathways 
consist of many genes, they can be disrupted by the deregulation of any one of several 
cancer genes. For example the Rb pathway can be blocked either by inactivation of 
Rb and p16
INK4
 or activation of CDK4 and Cyclin D1. Indeed deregulation of all these 
four genes has been found in multiple cancers and appears to follow an “exclusivity 
principle” (Vogelstein & Kinzler, 2004).  
 “Gatekeeper” pathways are those that when disrupted within the appropriate cell 
initiate tumourigenesis. The gatekeeper pathways are different between tissues e.g. the 
Rb1 is a gatekeeper for retinoblastoma, but in colon cancer that role is performed by 
the APC pathway. For many tissues the gatekeeper pathway is not known. It is still 
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not clear whether some tissues may have multiple gatekeeper pathways or just 
one(Vogelstein & Kinzler, 2004). 
 
Besides the different gatekeeper pathways, the process of carcinogenesis is variable 
between different cell types in other ways as well. For example, it has been found that 
mutations of the same cancer genes can occur at different stages of cancer 
development in different tissues. Consequently the timing of carcinogenic traits 
associated with those cancer genes also differs between cancers e.g. one tumour type 
may acquire resistance to apoptosis at a much earlier stage than other tumour types. 
Furthermore, cancer genes can have distinct effects in different cellular contexts. 
Activation of KRAS2 initiates the neoplastic process in pancreatic duct, but not in 
other tissues. Hence, a given cancer gene may be implicated in some tumour types, 
but not others (Hanahan & Weinberg, 2000, Vogelstein & Kinzler, 2004).  
The molecular processes underlying carcinogenesis also seem to be partially different 
between liquid tumours (e.g. leukaemia) and solid tumours (e.g. liver cancer). Solid 
tumours appear to require several mutations in order to develop malignant tumours, 
while liquid tumours perhaps only need one or two. Moreover, for liquid tumours 
chromosomal translocations that activate oncogenes are much more common than for 
solid tumours. It is probable then that the genesis of liquid tumours may follow quite 
different pathways from that of solid tumours(Vogelstein & Kinzler, 2004).  
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1.1.2 Genetic and epigenetic mechanisms of gene disruption in cancer 
All normal somatic cells of an individual contain copies of the same genome. By 
some manner the functioning of cancer genes and of the pathways which they control 
must be disrupted in cancer cells for tumours to form. Two fundamentally different 
mechanisms exist by which this can occur: genetic mutations and epigenetic defects. 
Genetic mutations permanently modify genes by altering their DNA sequence. In 
cancer genetic mutations activate oncogenes and deactivate tumour suppressor genes. 
Occasionally mutated cancer genes are germ-cell transmitted and underlie the 
predisposition of related individuals to familiar cancers (e.g. BRCA1 to breast cancer 
and Rb1 to retinoblastomas) (Vogelstein & Kinzler, 2004). In most cases though, 
cancer genes are disrupted within the somatic cells of individuals. The recent 
deployment of the powerful DNA sequencing technologies to the sequencing of 
tumour genomes has confirmed the wide-spread occurrence of somatic mutations in 
cancer genes. One study sequenced a malignant melanoma cell and a lymphoblastoid 
cell line (representing germline DNA) originating form the same individual 
(Pleasance et al., 2010a). They identified more than 30000 somatic base substitutions 
in the melanoma, affecting 292 coding genes and 319 non-coding genes. A second 
study used the same approach for a small-cell lung carcinoma cell line and a 
lymphoblastoid cell line derived from a different patient (Pleasance et al., 2010b). 
They identified more than 22000 somatic mutations including 134 in coding genes 
and 182 in non-coding genes. It is expected that the mutated genes in these cancers 
represent both “passengers” as well as “drivers” i.e. mutations that are by-products of 
carcinogenesis, as well as those which were crucial to the formation of the tumour.  
Gene mutations can be subtle or prominent. Subtle mutations include changes of a 
single nucleotide base (point mutations) or small insertions and deletions within a 
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gene. Missense mutations (change in a single nucleotide resulting in amino acid 
substitution) can affect normal functioning of a protein. One of the most commonly 
mutated genes in several cancer types is BRAF, resulting in stimulation of aberrant 
tumour growth. Oncogenic mutations for BRAF are missense mutations within its 
kinase domain that disrupt its molecular structure rendering it constitutively active 
(Wan et al., 2004).  Nonsense mutations (change in a nucleotide causing a premature 
end in protein chain) and frameshift mutations (changes in reading frame) alter large 
parts of proteins. For example APC is a tumour suppressor gene that is often 
inactivated in cancers by nonsense and frameshift mutations (Samowitz et al., 2007). 
Alternatively, mutations in cancer can be much more prominent such as deletions of 
large chromosomal regions, translocations of genes to new locations, and copy 
number amplification. MDM2 is an oncogene that acts to repress apoptosis by tagging 
P53 for degradation and blocking its activation. In several cancers the gene for MDM2 
is amplified so that several functional copies are present that can target P53(Oliner et 
al., 1992).  Moreover, gross chromosomal abnormalities are found in all solid 
tumours. This results in loss of heterozygocity, with a large fraction of alleles being 
lost in cancer cells (Duesberg, 2003). 
One interesting hypothesis is that acquisition by cancer cells of genetic instability -
and hence increased mutation rate- is required to allow the acquisition of sufficient 
number of mutations for cancer appearance within a lifetime (Loeb, 1991). In favour 
of this “mutator phenotype” idea some hereditary cancer genes are involved in genetic 
instability, e.g. ATM and BRCA1 (Vogelstein & Kinzler, 2004). Many cancers also 
possess somatic mutations of genes that are involved in sensing DNA damage and in 
coordinating proper chromosomal segregation (Lengauer et al., 1997). The matter of 
whether genetic instability is a side-effect, a contributing factor, or absolutely 
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essential to the process of cancer formation is still being debated. Either way, whether 
sufficient mutations to cause cancer arise in a cancer cell as a result of the natural 
mutation rate or require the prior acquisition of a mutator phenotype, genetic 
mutations have an essential role in cancer. 
Unlike genetic mutations, epigenetic mechanisms regulate the expression of genes in 
a mitotically heritable manner without affecting their DNA sequence. Epigenetic 
regulation of genes is fundamental for cell development, differentiation, and 
maintenance. For example hepatocytes and nerve cells express different genes even 
though their genomes are identical, due to differential epigenetic regulation. The basic 
units of chromosomes are nucleosomes, DNA wrapped around an octomer core of 
histone proteins. Gene expression is epigenetically regulated through alterations of 
this basic unit by methylation of DNA, covalent modification of histone, and non-
covalent nucleosome repositioning and utilisation of histone variants (Berger, 2007). 
DNA methylation is the addition of methyl groups on cytosine residues found in CpG 
nucleotide duplets. In mammals CpG sites are disproportionally concentrated in the 
genome in regions called CpG islands, usually found close to the 5’ end of genes.  A 
large fraction of human promoters contain CpG islands which can permanently 
silence gene transcription when methylated (Larsen et al., 1992).  Various forms of 
covalent modifications of histones exist including acetylation, methylation, 
SUMOylation, ubiquitylation, and phosphorylation. Modifications of histone can 
either activate or repress associated genes according to the modification and type of 
residue affected. The positioning of nucleosomes affects the ability of transcription 
factors to bind to DNA and activate transcription (Jiang & Pugh, 2009). The presence 
of alternative histone variants in the nucleosome can also affect the rate of gene 
transcription (Santenard & Torres-Padilla, 2009). 
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Just as for genetic mutations, defects in the epigenome have been implicated in cancer 
(Feinberg, 2007, Jones & Baylin, 2007, Sharma et al., 2010). Cancer genomes are 
characterized by genome wide hypomethylation and hypermethylation of specific 
genes. Hypomethylation results in the activation of oncogenes, while 
hypermethylation results in silencing of tumour suppressor genes. For examples Rb is 
silenced in cancers by hypermethylation (Greger et al., 1989) while PAX2 expression 
is induced by tamoxifen in ovarian tissues stimulating proliferation and ovarian 
carcinogenesis by hypomethylation (Wu et al., 2005). Loss of global methylation can 
also contribute to carcinogenesis by causing genomic instability.  Methylation is 
responsible for silencing repeated DNA sequences. Global loss of methylation for 
example results in activation of transposable elements which cause insertional 
mutations. Repetitive DNA sequences also promote recombination resulting in 
chromosomal aberrations and translocations (Wilson et al., 2007). Cancer cells also 
exhibit widespread changes in their histone acetylation and methylation patterns. 
Changes in the nucleosomal positioning in the promoters of genes have also been 
linked with inappropriate gene regulation in cancers. The SWI-SNF complex is an 
ATP-dependent chromatin remodeling complex made up of 8-11 components that 
regulate gene expression by modifying the nucleosome into a conformation that 
facilitates the initiation of transcription. This complex has an important role in the 
regulation of cell division and differentiation. Loss of several protein components of 
the SWI-SNF complex occur in cancer and are involved in the cancer process 
(Reisman et al., 2009). 
 
To summarise, both genetic and epigenetic mechanisms are involved in deregulation 
of genes in cancers. In certain instances the two mechanisms are alternative methods 
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of deregulating cancer genes e.g. in colon cancer the APC gene is the gatekeeper that 
can be silenced either by genetic mutations or by hypermethylation. Examination of 
colorectal tumours reveals that the two processes are almost mutually exclusive, 
presumably because only one is needed to silence the gene (Esteller et al., 2000). In 
other cases though genetic and epigenetic processes can cooperate e.g. in some 
primary tumours one p16 allele is silenced by methylation while the other is lost by 
chromosomal deletion (Merlo et al., 1995). In certain cases epigenetic defects of a 
pathway in cancer predate the genetic mutations and it has been suggested that they 
may predispose cells to accumulate genetic mutations in the same pathways to drive 
tumour progression (Baylin & Ohm, 2006). 
 
1.1.3 Mechanisms of carcinogenesis by exogenous chemicals 
It has been recognised for a long time that cancers can have either endogenous or 
exogenous instigators. Cancers with endogenous origins are driven by the natural 
biochemical and metabolic cellular processes. Conversely, cancers with exogenous 
origins are induced by environmental agents that increase the incidence of tumours in 
their target organ(s). The relative contribution of endogenous and exogenous sources 
on the incidence of cancers in the human population has involved considerable debate 
(Shuker, 2002, Irigaray & Belpomme, 2010, Loeb & Harris, 2008). Ultimately, it can 
be deduced from the multi-stage progressive model of carcinogenesis that both 
endogenous and exogenous carcinogenic processes have to act by generating 
epigenetic and genetic defects in key pathways of incipient cancer cells. Endogenous 
sources of genetic mutations of cancer genes which arise spontaneously in cells are 
well understood and accepted. These include the depurination or deamination of DNA 
bases, the misincorporation of nucleotide bases during DNA replication, and damage 
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of DNA by metabolically generated reactive intermediates such as free radicals 
(Jackson & Loeb, 2001). At present the mechanisms which control and maintain the 
epigenetic status of cells are not well understood, hence it is not clear how they arise. 
Nevertheless, it is possible that spontaneous epigenetic errors may drive cancer 
initiation and maintenance  (Wilson et al., 2007). 
 
Besides the endogenous causes of cancer, hundreds of exogenous carcinogenic agents 
are currently known, including ionizing radiation, biological agents, and chemical 
substances. Chemical carcinogens are particularly worrisome due to the increased 
exposure of humans to compounds through the environment, workplace, and as 
medications. Therefore, a considerable effort has been invested into studying the 
mechanisms of chemical carcinogenesis. Various different mechanisms by which 
chemical carcinogens may induce cancers have been proposed (Irigaray & Belpomme, 
2010, Butterworth et al., 1995, Williams, 2001, Silva Lima & Van der Laan, 2000, 
Bombail et al., 2004, Hernandez et al., 2009).  
 
One commonly used classification of carcinogenic mechanisms is genotoxic (GNTX), 
also known as mutagenic and DNA-reactive, and the non-genotoxic (NGTX), also 
known as non-mutagenic and non-DNA reactive.  GNTX compounds contain 
chemical groups, or are chemically modified to contain active chemical groups, which 
interact and damage DNA. The majority of GNTX carcinogens are procarcinogens 
which have to be converted first to DNA-reactive chemicals by metabolic processing. 
(Nebert & Dalton, 2006). On the other hand, NGTX mechanisms of carcinogenesis do 
not rely on direct damage of DNA. Instead NGTX carcinogens act by either 
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increasing indirectly the mutation rate in target cells or by facilitating the expansion of 
initiated cancer cells (Table 1.1).  
 
Table 1.1 Postulated mechanisms of chemical carcinogens 
Mechanism Carcinogenic effects 
Genotoxicity Reactive chemical groups interact with DNA directly to 
induce DNA mutations 
NON-GENOTOXIC MECHANISMS 
Stimulation of free radicals Free radicals can damage DNA to cause mutations; 
perturb intracellular signaling; cause cell death and 
inflammation 
Cytotoxicity Death of cells in target organs results in regenerative 
hyperplasia; inflammation 
Immunosuppression Initiated cells can escape immune surveillance 
Targeting of cell receptors Endocrine Modification; Mitogenic; anti-apoptotic; 
CYP450 activation 
Altered epigenome Altered expression of oncogenes and tumour-
suppressors; genetic instability 
Inhibition of gap junctional 
intercellular communication 
 
Loss of homeostatic communication between cells 
 
The mechanisms of carcinogenesis described above are not mutually exclusive. 
Indeed most carcinogens affect more than one of these mechanisms. For example 
many NGTX carcinogens which are cell receptor agonists also inhibit gap junctional 
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intercellular communication (GJIC). GNTX mechanisms of carcinogenesis are 
intuitively the most straightforward to understand. An example of a GNTX 
carcinogen is 2-acetylaminofluorene (2-AAF). This chemical is not mutagenic per se, 
but is metabolically activated by the liver first to N-hydroxy-2-AAF and then to 
esterified derivatives such as acetoxy or sulfoxy moieties. These two metabolic 
products are strongly electrophilic and bind covalently to DNA. In vivo animal studies 
have shown 2-AAF to be a potent liver, bladder, and kidney carcinogen (Ogiso et al., 
1985). Hundreds of GNTX carcinogens are known, including most recognised human 
carcinogens (Purchase, 1994). Each cell contains intricate machinery responsible for 
repairing damaged DNA. However some of the DNA adducts formed following 
GNTX exposure are incorrectly repaired during DNA replication, resulting in 
mutations.  The increased mutation rate in cells exposed to GNTX carcinogens 
increases the probability of a detrimental mutation occurring within a cancer gene. 
 
Evidence also exists that several GNTX compounds also possess epigenetic faculties 
which may be important in cancer development by facilitating the expansion of the 
initiated cells. Tamoxifen is a hepatocarcinogenic GNTX compound (Gamboa da 
Costa et al., 2001) which also induces global DNA hypomethylation, 
hypomethylation of repetitive sequences, and altered patterns of histone methylation 
(Tryndyak et al., 2007). Similarly 2-AAF exposure causes hypermethylation of the 
p16(INK4) gene in the liver, as well as global and long interspersed nucleotide 
element-1-associated histone H4 lysine 20 trimethylation (Bagnyukovay et al., 2008). 
2-AAF also has anti-apoptotic propertied arising from blockage of the liver 
mitochondrial proapoptotic pathway from the early stages of carcinogenesis (Klohn et 
al., 2003).  
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NGTX carcinogens can also indirectly damage DNA damage and subsequently cause 
mutations through increased production of free radicals, i.e. reactive oxygen species 
(ROS) and reactive nitrogen species (RNS). During inflammation both ROS and RNS 
are produced by macrophages and other phagocyting cells. ROS can also be 
byproducts of metabolism of exogenous substances by CYP450s or of normal cellular 
metabolism. Multiple antioxidant and scavenging systems exist to remove ROS and 
RNS. Oxidative and nitrate stress occurs when these systems are unable to clear an 
excess of free radicals. High level of ROS and RNS can then damage DNA and other 
macromolecules or even cause cell death. In recent years it has also been found that 
the ROS and RNS also have physiological cellular signaling roles within cells. They 
can especially affect cell proliferation and apoptosis through the MAPK and NF-
kappa pathways. Therefore this is an alternative way by which free radicals can affect 
carcinogenesis (Roberts et al., 2010). 
 
A common mechanism of many NGTX carcinogens is the perturbation of normal cell 
physiology through inappropriate activation or repression of cellular receptors. These 
then result in the propagation of multiple cellular effects that facilitate cancer 
development. Several recognised human NGTX carcinogens affect cellular signalling 
by binding to receptors (e.g. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) binding the 
aryl hydrocarbon receptor; estrogenic compounds binding the estrogen receptor; 
progestins binding to the progesterone receptor). Several NGTX hepatocarcinogens 
are also known to target cellular receptors in the liver, for example 4-chloro-6-(2,3-
xylidino)-pyrimidynylthioaceticacid (Wy-14,643) induced carcinogenicity requires 
activation of the peroxisome proliferator activated receptor alpha (PPARα) (Gonzalez 
et al., 1998). Cellular receptors can drive carcinogenesis through stimulation of cell 
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proliferation, inhibition of apoptosis, changes in the epigenome, induction of CYP450 
enzymes, altered metabolism etc. The increased rate of proliferation may allow the 
generation of new mutations as the rate of spontaneous mutation is higher in 
replicating than in quiescent cells. Additionally, conversion of DNA adducts to 
mutations occurs when cells are stimulated to enter the cell cycle. The inhibition of 
apoptosis may allow the survival of cells carrying mutations that would stimulate 
apoptosis, so that they can survive and accumulate more mutations at subsequent 
stages. Induction of CYP450s is a mechanism by which ROS may be generated and 
result in DNA damage. 
 
Another established mechanism of NGTX carcinogens is cytotoxicity followed by 
regenerative proliferation. Such chemicals cause cell death in their target organs and 
this is followed by proliferating of the remaining cells in order to restore the damaged 
organ. For cytotoxic chemicals the doses which cause cytolethality are closely 
associated with the carcinogenic doses. It is thought that this induced 
hyperproliferative state can drive carcinogenesis through various ways (Butterworth et 
al., 1995). The first is the increased rate of cell proliferation. Second, the state of 
inflammation causes the generation of free radicals which may damage DNA. Thirdly, 
the secretion of growth factors which allow tissue repair may facilitate growth of pre-
neoplastic cells.  
 
Immunosuppression, inhibition of gap junctional intercellular communication (GJIC), 
and disruption of the cellular epigenome have also been suggested as mechanisms of 
NGTX carcinogenesis. Numerous components of the immune system are thought to 
be involved in cancer immunosurveillance whereby nascent transformed cells are 
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recognised and removed. Suppression of the immune system allows a greater 
proportion of incipient cancer cells to escape the host immune system and initiate 
cancer development (Zitvogel et al., 2006). An example of a chemical with such 
properties is cyclosporine, a compound that is used to suppress the immune system 
after organ transplant. Unfortunately its immunosuppressive activity also results in 
increased malignancies (Hojo et al., 1999). Gap junctions are formed between 
adjacent cells whose plasma membranes link to form channels around the cells, that 
are thought to be important for homeostasis. Through these channels small molecular 
substances can travel between cells. Disruption of the GJIC between cells affects cell 
growth and cell death. GJIC is a common target of many NGTX carcinogens, e.g. 
phenobarbital, Aroclor, pregnenolone-16 alpha-carbonitrile (Kolaja et al., 2000).  
 
Exposures to many carcinogens results in an altered epigenome. The disruption of the 
cellular epigenome can contribute to cancer by directly deregulating critical cancer 
genes. For example in many cancers, tumour suppressor gene P16 is hypermethylated 
and the oncogene RAS is hypomethylated. Alternatively, altered epigenome can 
promote carcinogenesis by causing genetic instability. Indeed, global 
hypomethylation is commonly observed in cancers. Mechanisms by which exogenous 
insult can disrupt the epigenome have been suggested (depletion of the S-
adenosylmethionine and S-adenosylhomocysteine pools; repression of DNA 
methyltransferases; DNA damage; passive demethylation during cell replication; 
active demethylation) (Wilson et al., 2007, Pogribny et al., 2008). Arsenic is a NGTX 
carcinogen that is thought to act partly by altering the epigenome. It can induce global 
liver hypomethylation by depleting the S-adenosylmethionine pool (Zhao et al., 1997) 
and inhibiting the DNA methyltransferases (Reichard et al., 2007). 
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Several distinct mechanisms of carcinogenesis have been described here, while 
perhaps more remain to be identified in the future. Nevertheless, many more 
carcinogens exist than carcinogenic mechanisms. It is thus expected that groups of 
chemical carcinogens will cause tumours through similar mechanisms. Indeed, 
research has confirmed that groups of carcinogens act in similar fashion to cause 
cancer. This idea underpins the concept of a mode of action (MOA) for a carcinogen 
(Boobis et al., 2009b). MOA in cancer is defined as a biologically plausible series of 
key events which are initiated with the interaction of the substance with the cell and 
result in cancer formation. In contrast to MOA which is a plausible hypothesis of how 
a carcinogen works, the mechanism of action is a more complete and detailed 
description of the events driving carcinogenesis. Key events are quantifiable 
consequences of exposure (e.g. biochemical processes or histopathological 
alterations) which are necessary or a biological marker of a necessary event to the 
eventual carcinogenesis. A key event is necessary, but often not sufficient for cancer 
formation. Associative events are not causal, but are reliable markers of key events 
(U.S. Environmental Protection Agency, 2005). The MOA therefore forms a useful 
framework for studying chemical carcinogens and their risk to humans. As an 
example, for chloroform the MOA is cytotoxicity followed by regenerative 
hyperplasia. Chloroform does not damage DNA, but causes cell death in the mouse 
liver followed by regenerative cell proliferation at the same doses that cause liver 
tumour formation (Larson et al., 1994). Key events of chloroform carcinogenicity are 
(1) biotransformation of chloroform to reactive phosphogene (2) Phosphogene-
induced cytotoxicity and cell death of hepatocytes (3) regenerative proliferation (4) 
development of tumours (Boobis et al., 2009b).  Another MOA is activation of 
PPARα by agonists (e.g. Wy-14,643; Di(2-ethylhexyl)phthalate (DEHP)) resulting in 
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liver hepatocarcinogenesis in rodents. The key events are altered cell proliferation, 
altered apoptosis, and selective clonal expansion (Klaunig et al., 2003) .  
 
1.2 MicroRNAs have important roles in cancer 
1.2.1 Non-coding RNAs are conserved in eukaryotes 
The classic view in molecular biology had been that RNA is a more or less passive 
intermediate in the process of gene expression, possessing no regulatory functions. 
This notion has been overturned in the past decade with the discovery in eukaryotes of 
endogenous small non-protein coding RNAs which have important physiological roles 
in gene regulation and for protecting genome stability.  At present three classes of 
small non-coding RNA are known: the piwi-interacting RNAs (piRNAs), the short 
interfering RNAs (siRNAs), and microRNAs (miRNAs). These non-coding RNAs act 
to silence homologous sequences found within the organism by multiple mechanisms 
(Moazed, 2009). PiRNAs are 24-30 nucleotides long and have been found in the 
germline of animals. They act to silence selfish DNA such as transposons, thus 
protecting genetic stability (Klattenhoff & Theurkauf, 2008).  Endogenous siRNAs 
and miRNAs differ from piRNAs in being 21-25 nucleotides long, being active in 
both somatic and germline cells, have been found in both plants and animals, and 
originate from double stranded precursors  (Carthew & Sontheimer, 2009).     
 
Animal miRNAs have been extensively studied in recent years due to their important 
roles in physiology and pathology, including cancer (Bartel, 2004, Bartel, 2009). 
Despite the importance of miRNAs, lin-4 which was the first miRNA to be identified 
as such, was only discovered in 1993. Lin-4 was initially identified as a heterochronic 
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non-coding RNA which was involved in the timing of larval development in 
C.elegans (Lee et al., 1993). As lin-4 was only detected in nematodes it was thought 
that this gene was a peculiarity restricted to this animal. The big breakthrough came 
with the isolation of a second nematode miRNA, let-7, in 2000. Unlike lin-4 this 
miRNA had homologs in several species, including human (Pasquinelli et al., 2000, 
Reinhart et al., 2000). This finding revealed that a non-coding RNA was an 
evolutionary conserved mechanism of gene regulation. The field of miRNAs only 
really grew with the subsequent isolation of hundreds of miRNAs shortly afterwards 
(Lagos-Quintana et al., 2001, Lau et al., 2001, Lee & Ambros, 2001).  
 
It is now known that miRNAs are evolutionarily conserved, some of them very 
broadly, while others are restricted to more closely related species, and have been 
discovered in the genome of all known plant and animal genomes (Carthew & 
Sontheimer, 2009, Bartel, 2004). MiRNAs are a fairly abundant class of genes in 
mammals, as it has been estimated that 2-3% of all genes code for miRNAs (Alvarez-
Garcia & Miska, 2005). The last few years have seen a continued increase in the 
number of identified miRNAs in various species. The latest release of the miRNA 
database has 17341 mature miRNAs in 142 species (miRbase database Dec 2010). In 
that database there are 1048 miRNAs identified in humans, 672 in mice, and 408 in 
the rat.  
 
1.2.2 Biogenesis and function of mature miRNAs 
MiRNA genes are located either within protein coding genes or at their own 
independent intergenic loci. A large fraction (30-40%) of miRNAs is positioned 
within protein coding genes, usually within introns, but can be found within exons as 
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well. Intergenic miRNAs have their own promoters and regulatory elements. The 
generation of the mature, functioning miRNAs from these genes is a multi-step 
process requiring the activity of numerous enzymes. Most miRNAs are transcribed by 
the same enzyme that performs mRNA transcription, DNA polymerase II (Lee et al., 
2004), although some miRNAs are transcribed instead by RNA polymerase III 
(Borchert et al., 2006). The canonical pathway of miRNA generation (See Figure 1.2) 
starts with the transcription of a long primary-miRNA (pri-miRNA) that can be 
hundreds to thousands of kilobases in length. A distinguishing characteristic of 
miRNA biogenesis is the folding of the pri-miRNA onto itself to form hairpin 
structures. A given pri-miRNA can contain from one to six mature miRNAs located 
within such intramolecular hairpins. The pri-miRNA will subsequently undergo two 
cleavage steps from RNAse III type enzymes in order to release the mature 
miRNA(s). While still in the nucleus the pri-miRNA is cleaved by the microprocessor 
complex made up from DiGeorge Syndrome Critical Region 8 (DGCR8) and Drosha. 
The former protein recognizes double-stranded RNA hairpins and positions Drosha to 
process the pri-miRNA and release the 60-80 nucleotide long pre-miRNAs. These 
molecules are then transported from the nucleus to the cytoplasm by Exportin-5 and 
Ran-GTP.  In the cytoplasm the pre-miRNA is processed further by Dicer which cuts 
the pre-miRNA at 21-24 nucleotides from one end to form a miRNA-miRNA* 
duplex. The mature miRNA strand is then selectively incorporated onto the multi-
protein RNA activated silencing complex (RISC), while the miRNA* is usually 
degraded and is found at much lower steady-state levels. The incorporated mature 
miRNA then acts as the guiding strand directing the RISC to silence its mRNA target 
(see later). The conserved argonaute family of proteins which are contained within the 
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RISC are the effectors of RISC-induced silencing of targets (Bartel, 2004, 
Sotiropoulou et al., 2009).   
 
An alternative process by which mature miRNAs can be generated has also been 
identified. These miRNAs, termed mirtrons, are localised within introns and are 
transcribed along with the protein-coding gene in which they reside. Pre-miRNAs are 
then generated directly from the introns by activity of the spliceosome and 
debranching enzymes.  These pre-miRNAs are then exported to the cytoplasm and 
processed to mature miRNAs as in the canonical pathway (Berezikov et al., 2007) 
(Figure 1.2). 
Chapter 1 
 - 46 - 
 
Figure 1.2 microRNA biogenesis in mammals 
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Fig.1.2 In the canonical pathway pri-miRNAs are transcribed by DNA polymerase II or III. 
This are capped and contain a polyA tail. The pri-miRNA folds into itself to form one to six 
hairpin structures containing base-pair stems (here one is shown). Within these intramolecular 
structures the mature miRNA sequences are contained. Drosha and DGCR8 process the pri-
miRNA to release the ~70 nucleotide long pre-miRNA. In an alternative pathway for mirtrons 
pre-miRNAs are formed by the splicing machinery without forming pri-miRNA first. The 
pre-miRNA are transported to the cytoplasm by exportin 5. Within the cytoplasm the pre-
miRNA is processed by dicer/TRBP in mammals and the mature miRNA strand is loaded 
onto the RISC complex. 
 
 
Another processing mechanism during biogenesis of miRNAs is editing of their 
sequence. The adenosine acting on RNA (ADAR) enzyme drives the change of 
adenosines to inosines in RNA duplexes. This results in the change of a stable 
adenosine:cytosine pairing to a less stable inosine:cytosine. The miRNA editing can 
have profound effects on the processing and functioning of the miRNA. This editing 
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blocks processing of the pri-miR-151 by Drosha (Kawahara et al., 2007). For at least 
one miRNA, miR-376, RNA editing alters the seed region of the miRNA so that the 
miRNA targets a different set of genes (Kawahara et al., 2007).  
 
Bioinformatic methodologies predict that approximately 30% of all mRNAs are 
subject to miRNA regulation(Krek et al., 2005, Bartel & Chen, 2004).  Additionally, a 
given miRNA is thought to be able to regulate the levels of hundreds or possibly 
thousands of genes. It has been shown experimentally that manipulation of the levels 
of a miRNA affected the expression of thousands of genes both at the level of mRNA 
(Lim et al., 2005) and protein output (Selbach et al., 2008, Baek et al., 2008). 
MiRNAs and their target mRNAs display appreciable, but not complete, sequence 
complementarity, allowing Watson-Crick pairing of the two nucleotide strands. For 
animal miRNAs this is usually imperfect pairing and will result in bulges and 
mismatches. Strong repression efficiency depends on pairing of 7-8 nucleotide regions 
in the 3’ UTR of mRNA to the “seed” region of the miRNAs (residues 2 to 8 on the 5’ 
end). Repressional efficiency is also increased if the mRNA nucleotide at position one 
is an adenosine and at position 9 either an adenosine or uracil. Usually multiple 
binding sites for the regulating miRNAs can be found on the 3’UTR of mRNAs. 
MiRNA-mRNA pairings on 5’UTR or the coding regions of the mRNA can also 
induce post-translational silencing, but are less effective  (Baek et al., 2008, Grimson 
et al., 2007). When miRNAs were first discovered it was thought that they acted 
exclusively through translational repression. It was later found though that miRNAs 
can silence genes by induction of mRNA degradation and/or inhibition of translation. 
It is still not clear what determines whether the target mRNA is cleaved or 
translationally repressed. The mechanisms of miRNA regulation are still being 
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investigated and debated (Carthew & Sontheimer, 2009, Filipowicz et al., 2008, 
Eulalio et al., 2008)  (Figure 1.3).  
 
Figure 1.3 Proposed mechanisms of microRNA-induced silencing of target genes 
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Fig.1.3 Incomplete sequence complementarity between miRNA and mRNA, especially 
between residues 2-8 on 5’ end of miRNA to 3’ UTR of mRNA, directs the RISC multi-
protein complex to silence the mRNA. Silencing can occur by mRNA degradation or 
translational repression, and the mechanisms are still under investigation. 
 
Degradation of mRNAs is not by direct cleavage by the RISC complex, but instead is 
the result of destabilization of target genes. First the poly(A) tail is shortened. Then 
the mRNA can have its cap removed and degraded in a 5’ to 3’ direction or be 
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degraded in a 3’ to 5’ direction while its cap is intact. Translation of a mRNA entails 
initiation, elongation, and termination. Mechanisms by which miRNA can block 
either the initiation or elongation of translation have been suggested: RISC complex 
competes with binding of the eukaryotic initiation factor (eLF) 4E onto the 5’cap to 
initiate translation; it may prevent the association of the 60S ribosomal subunit with 
the pre-initiation complex; deadenylation of the mRNA tail can block its 
circularization; ribosomes may be induced to drop-off from the mRNA prematurely.  
Which of these models of translational repression are valid is an area of active 
research.  
 
1.2.3 MicroRNAs in cancer: small but deadly 
Early suspicions that miRNAs may be involved in cancer were raised when it was 
found that miRNAs regulate cell proliferation, apoptosis, and differentiation, 
processes which are important in cancer (Bartel, 2004). Since then evidence has been 
amassed confirming the important roles of these genes in cancer development. A first 
observation was that more than 50% of miRNA loci are located at fragile sites or 
cancer-associated genomic regions – such as sites of minimal loss of heterozygocity 
and common breakage sites. Such areas of non-random chromosomal abnormalities 
are indicative that those regions harbour cancer genes (Calin et al., 2004, Calin & 
Croce, 2006). 
 
Second, miRNAs expression arrays have showed that in all types of tumours thus far 
the miRNA profile is distinct from their corresponding healthy tissue. For example 
deregulation of miRNA profiles has been observed in tumours of the liver (Pineau et 
al., 2010), pancreas (Lee et al., 2007), ovaries (Iorio et al., 2007), lung  (Yanaihara et 
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al., 2006), neuroblastoma (Chen & Stallings, 2007), breast , colorectal (Slaby et al., 
2007), and melanoma (Schultz et al., 2008). Importantly, the miRNA signatures of 
tumours have been found to be informative on the diagnosis, progression, prognosis, 
and treatment of human cancers (Calin & Croce, 2006).  Third, it was demonstrated 
that inhibition of the miRNA biogenesis and processing cellular machinery is 
sufficient to promote carcinogenesis. Blockage of Dicer, Drosha, or DGCR8- 
enzymes essential to the production of mature miRNAs- promoted cell transformation 
and tumourigenesis (Kumar et al., 2007).   
 
Finally, functional studies have linked miRNAs which are deregulated in cancer with 
the acquisition of cancer traits by developing cancer cells (Sotiropoulou et al., 2009, 
Esquela-Kerscher & Slack, 2006). MiRNAs bring about their functional effects in 
cancer by targeting oncogenes, tumour-suppressor genes, and the epigenetic 
machinery. Hence miRNAs themselves act as oncogenes or tumour-suppressors. 
Selected examples of miRNAs involved in cancer are shown in Table 1.2 below. 
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Table 1.2 Examples of microRNAs implicated in cancer 
 
MiRNA Example of known targets Effect of cancer deregulation 
Let-7 family Ras cell proliferation and 
differentiation 
miR-17-92 
cluster 
E2F1 cell proliferation 
miR-34 family Bcl-2; cyclin D1; SITR1; CDK1 Inhibit apoptosis, cell cycle 
arrest, and senescence 
miR-21 PTEN Evasion of apoptosis 
miR-221/222 c-kit Stimulation of angiogenesis 
miR-15/miR-16 Bcl-2 Evasion of apoptosis 
miR-29 family DNMT3a and DNMT3b Altered methylation 
miR-200 family Zeb1 and Zeb2 epithelial to mesenchymal 
transition  
miR-101 EZH2; MCL-1 Altered chromatin status &               
anti-apoptosis 
miR-106 P21/CDKN1A Resistance of anti-growth signal 
miR-122 Cyclin G1 Cell cycle 
miR-96/182 FOXO Evasion of apoptosis 
miR-31 RhoA Invasion and metastasis 
miR-10b TWIST Invasion and metastasis 
 
The underlying mechanisms by which the expression of key miRNAs is altered in 
cancer are still under investigation. So far epigenetic changes, dysregulation by 
transcription factors, mutations, chromosomal alterations, and defects in the miRNA 
biogenesis machinery have been implicated with miRNA deregulation in cancer 
(Deng et al., 2008, Croce, 2009). From the fact that many miRNA genes map to 
chromosomal regions that are altered in cancers, it can be deduced that chromosomal 
deletions and amplifications will deregulate miRNAs (Calin et al., 2004). One well-
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known example is the deletion of the chromosomal region containing the tumour 
suppressors miR-15a and miR-16-1 in 50% of patients with chronic lymphocytic 
leukemia (CLL) (Calin et al., 2002). Expression of oncogenic miRNAs can also be 
enhanced in cancers by amplification of the miRNA locus as has been found for the 
miR-17-92 cluster (Hayashita et al., 2005). In theory point mutations of miRNAs 
could alter regulation of its target genes e.g. a substitution in its seed sequence. Yet, 
so far no miRNAs with somatic point mutations that are associated with cancer have 
been identified. Mutations can also affect miRNA regulation of genes if they affect 
the binding of miRNAs to their target genes. One identified case is for the oncogene 
HMAG2 which is expressed in multiple types of cancer. Chromosomal translocation 
of this gene results in loss of binding sites of let-7 on its 3’ UTR releasing it from 
miRNA regulation (Mayr et al., 2007). 
 
 Altered methylation has also been shown to deregulate several miRNAs in multiple 
cancers. The members of the miR-34 family (miR-34a, miR-34b, and miR-34c) are 
silenced by methylation in several cancer types (Hermeking, 2010). MiR-203 shows 
altered methylation in ovarian (Iorio et al., 2007), oral (Kozaki et al., 2008), and liver 
cancers (Furuta et al., 2010). In pancreatic cancers hypomethylation was correlated 
with increased expression of the miR-200a/200b/429 cluster (Li et al., 2010). 
Research has identified numerous transcription factors, cytokines, and hormones that 
regulate expression of miRNAs. For example p53 binds to the promoter of the miR-
34a and miR-34b/c miRNAs. Deregulation of p53 is common in cancers and results in 
reduced expression of miR-34a (Hermeking, 2010). Therefore, perturbations of 
upstream factors can also deregulate miRNAs in cancers. 
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1.3. Liver is a frequent target of chemical carcinogens  
1.3.1. Liver architecture and function 
The liver is a large complex organ with multiple key functions in physiology and 
disease. This organ is a frequent target of exogenous chemicals, including carcinogens 
(Hardisty & Brix, 2005).  This is due to the metabolising activities of hepatocytes 
which activate many chemicals to a more reactive metabolite capable of attacking 
DNA. Additionally, the liver is exposed to high concentrations of orally ingested 
chemicals which pass to it directly from the gastrointestinal tract.  
 
In mammals the liver is an abdominal organ located below the diaphragm. 
Mammalian livers have a lobular structure consisting of four anatomically distinct 
areas (right, medial, left, and caudate lobes). In humans the largest lobe is the right 
one, while in rats it is the left lobe. The right and left lobes are divided further by 
veins into smaller parts (anterior-posterior for the right lobe; medial and lateral for the 
left lobe). Lobes are made up of roughly hexagonal compartments called lobules 
which are the fundamental structural and functional units of the liver (Ishibashi et al., 
2009). In the centre of each lobule is a hepatic venule from which one-cell thick rows 
of 15-25 hepatocytes radiate outwards. Oxygen, nutrients, endogenous and exogenous 
substances are carried to the hepatic lobules through the hepatic portal vein and the 
hepatic artery. The former transports venous blood containing nutrients and other 
ingested substances from the gastrointestinal tract. The hepatic artery carries 
oxygenated blood to the liver. In resting animals 25-30% of their circulation is present 
at any one time within the liver. The hepatic portal vein, hepatic artery, and the bile 
duct are located in the portal area at the edges of the lobules (Figure 1.4).  
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Figure 1.4 Architecture of hepatic lobules 
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Fig. 1.4 Adapted from Ishibashi et al. 2009. Hepatic lobules are the main structural and 
functional units of the liver. In the diagram three hepatic lobules are shown with their roughly 
hexagonal shapes. At the centre of each lobule is a hepatic venule from which rows of 
hepatocytes radiate outwards. At the edges of the lobules are portal areas containing hepatic 
arteries, hepatic portal veins, and bile ducts. 
 
Between the hepatocyte rows flows blood from the portal area within specialised 
blood vessels called sinusoids. Eventually the blood originating from the portal area 
drains from the sinusoids into the hepatic venule, to larger hepatic veins, and into the 
vena cava from where it is exported from the liver. In the opposite direction to the 
blood flows bile, a digestive fluid that assists fat metabolism. Bile is produced by 
hepatocytes and is transported to the bile ducts located in the portal area through 
minute channels called bile canaliculi. Bile then flows to the gall bladder where it is 
stored (Ishibashi et al., 2009) (Figure 1.5).  
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Figure 1.5 Flow of substances through the liver 
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Fig.1.5 Adapted from Ishibashi et al. 2009. Blood flows from the portal area via the sinusoid 
into the hepatic venule. Bile flows in the opposite direction from hepatocytes to the bile duct 
through the bile canaliculi (not shown). Hepatocytes absorb, secrete, and modify substances 
as they flow within the blood through the sinusoid. The sinusoid is made from endothelial 
cells and also contains Kupffer cells (KC), Hepatic stellate cells (HSCs), and natural killer 
cells (NK) (not shown). 
 
All hepatocytes appear similar when viewed microscopically. Nevertheless, there 
exists diversity in their functional properties according to their location within hepatic 
lobules.  Expression of genes is different for hepatocytes along the axis from the 
periportal to the central venule region. The hepatic heterogeneity facilitates the proper 
functioning of the liver. First it allows the development of hepatocytes with distinct 
functional properties and therefore a liver capable of more diverse responses. Second 
substances that progress through the sinusoid can be sequentially metabolised 
(Gumucio, 1989). 
 
The most abundant cells of the liver are the hepatocytes which constitute 60% of total 
cells in the liver and 80% of the liver volume. Besides hepatocytes at least fourteen 
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other cell types can be found in the liver (Malarkey et al., 2005). The next most 
abundant liver cells after the hepatocytes are the sinusoidal endothelial cells (SEC). 
These cells constitute 20% of liver cells and make up the walls of the sinusoid. Unlike 
normal epithelial cells SECs are fenestrated, which facilitates the flow of solutes into 
the space of Disse where they can be acted upon by hepatocytes. The third most 
abundant cells are KC which make up 15% of liver cells. These are macrophages that 
are found within the sinusoidal space and remove big particulate material by 
phagocytosis. They also produce a number of cytokines. Hepatic stellate cells (HSC), 
also known as Ito cells, represent 5% of the liver population and are found in the 
space of Disse. Liver-specific NK cells, also known as Pit cells, can be found between 
SECs and fibroblasts. They constitute 1% of liver cells. Collectively the SECs, KC, 
HSC, and NK cells are known as the hepatic sinusoidal cells as they are associated 
with this structure. Also fairly abundant (4% of liver cells) are biliary epithelial cells 
(also called cholangiocytes) which make up the lining of the bile duct. 
  
Hepatocytes are the parenchymal cells of the liver responsible for performing the 
diverse functions of the liver. About half of the volume of hepatocytes is attributable 
to organelles. Hepatocytes are a major centre for the production of energy (in the form 
of glucose) and secrete it to the blood. Hexokinase, phosphoenolpyruvate 
carboxykinase, and glycerol kinase, drive the production of glucose from 
carbohydrates, amino acids, and glycogen respectively (Williams & Iatropoulos, 
2002) . Hepatocytes are also the main cells responsible for biotransformation of 
xenobiotic chemicals. This biochemical processing converts lipophilic xenobiotic 
chemicals into more water soluble compounds that can be excreted from the body. 
Phase I reactions oxidise, reduce, or hydrolyse the chemicals. The most common 
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phase I event is oxidation by P450 enzymes. In phase II metabolism conjugating 
enzymes attached an ionizable functional group (such as glucuronyl or sulphate) to 
the molecules to make them water-soluble, as well as to often deactivate them. The 
enzymes responsible for both phase I and phase II metabolism are abundant within the 
endoplasmic reticulum of hepatocytes (Williams & Iatropoulos, 2002). 
   
1.3.2. Aetiology, types, and frequencies of liver cancers 
Liver cancers originate in the hepatic tissue itself, rather than tumours which arise in 
different tissues and metastasise to the liver. Liver cancers are the sixth most frequent 
cancer worldwide with more than 600000 new cases every year. The levels of liver 
cancer have been increasing worldwide over the past decades. The incidence of liver 
cancers is 2.5 fold more frequent in males than females. For both sexes the incidence 
of the disease is much higher in the developing world. The most important risk factors 
for liver cancer are viral infections (hepatitis B or C) and dietary aflatoxins. Several 
other risk factors have been identified such as alcoholic liver disease, obesity, 
steatosis, hemochromatosis, smoking, and oral contraceptives (Kamangar et al., 
2006).   
 
In adults the most common forms are hepatocellular carcinomas (HCC) which 
account for 85% of primary liver cancers and cholangiocarcinomas (cancers of bile 
ducts) which account for 10% of liver cancers. Rarer liver cancers include 
hepatoblastomas (liver cancers found in infants and children), 
hemangioendotheliomas (cancers of the blood vessels), tumours displaying mixed 
hepatocyte/cholangiocyte phenotype, as well as a number of other cancer forms . In 
humans HCC is an aggressive disease with low survival rates. It can arise in both 
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normal livers, as well as from cirrhotic livers and the genetic pathways involved may 
differ between them (Farazi & DePinho, 2006). Development of HCC is a slow 
sequential process, with intervals in some cases of up to 30 years between hepatitis B 
and C induced cirrhosis and subsequent cancer. As in most cancers both epigenetic 
and genetic events are implicated with the disease. It is interesting to note that during 
this long preneoplastic phase most changes in gene expression are quantitatively 
driven by epigenetic factors (Thorgeirsson & Grisham, 2002). These epigenetic 
changes are not sufficient to cause carcinogenesis, as only a fraction of cirrhotic livers 
will eventually develop HCC. Hence, subsequent genetic mutations are required. 
Epigenetic alterations are likely to provide the conditions that facilitate the occurrence 
of the driving genetic mutations. The epigenetic alterations may also precede 
subsequent mutations, as for example the methylation of c-myc at early stages, and 
amplification of the gene later on.  
 
An interesting question is which types of cells can give rise to liver cancers following 
carcinogen treatment. Cancers are initiated in replication-competent cells whose 
lineage survives long enough to accumulate carcinogenic modifications. However, 
many terminally differentiated cell types are short-lived or have lost their replicative 
potential. Recent years have seen the isolation from several types of normal tissues of 
adult stem cells which are long-living and can replicate. This has led to the hypothesis 
that in many tissues (e.g. colon and brain) cancers originate from adult stem cells 
(Hermann et al., 2010). The liver though is a peculiar organ in that its mature cells, 
which are normally quiescent, possess the ability to proliferate following suitable 
stimulation. Hepatocytes and cholangiocytes can start proliferating rapidly after 
hepatectomy of 2/3 of the liver and rapidly reform the organ after two rounds of 
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hepatocyte replication. The regeneration is driven by many growth factors and 
cytokines that are released in the blood after hepatectomy (Michalopoulos & 
DeFrances, 1997, Michalopoulos, 2007). Serial transplantation of hepatocytes 
between mice showed that hepatocytes still retain their proliferative potential after at 
least 69 doublings (Overturf et al., 1997). The fact that hepatocytes and 
cholangiocytes possess the properties necessary to form liver cancers suggests that 
they are potential targets of chemical hepatocarcinogens, cholangiocytes giving rise to 
cholangiocarcinomas and hepatocytes to HCC. 
 
On the other hand, animals also host a population of hepatic progenitor cells, termed 
oval cells in rodents, which possess bipotential replicative potential and reside 
between the hepatocyte canaliculi and bile ducts. These cells can expand and 
differentiate into either hepatocytes or cholangiocytes if given an appropriate 
stimulus. It is thought that they form a reserve for liver regeneration when the mature 
liver cells are unable to regenerate after injury (Roskams et al., 2004). Several animal 
models have displayed oval cell activation and differentiation. The Solt-Farber model 
of carcinogenesis starts with treatment of animals with an initiating carcinogen (such 
as diethylnitrosamine (DEN) followed by two week 2-AAF exposure and partial 
hepatectomy (Solt et al., 1977). 2-AAF is used to block hepatocyte proliferation. 
Following hepatectomy oval cells are activated and proliferate to regenerate the liver. 
Additionally some rare forms of livers cancers show a mix of hepatocyte and 
cholangiocyte properties, suggesting that these cancers probably arise from the 
progenitor oval cells. The capacity of progenitor cells to form liver cancers was 
demonstrated by oval cells isolated from mice deficient in p53 which could induce 
HCC when transplanted to athymic nude mice(Dumble et al., 2002). Oval cells 
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therefore can also form HCC. The liver then contains three populations of long-living, 
replication-competent cells that can be acted upon by chemical carcinogens to form 
tumours: hepatocytes, cholangiocytes, and oval cells. As of present, there exists no 
definite way to identify the cellular targets of chemical carcinogens, with most of the 
evidence being circumstantial (Figure 1.6).  
 
Figure 1.6 Cellular origins of liver cancers induced by carcinogens 
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Fig. 1.6 Adapted from Roskams et al. 2006. Progenitor cells (oval cells in rodents) are 
bipotential and can give rise to either hepatocytes or cholangiocytes. The most common liver 
cancers in adults are HCC and cholangiocarcinomas. These can arise from hepatocytes and 
cholangiocytes respectively. Rare liver cancers show intermediary or mixed 
hepatocyte/cholangiocyte properties and are thought to arise from progenitor cells. The 
contribution of oval cells to HCC is still not clear.  
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The non-parenchymal cells of the liver are also involved in chemical carcinogenesis 
by affecting the initiation and progression of liver cancer. Indeed, transgenic mice 
where PPARα is expressed only in hepatocytes, do not develop tumours following 
Wy-14,643 treatment, demonstrating the essential role of non-parenchymal cells 
(Yang et al., 2007). Activation of KC results in the generation of ROS as well as the 
secretion of growth factors and inflammation molecules such as TNF-α, IL-1, and IL-
6, which can drive hepatic carcinogenesis (Roberts et al., 2007).  HSCs are important 
for the development of fibrosis and cirrhosis  (Krizhanovsky et al., 2008).  
 
1.3.3 Phenobarbital is a prototype of non-genotoxic hepatocarcinogens 
Phenobarbital (PB) has been under continual usage by humans since 1912 for its 
strong sedative and anticonvulsant properties. Even though its usage has declined in 
recent decades, it still remains the most widely-used antiepileptic drug worldwide 
(Kwan & Brodie, 2004). PB is also a prototype of rodent liver NGTX carcinogens that 
cause transient hyperplasia and liver enlargement. Numerous in vivo and in vitro 
genotoxicity tests have been performed for PB (DNA damage in vivo, assays for 
bacterial gene mutations, mammalian gene mutations, chromosomal aberrations etc.), 
which concluded that PB is a NGTX compound. The carcinogenic potency of PB is 
species and strain specific. The C3H and B6C3F1 mice strains are much more 
susceptible to liver tumour induction by PB than the C57BL mouse strain, developing 
adenomas and carcinomas in multiple studies (Whysner et al., 1996). Rats are also 
more resistant to PB-induced tumours than the susceptible mouse strains, developing 
only altered hepatic foci and/or adenomas. PB is also a powerful promoter of HCC in 
livers of mice and rats initiated with several genotoxic agents, such as 2-AAF 
(Whysner et al., 1996). For humans large epidemiological studies examining cohorts 
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of thousand of patients concluded that PB is not carcinogenic at doses which cause 
liver tumours in rodents (Olsen et al., 1995);(Lamminpaa et al., 2002). Based on these 
observations the latest IARC evaluation has concluded that “inadequate evidence” 
exists for carcinogenicity of PB in humans, while “sufficient evidence” exists that it is 
carcinogenic in experimental animals (International Agency for Research on Cancer 
2001). A defining characteristic of PB is the strong induction in the liver of the 
cytochrome 450 type 2b (CYP2B) family. Members of this gene family are found in 
humans, mouse, and rat (Cyp2B9 and Cyp2B10 in mouse, Cyp2B1 and Cyp2B2 in 
rat, and CYP2B6 in human). PB also induces other enzymes (e.g. Cyp2C and 
Cyp3A), but not as potently. PB-type inducers are a set of structurally diverse 
chemicals which nevertheless display similar strong inductions of Cyp2B. Species 
differences exist as well, with some compounds inducing Cyp2B in one animal, but 
not in others. PB-type compounds include PB, 1,4-bis[2-(3,5-
dichloropyridyloxy)]benzene (TCPOBOP), methoxychlor,  dieldrin, acetone, o,p’-
DDT, oxazepam, and methoxychlor (Sueyoshi & Negishi, 2001).  
 
PB exposure of hepatocytes results in the activation of two members of the nuclear 
receptor family, the constitutive androstane receptor (CAR) and the pregnane X 
receptor (PXR). Nuclear receptors are transcription factors with characteristic 
modular structures that are activated by extracellular or intracellular ligands, bind to 
DNA, and affect gene expression. Due to the fact that CAR and PXR lack an 
identified endogenous ligand, they have been classified as orphan nuclear receptors. 
CAR and PXR have also been classified as xenobiotic receptors, receptors which 
show promiscuous binding to toxic byproducts of metabolism or exogenous 
chemicals. CAR is responsible for generating most of the pleiotropic effects of PB in 
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the liver, including cancer ((Timsit & Negishi, 2007); (Li & Wang, 2010).  Inactive 
CAR is located in the cytoplasm as part of a multi-protein complex. PB does not bind 
to CAR, but instead activates it indirectly by causing its nuclear translocation through 
PP2A phosphorylation. Within the nucleus of hepatocytes the active CAR propagates 
multiple cellular effects by directly regulating genes or by affecting other transcription 
factors (Figure 1.7). 
 
Figure 1.7 Phenobarbital drives the CAR to the nucleus 
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Fig. 1.7 Inactive CAR is located in the cytoplasm as part of a multi-protein complex including 
CCRP and HSP90. PB activates CAR by stimulating its translocation into the nucleus where 
it propagates multiple short and long term effects (detoxification response, suppression of 
gluconeogenesis, etc.). PB does not bind directly to CAR, but instead activates it indirectly 
through PP2A.  PP2A dephosphorylates CAR at serine 202, releasing it from the complex and 
allowing it to translocate into the nucleus. The mechanism by which PB activates PP2A in 
order to stimulate CAR activation is currently not known. 
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Induction of the phase I and phase II metabolizing genes by CAR is thought to be an 
adaptive response aiming to protect the liver from toxic damage. In the nucleus CAR 
forms heterodimers with the retinoid X receptor alpha (RXRα) and activates CYP2B 
by binding onto a PB responsive element found in the promoter region of the genes 
(Wei et al., 2000). CAR is also responsible for the induction of several other phase I 
and II metabolizing genes after PB exposure, such as P450s, drug transporters such as 
Mrp2 and Mrp4, sulfotransferases, glutathionine-S-transferase, and organic ion 
transporters (Ueda et al., 2002);(Assem et al., 2004). CAR can also regulate genes 
indirectly by acting as a co-regulator of gene transcription. Within the nucleus CAR 
binds to and represses Forkhead box other (FOXO) 1, which antagonises 
gluconeogenesis (Kodama et al., 2004).  CAR also antagonises transcriptional activity 
of the Hepatic nuclear factor-4 (HNF4) which is involved in lipid and glucose 
metabolism.  This is achieved by competition for binding motifs of genes and 
coactivator PGC-1α  (Miao et al., 2006). 
 
Some PB effects are CAR-independent. Ueda et al. 2002 compared transcript profiles 
of CAR wildtype and knockout mice 12 hours after exposure to PB dose. They found 
that a significant proportion of genes affected by PB were independent of CAR (60 
out of 144). PB can also induce the PPARα receptor in CAR and PXR knockout 
hepatocytes, but this effect is repressed in wildtype animals (Tamasi et al., 2009). 
Importantly though, experiments with CAR knockout animals demonstrated that 
activity of the receptor is essential for the development of HCC (Wei et al., 2000) 
(Yamamoto et al., 2004); (Huang et al., 2005). In the CAR knockout mice there is no 
transient increase in hepatocyte proliferation or increase in liver size following acute 
PB or TCPOBOP exposure. CAR knockout mice which were initiated with DEN and 
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promoted with PB or TCPOBOP had more apoptotic bodies, fewer altered hepatic 
foci (AHF), and developed no adenomas or carcinomas. In contrast all wildtype 
animals developed liver cancers.  
 
Activation of CAR is therefore essential to the hepatocarcinogenesis of PB-type 
compounds. It is thought that the CAR-dependent increases in proliferation and 
suppression of apoptosis drive the progression of spontaneous or chemically initiated 
preneoplastic cells (Holsapple et al., 2006). In accordance with this PB induces more 
AHF and cancers in aged rats which contain more spontaneous preneoplastic cells 
(Ward, 1983). The induction of hepatocyte proliferation by PB is transient as judged 
by numerous studies utilizing hepatic labeling index and BRDU staining. However, 
PB treatment also results in increased number and size of AHF. These are distinct 
regions made up of cells with altered morphology and histology. These foci develop 
in the liver prior to the appearance of tumours and may develop to adenomas and 
carcinomas. There is experimental evidence that PB treatment increases proliferation 
and suppresses apoptosis of preneoplastic cells within these AHF. ((Kolaja et al., 
1996)) examined male mice and rats which were fed 10, 100, and 500 mg/kg PB after 
initiation with DEN. The 100 and 500 doses resulted in the development of hepatic 
foci, within which there was increased DNA synthesis and decreased apoptosis. 
(Schultehermann et al., 1990) reported on N-nitrosomorpholine initiation in female 
rats followed by PB promotion. In the PB promoted animals there was increased 
number of foci, faster foci enlargement, and finally cancers. Within the foci, 
proliferation was 10-fold higher than in normal tissue. Apoptosis was lower in PB-
promoter foci than in controls, and was increased if PB treatment was removed. 
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The MOA of PB-type inducers is then considered to be the activation of CAR which 
results in multiple cellular effects. The key events consist of activation of CAR, 
increased proliferation, suppression of apoptosis, hypertrophy, and development of 
altered hepatic foci (Holsapple et al., 2006). Besides the key events identified above, 
PB also causes other events which have been suggested to be involved in its 
hepatocarcinogenesis. These include oxidative stress, inhibition of GJIC, and 
alterations in DNA methylation. It has been suggested that oxidative stress resulting 
from CYP2B induction contributes to hepatocarcinogenesis (Imaoka et al., 2004). 
However, it is also possible that induction of CYP2B is a side-effect of CAR 
induction that is irrelevant to the process of carcinogenesis. Just like many other 
NGTX carcinogens, PB also causes a disruption of the GJIC in hepatocytes. 
Treatment with tumour-promoting dose of PB of rats for seven days blocked GJIC by 
50% (Kolaja et al., 2000). Also, connexin-32, the major gap junction protein, was 
reduced following PB exposure in male Fischer rats (Neveu et al., 1994). In mice PB 
doses affected GJIC of the B6CF31 mice but not of the C57BL/6 mice (Warner et al., 
2003).  Interestingly, species differences seem to exist in the role of GJIC in PB-
induced carcinogenesis. Connexin 32 mutant mice develop more tumours after DEN 
initiation and PB promotion than wildtype (Dagli et al., 2004). However, rats with 
similar experimental treatement had increased number of lesions, but not an increased 
incidence of tumours  (Hokaiwado et al., 2005). Studies have also determined that PB 
affects both global and gene-specific DNA methylation. A 20% decrease in global 
DNA methylation was reported for sensitive B6CF31 mice strain at 1,2, and 4 weeks, 
but not for the more resistant C57BL/6 strain (Counts et al., 1996) . The methylation 
of multiple genes was altered at two and four weeks after PB exposure in the B6CF31 
mice compared to C57BL/6 mice (Phillips et al., 2009a). Methylation patterns were 
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also distinct between CAR wildtype and CAR knockout mice at 23 weeks (when foci 
appear) and 32 weeks (when tumours appear)  (Phillips et al., 2009b). Analysis of the 
genes altered by methylation in these studies in the B6CF31 and CAR wildtype mice, 
but not in the C57BL/6 or the CAR KO animals, identified a number of genes 
involved in cancer pathways.  
 
At the molecular level PB has to induce cancer by altering critical cell cycle and 
apoptotic pathways. Various genes involved in these cellular responses have been so 
far linked to PB-induced carcinogenesis. A recent interesting study has revealed a 
pathway where CAR activates c-myc, which subsequently activates FoxM1. This 
cascade then drives hepatic proliferation after CAR activation in mice (Blanco-Bose 
et al., 2008). Also, unlike tumours caused by DEN treatment, 80% of tumours 
generated by DEN initiation followed by PB promotion contained b-catenin mutations 
(Aydinlik et al., 2001). Anti-apoptotic effects of CAR have been associated with the 
induction of mdm2 (Huang et al., 2005) and of gadd45b (Columbano et al., 2005).  
 
As has been mentioned above, extensive epidemiological evidence supports that PB is 
not carcinogenic in humans. The molecular underpinnings of the different response of 
human and rodents to PB are still not clear. Comparisons of rat and human primary 
hepatocytes reveal that although PB induces CYP2B in both, only in rats is DNA 
synthesis stimulated (Hirose et al., 2009). This and other studies indicate that PB may 
affect proliferation and apoptosis of rodent hepatocytes, but not of humans. There 
exist obvious practical difficulties of studying the effects of PB treatment on the 
human liver in vivo. One interesting model for studying species-differences of PB 
effects are transgenic mice which lack the murine CAR and PXR receptors, but 
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instead contained the human CAR and PXR homologs. Treating these mice resulted in 
induction of CYP2B10 in wildtype and humanised mice, but not in knockout. 
However, cell proliferation and HCC were only observed in wildtype mice. These 
data suggest that human and mouse CAR may affect different genes involved in cell 
cycle (Ross et al., 2010). 
  
1.3.4 Involvement of miRNAs in hepatocellular carcinoma 
MiRNAs are abundant in liver and play important physiological and pathological 
roles in this organ (Bala et al., 2009). Proteomics have also demonstrated that a single 
miRNA can have profound effects on protein expression. MiR-34a transfection into 
the human liver cell line HepG2 resulted in thirty four proteins being downregulated, 
with 15 probably being downstream targets of the miRNA. Interestingly, they found 
that only 11% of proteins that were downregulated by miR-34a transfection also 
displayed a decrease in transcript levels (Cheng et al., 2010). 
 
Evidence has been accumulating in recent years that, just as for other cancers, 
miRNAs are involved in both the initiation and maintenance of liver cancers. 
Numerous studies have shown altered expression in liver tumours (Pineau et al., 2010, 
Gramantieri et al., 2007, Jiang et al., 2008, Kutay et al., 2006, Ladeiro et al., 2008, 
Meng et al., 2007, Ura et al., 2009, Hou et al., 2011). Profiling studies have also 
shown that the miRNA profile of tumours is connected with the aetiology, 
malignancy, and the underlying gene mutations. For example Ladeiro et al. 2008 
associated deregulations of specific miRNAs with hepatitis B infection, alcohol 
consumption, and HNF1alpha and B-catenin mutations. Ura et al. 2009 reported that 
hepatitis B and hepatitis C infected tissue affected a distinct group of miRNAs which 
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were involved in the progression to hepatocellular carcinoma (HCC). In another study 
expression of specific miRNAs was associated with a subclass of HCC which 
displayed overactive IGF signalling (Tovar et al., 2010).  
 
The requirement of normal miRNA signalling to prevent hepatic tumours was 
demonstrated in a conditional knockout mouse model in which dicer1 was deleted 
specifically in hepatocytes three weeks after birth. Hepatocytes in these animals 
lacked mature miRNAs. At one year of age two-thirds of these mice developed HCC, 
clonally derived from dicer1 knockout hepatocytes (Sekine et al., 2009). It has also 
been shown in vivo that a single miRNA can affect the progression of liver cancers. 
Mir-26a is a cell-cycle regulating miRNA that is lost in liver cancer cells. Introduction 
of this miRNA into mouse models of HCC using virus carriers protects from 
progression of the disease (Kota et al., 2009). Several specific miRNAs have been 
linked with HCC. MiR-21 and miR-221 are oncogenes. MiR-21 is highly 
overexpressed in HCC and liver cancer lines and promotes hepatocyte growth by 
targeting PTEN (Meng et al., 2007).  MiR-221 is upegulated in 71% of HCC and 
controls cell cycle regulators p27 and p57 (Fornari et al., 2008). MiR-122 is a tumour-
suppressor downregulated in 50-70% of HCC and correlates with loss of hepatocyte 
phenotype and increased invasiveness (Kutay et al., 2006, Coulouarn et al., 2009). 
Mir-199a/b-3p is a miRNA with a high expression, the frequent repression of which 
in HCC is associated with aberrant activations of the PAK4/Raf/MEK/ERK pathway  
frequently repressed in HCC (Hyun et al., 2009) Other miRNAs that have been 
implicated in HCC include let-7 family, miR-18, miR-301, miR-373, and miR-224 
(Bala et al., 2009). More functional studies are needed to clarify the functional 
significance of the deregulation of these miRNAs in HCC. 
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1.4. Cancer risk assessment strategies 
1.4.1. Rodent lifetime bioassays are the benchmark for risk assessment 
An essential requirement for regulated chemicals (such as drugs, pesticides, industrial 
chemicals, and food additives) is to evaluate their carcinogenic potencies to humans. 
This is a necessary step to prevent unnecessary exposure of the public to chemicals 
which will lead to the development of cancers. Unfortunately, risk assessment for 
carcinogenicity of chemicals is currently a laborious, complicated, time-consuming, 
and costly process (Butterworth et al., 1995). Risk assessment currently entails tests 
for genotoxicity, two-year cancer bioassay in rodents, MOA considerations, and 
extrapolations of animal data to humans (Boobis et al., 2009a).  
 
The rodent lifetime bioassay has remained a central requirement for the evaluation of 
chemicals for several decades. It involves testing both sexes of a rat and mouse strain 
to the maximum tolerated dose (MTD) for a period of two years, which represents the 
lifetime of these animals. Typically 50 animals are used per sex per dose group. MTD 
is the highest dose that is not sufficiently toxic to result in significant effects on 
animal health. The value of this assay rests on the assumption that rodents and 
humans are comparable in respect to carcinogen hazard; therefore in the absence of 
extenuating information animal tumours are relevant to humans (Butterworth et al., 
1995).  
 
GNTX carcinogens can be identified reliably and quickly using a weight of evidence 
approach which takes into account structural information, in vitro assays, and in vivo 
DNA damage assays (Weisburger & Williams, 2000, Kirkland et al., 2005). 
Development of chemicals with GNTX properties can then be terminated at an early 
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stage. On the other hand, currently no short-term tests that can predict NGTX 
carcinogenicity exist. This is due to the fact that these carcinogens do not damage 
DNA and have multiple MOA. Consequently, most of the tested chemicals that result 
in the induction of tumours in the two-year bioassay will act through NGTX 
mechanisms. (VanOosterhout et al., 1997) examined the databases of all 
pharmaceutical that were tested for carcinogenicity which applied for a marketing 
authorisation in Germany and Netherlands.  Of the 221 tested compounds only six had 
evidence of genotoxicity. A second study by NTP looked at 301 chemicals which 
were tested for rodent carcinogenicity. Of those 40% were NGTX carcinogens, with 
only 13% being GNTX carcinogens (Ashby & Tennant, 1994).   
 
The MOA of a carcinogen is also increasingly accepted as an important aspect in 
assessing human relevance of rodent carcinogens (Boobis et al., 2009b, Holsapple et 
al., 2006, Boobis, 2010). In certain cases the MOA of rodent carcinogens has been 
found to be irrelevant for humans. Additionally, the MOA of a rodent carcinogen may 
be specific to a high dose used in a bioassay, and irrelevant to the lower doses to 
which humans are exposed. Certain chemicals induce a2u-globulin nephropathy in 
male rats (e.g. d-limonene and unleaded gasoline). For these chemicals the MOA is 
accumulation of α2u-globulin in the kidney causing cell death, hyperplasia, and renal 
tumours. This MOA is irrelevant for female rats, mice, and humans as α2u-globulin 
does not accumulate in the kidney of these animals. Hence, regulatory agencies accept 
that chemicals with this MOA do not pose a human cancer risk (Whysner & Williams, 
1996). As noted above epidemiological studies indicate that PB is probably not 
carcinogenic in humans. Therefore, chemicals with a PB-type MOA are probably not 
a human cancer hazard. 
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An important aspect of risk assessment is the extrapolation of rodent tumour data to 
humans. Both toxicokinetic and toxicodynamic parameters of chemicals are important 
for this evaluation. Toxicokinetic parameters include the uptake, processing, exposure 
of tissues, metabolism and excretion of the chemical from the body and relates 
exposure of the chemical to its toxic effects. Toxicodynamics is the mechanisms by 
which chemicals produce their biological effects. If it is established that the MOA of a 
rodent carcinogen is not plausible in humans, taking into account kinetic and dynamic 
factors, then rodent tumour data can be ignored. If the MOA of a rodent carcinogen is 
not identified or is considered plausible in humans then the human cancer risk is 
determined. For risk assessment purposes a clear distinction is made between GNTX 
and NGTX carcinogens. It is currently considered that for GNTX carcinogens their 
risk is non-thresholded and linear, so that there is no safe exposure level (U.S. EPA 
2005). Unlike GNTX carcinogens, NGTX carcinogens are considered to be reversible 
and to have a dose threshold. The reversibility is due to the fact that, at least initially, 
they do not induce DNA damage and mutations. The threshold exists because 
sufficient dose is necessary to cause a biological effect e.g. proliferation, necrosis etc. 
The existence of a threshold means that for chemicals with NGTX carcinogenic 
properties a safe level of exposure can be determined. The no observable adverse 
effect level (NOAEL), the highest dose of exposure that has been determined 
experimentally or by observation to have no adverse effects, of the most sensitive 
species/stain/gender is then extrapolated to humans with the addition of a safety 
factor. Commonly this is set at a maximum human exposure of a concentration that is  
100x less than the NOAEL (factor of 10 for interspecies differences and a further 
factor of 10 for sensitive individuals) (Butterworth et al., 1995). 
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1.4.2 Alternative strategies to the rodent lifetime bioassays 
The rodent bioassay is very expensive, costing million of pounds for each compound 
tested and requiring up to two years to be completed. Hence, the bioassay adds a 
considerable cost to the development costs of new chemicals. Moreover, a positive 
finding in the bioassay can delay significantly or halt the development of new 
compounds, which have been developed at a considerable cost. The expense of the 
assay also prevents the testing of many compounds such as environmental pollutants 
to which humans are exposed. Therefore, various alternatives to the rodent bioassay 
have been pursued with some positive results, but so far none has been sufficiently 
validated to replace the two-year animal bioassay (Table 1.3). 
 
Table 1.3 Alternative methods to the two-year rodent assay  
Method Concept Potential Advantages 
In silico Prediction of carcinogenicity using 
structural information of compound 
Fast and cheap 
In vitro Model the liver responses in vitro  No need for animal testing; cheaper 
and faster than animal models 
Human stem 
cells 
Test compounds in human stem cell 
derived models of the liver 
More relevant to humans than rodent 
models 
Transgenic 
mouse 
models 
Use transgenic mice which are 
more sensitive than wildtype 
animals  
Tumours will appear faster in 
transgenic than in wildtype animals 
“-omics” 
technologies 
Examine expression profiles after 
short-term chemical exposure  
Acquire mechanistic information ; 
earlier prediction of carcinogenicity  
 
Each of these alternative strategies has certain advantages and disadvantages. The use 
of the “-omics” technologies is at present one of the better prospects. They rely on the 
use of global profiling platforms which allow the quantification of selected parameters 
Chapter 1 
 - 74 - 
 
e.g. transcripts (transcriptomics), proteins (proteomics), or metabolites 
(metabonomics). The central concept behind the use of “omics” for toxicology is that 
chemicals with similar mechanisms will generate characteristic profiles after short-
term treatment. These “signatures” can then be used to both analyse the MOA of a 
given chemical and to predict its carcinogenic potency after short-term exposure 
(Blomme et al., 2009).  
 
So far most effort has gone into examination of mRNA expression following 
carcinogen treatment. (Hamadeh et al., 2002)reported that structurally diverse 
compounds produced gene expression profiles according to class of the tested 
compound. (Ellinger-Ziegelbauer et al., 2005) examined liver mRNA expression after 
treatment of rats with four GNTX carcinogens and four NGTX carcinogens for up to 
14 days and reported distinct cellular effects of the two classes. (Ellinger-Ziegelbauer 
et al., 2008)used a training set of five GNTX carcinogens, five NGTX carcinogens, 
and three non-hepatocarcinogens to identify biomarkers. The generated classifier was 
then used to classify a set of 16 other carcinogens (5 GNTX hepatocarcinogens, 6 
NGTX hepatocarcinogens, and 6 non-hepatocarcinogens), which it did with an 88% 
accuracy. In principle then it appears that transcriptomic signatures derived after 
short-term in vivo exposure have potential for assessing the carcinogenic potential of 
chemicals. 
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 1.5 Justification, hypothesis, and objectives 
  
Justification of project 
 
The possibility of utilising rodent hepatic miRNA signatures following short-term 
chemical treatment for assessing the chemical risk hazard has remained so far largely 
unexplored. It is a fact that many fewer miRNAs exist than mRNAs (hundreds 
compared to thousands). Nevertheless, miRNA signatures have proved better at 
classifying tissue origin and development stage of cancer than mRNA signatures (Lu 
et al., 2005, Rosenfeld et al., 2008). The classification and predictive content of 
miRNA profiles may be even more pronounced during the early stages of 
hepatocarcinogenesis when epigenetic events are more important. Moreover, miRNAs 
can also regulate cellular responses (e.g. cell proliferation, differentiation, and 
apoptosis) that are important drivers of chemical hepatocarcinogenesis. It is possible 
then that deregulation of miRNAs by chemical carcinogens may be an important 
event in the process of carcinogenesis induced by many chemicals. Therefore, there is 
a valid and timely requirement to examine more thoroughly the usefulness of 
miRNAs in cancer risk assessments.  
 
Few studies so far have examined the effects of chemical treatments on the expression 
of liver miRNAs. The results of such studies have produced evidence that miRNA 
profiles are deregulated by chemical carcinogens long before the appearance of 
tumours. One study examined the effect of continual treatment with a carcinogenic 
dose of tamoxifen for 24 weeks in female Fischer rat on the expression of liver 
miRNAs (Pogribny et al., 2007). This study found 33 miRNAs with significant 
changes in their expression in tamoxifen-treated animals and confirmed the 
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downregulation of selected protein targets in the pre-cancerous liver tissue. Many of 
these protein targets were involved in carcinogenesis e.g. Rb1, E2F1, BCL2 etc. A 
second study examined the effect of exposure to a carcinogenic dose of Wy-14,643 
for two weeks (Shah et al., 2007). At this point 27 miRNAs were differentially 
expressed. Among them was let-7c, which was found to be consistently 
downregulated from 4 hours up to 11 months when tumours appear. The let-7c 
repression initiated a signaling cascade that drives hepatocyte proliferation. It was 
also shown that let-7c was not repressed following Wy-14,643 treatment in a 
humanised PPARα model which is much less susceptible to liver tumours induced by 
this chemical (Shah et al., 2007). The complete carcinogen 2-acetylaminofluorene (2-
AAF) has also been examined and found to affect expression of liver miRNAs 
(Pogribny et al., 2009a). The miRNA profiles of animals treated with carcinogenic 
dose of 2-AAF were examined at 12 and 24 weeks. They found deregulation of 
miRNAs and their protein targets at both timepoints, with some miRNAs showing a 
temporally progressive increase in their deregulation. 
 
On the other hand two studies found little or no effects of carcinogenic treatments on 
liver miRNAs. In the first study mice and rats were treated with 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) for up to 3 days (Moffat et al., 2007). Dioxin 
toxicity is mediated through the AH receptor. Their analysis revealed that AH 
signalling affected very few miRNAs, and the levels of change in expression were 
minimal in magnitude. A second study examined mice fed doses of benzo[a]pyrene 
(BaP) for 4 and 24 hours. As expected the treatment resulted in considerable changes 
in the expression of mRNAs. However, no miRNAs were significantly altered by this 
treatment (Yauk et al., 2010). 
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Hypothesis 
 
That the hepatic miRNA profiles of rodents following short-term chemical treatment 
will facilitate the mechanistic understanding and the earlier identification of 
carcinogens, especially those with NGTX MOA 
 
Objectives of project  
Microarrays were used to extract the hepatic miRNA profiles of animals treated with 
NGTX and GNTC carcinogens in their diet for periods up to 90 days. The extracted 
miRNA profiles were then examined for their potential to: 
 
(a) Classify chemicals according to their MOA 
(b) Predict their carcinogenicity in two-year rat bioassay 
(c) Elucidate the role of miRNAs in chemical hepatocarcinogenesis 
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2.1 Chemicals and reagents used 
 
For RNA extraction the Trizol reagent was purchased from Invitrogen. RNase Zap 
and DNA/RNA/nuclease free microcentrifuge tubes were purchased from Applied 
Biosystems. The integrity of the extracted RNA was assessed using the RNA Nano kit 
which was obtained from Agilent. The reagents for performing miRNA microarrays 
(microarray slides, microRNA complete labelling and hybridisation kit, gene 
expression washing buffer, gasket backing slides) were purchased from Agilent.  
 
Reagents, probes, and primers for real-time quantitative polymerase chain reaction 
(qPCR) were purchased from Applied Biosystems. For semi-quantitative PCR the Tfi 
polymerase and the PCR primers were purchased from Invitrogen. Reverse 
transcription was performed using M-MLV enzyme (Promega). Random hexamers 
were purchased from Qiagen and the dNTP mix from Invitrogen. A 5x loading buffer 
from Invitrogen was used to load PCR products into gels. For RNA ligase-mediated 
rapid amplification of 5´ cDNA ends (RLM-RACE) the Generacer kit was purchased 
from Invitrogen. 
 
For DNA extraction the DNeasy Blood & Tissue kit of Qiagen was used. Levels of 
global DNA methylation were assessed using the Methylamp Global DNA 
Methylation Quantification Ultra Kit of Epigentek 
 
The 100X Halt Protease inhibitor from Pierce was used during protein extraction. The 
BCA (bicinchoninic acid) protein assay from Pierce was used to quantify the protein 
extracts. Primary and secondary antibodies were purchased from Santa Cruz 
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biotechnologies, except for the β-actin primary antibody which was purchased from 
Sigma-Aldrich. The Novex Sharp pre-stained protein standard was obtained from 
Invitrogen. Protein bands were visualised using the SuperSignal West Dura Extended 
Duration Substrate (Pierce) and Hyperfilm which was purchased from GE Healthcare. 
All other buffers and reagents used were obtained from Sigma-Aldrich. 
 
2.2 Animal studies 
2.2.1 Tested compounds  
 
This project used liver samples generated from two animal studies which were 
conducted in 2007 (Dow, 2007a, Dow, 2007b) by industrial collaborators at the 
Syngenta Central Toxicology Laboratories. Details of the experimental design of 
the two studies which are reported here are taken from the research report 
summary documents produced for these two studies. They are included here to 
facilitate the understanding of the generated data from this project. All the compounds 
used were purchased from Sigma-Aldrich.  
 
The eight tested chemicals in these two studies are shown in Figure 2.1.  
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Figure 2.1 Chemicals used in animal studies. 
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2.2.2 Design of animal studies 
 
Nine-week old male Fischer rats were used in both animal studies, as this strain is 
commonly used in lifetime bioassays. Rats were given access to mains water and 
powdered diet ad libitum.  The tested compounds were fed to the animals at the 
desired dose through their diet. Liver tissue was obtained from animals at the 
designated times immediately upon sacrifice, snap frozen, and stored at -80 C
o
.  
The first study was a 90 day dietary study with various known hepatocarcinogens and 
non-hepatocarcinogens ((Dow, 2007b)). The animals were fed a carcinogenic dose of 
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carcinogens (as determined by reported two-year assays in Fischer rat) or the 
maximum tolerated dose (MTD) for the non-carcinogens. The MTD was the 
maximum dose used in the literature that did not result in unacceptable toxicity in a 90 
day study. The design of the 90 day study can be seen in Figure 2.2.  
 
Figure 2.2 Design of 90 day multicompound study 
 
 
The histopatholigical effects of these chemicals on the liver are described in sections 
3.1-3.2. For the second study (Dow, 2007a) animals were exposed to three PB doses, 
one carcinogenic (Butler et al. 1978) and two non-carcinogenic (Hagiwara et al., 
1996) for a period up to 14 days (Figure 2.3). 
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Figure 2.3 Design of 14 day PB dietary study 
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Throughout the two studies, treated animals were examined for evidence of overt 
toxicity. Besides the collection of liver samples data were also collected on important 
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parameters such as adjusted liver weight, hepatic Ki67 labelling index (LI), 
microscopic histopathology, and pathology in treated and control animals.  
 
2.3 MicroRNA microarrays 
2.3.1 RNA extraction  
 
Total RNA was isolated from the liver tissue using Trizol (Invitrogen) following the 
manufacturer’s instructions. RNase Zap (Applied Biosystems) was used to clean the 
benches and pipettes used, to remove potential RNase enzymes. To minimise RNA 
degradation frozen liver sections were thawed in Trizol and processed as quickly as 
possible.  From each liver sample a 50-100mg section of left lateral lobe was 
pulverised with a polytron homogenizer and total RNA was then extracted using 1ml 
of Trizol. Following homogenisation at room temperature the insoluble material was 
removed by centrifugation at 12000g for 10 minutes. Chloroform was added to each 
sample at 200μl and the samples were then shaken vigorously for 15 seconds, 
incubated at room temperature for two minutes, and centrifuged at 12000g for 15 
minutes to encourage phase separation. The top aqueous phase that contains RNA, but 
not DNA or protein, was then collected. To increase the purity of the extracted RNA 
chloroform extraction was performed twice. Total RNA (i.e. ribosomal RNA, mRNA, 
transfer RNA, miRNA etc.) was then precipitated from the aqueous solution. In order 
to remove proteoglycan and polysaccharide contaminants, which are widespread in 
the liver, the RNA was precipitated with a mixture of isopropanol and a high salt 
precipitation solution (0.8M sodium citrate and 1.2M sodium chloride) at equal 
volumes. The extracted RNA was then washed with 75% ethanol, air-dried, and 
dissolved in Tris- ethylenediaminetetraacetic acid (EDTA) buffer (TE buffer) at pH 
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8.0 or RNA-free water. The solution containing pure RNA was then aliquoted, and 
stored at -80C. 
 
 
 
 
2.3.2 Assessment of RNA quantity, purity and integrity 
 
The suitability of the extracted RNA samples for further usage was determined based 
on their quantification, purity, and integrity. The RNA quantity and purity of samples 
was assessed using a Nanodrop-ND1000 spectrophotometer (Nanodrop 
Technologies). Scanning spectrophotometry analysis is based on the observation that 
RNA has its maximum absorbance at 260nm, with pure RNA having a 260:280 ratio 
of 2.0-2.1. Hence low 260:280 and 260:230 absorbance ratios indicate the presence of 
impurities in the samples. The quantity and purity of all RNA samples used in 
miRNA microarrays was assessed by recording the absorbance at 260nm, the 260:280 
ratios, 260: 230 ratios, and the absorbance spectrum across the spectrophotometric 
range (220-350 nm). To assess the integrity of the RNA an RNA Nano 6000 kit was 
used, which runs on the Agilent 2100 bioanalyser. This technology is based on the 
movement of labelled-RNA at different speeds through micro-channels, depending on 
the size of the molecules. The bioanalyser software then automatically generates an 
RNA Integrity Number (RIN), a numerical assessment of RNA integrity, based on the 
electrophoretic profile of the sample i.e. degree of RNA degradation. A characteristic 
Agilent bioanalyser analysis of the RNA extracted from the liver samples here is 
shown in Figure 2.4.  
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Figure 2.4 Example of evaluation of sample RNA integrity 
 
Fig. 2.4 The integrity of RNA extracted from liver samples was evaluated using the 
Agilent 2100 bioanalyser and RNA Nano 6000 kit. In this figure an example is shown of the 
evaluation of an RNA sample by this method, with the automatically-generated high RIN 
value demonstrating the high integrity of the RNA sample.  
 
 
For miRNA profiling RNA samples were only used if they had an A260:280 ratio 
above 2.0 and an RIN larger than 7. 
 
2.3.3 RNA labelling, hybridisation, and scanning 
The miRNA hepatic expression was profiled using the Agilent miRNA microarray 
platform and the Agilent Rat miRNA microarray kit. This is a single-colour 
multiplexed microarray-platform with 8 identical microarrays printed on each slide. 
This microarray platform has been reported to produce accurate measurements 
spanning the range of 0.2amol to 2fmol of input RNA (Wang et al., 2007). The 
platform had also been used to profile tissue miRNAome in published studies 
previously  (Worley et al., 2008, Sato et al., 2009) The microarray comprises 350 in 
situ-synthesized rat miRNA 60mer oligonucleotides probes, based on the Sanger 
database v10.1 which contained all current identified rat miRNAs at January 2010. 
RIN=9.1 
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Also included on the microarrays were 23 QC and control probes. Each miRNA is 
represented by 2-4 probe sequences and 20-40 replicate features on each microarray.  
 
Samples were randomly assigned positions on the microarray slides to reduce non-
biological variation. For the 14 day PB dietary study (See chapter 4) RNA samples 
from three animals per day/dose group were examined. As there were 16 day/dose 
groups (e.g. Day 1 control, Day 1-treated with 50 ppm PB, Day 1-treated with 500 
ppm PB, and Day 1- treated with1000 ppm PB), RNA was profiled from 48 animals 
in total.  For the multicompound dietary study (See chapter 3) it was decided to focus 
on liver samples from animals treated with the tested compounds for 90 days rather 
than the two earlier timepoints. RNA was extracted and profiled for all 42 liver 
samples available from control and treated animals at 90 days (control n=5, DETU 
n=5, BP n=5, MON n=5, DEHP n=5, MP HCl n=5, 2-AAF n=5, Chl. Ac n=4, PB 
n=3). Also examined were six technical replicates (three control samples and three PB 
treated samples) for which RNA was re-extracted and processed together with the 
normal samples.  
 
RNA was labelled and hybridised using the miRNA complete labelling and 
hybridisation kit (Agilent). Total RNA (100ng) was single-colour labelled by 
enzymatic addition of Cyanine 3-pCp (Cy-3) at the 3’ end. Briefly, RNA was first 
dephosphorylated by incubating with calf intestinal phosphatase included in the kit for 
30 minutes at 37
o
C. The dephosphorylated RNA was denatured by addition of 100% 
DMSO and heating at 100
o
C for 10 minutes. The RNA was then transferred 
immediately to a water-ice bath to prevent reannealing. Ligation of Cy-3 to RNA was 
performed by incubating at 16
o
C for 2 hours with T4 RNA ligase that was included in 
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the kit. The RNA samples were then vacuum dried using a Speedvac (Savant). The 
dried and labelled RNA samples were reconstituted in hybridisation mix solutions 
(18μl labelled RNA, 22.5μl 2x hybridisation buffer, and 10x gene expression blocking 
agent; included in miRNA complete labelling and hybridisation kit and gene 
expression washing kits respectively), incubated at 100
o
C for five minutes, and placed 
immediately on ice. Hybridisation of the labelled RNA to the microarray slides 
occurred within the Agilent Microarray hybridisation kit (Agilent). Briefly, 
hybridisation solutions were loaded onto a gasket which was then overlaid with a 
microarray slide. The sandwiched slides were then clamped and placed in a 
hybridisation oven set at 55
o
C and 20 rpm for 20 hours.  After 20 hours of 
hybridisation the microarray slide was removed and washed with two washing buffers 
before being scanned using an Agilent scanner (G2505B) at the MRC microarray 
centre at Hammersmith Hospital. In Figure 2.5 a typical example of a scanned 
miRNA microarray image is shown.   
 
Figure 2.5 typical image of a microRNA microarray 
 
 
Data were extracted from the scanned microarray images using the Agilent Feature 
Extraction (FE) software v10.1. Also automatically generated by the Agilent FE 
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software is a number of quality control metrics that are useful for the evaluation of 
sample quality 
  
2.3.4 Pre-processing and normalisation of miRNA microarray data 
The expression value for each miRNA (the “gTotalGeneSignal”) was automatically 
generated by the Agilent FE software. This value is calculated as the sum of the signal 
of all features (spots) corresponding to a given miRNA on that microarray, after 
removal of outliers. Each miRNA is represented by 2-4 distinct probe sequences and 
20-40 replicate features on each microarray. The Agilent FE also automatically 
flagged miRNAs as being detected or not detected on each microarray. MiRNAs were 
determined as present if their signal magnitude was more than three times the signal 
error for any of its probes present on the microarrays. The miRNA signal threshold 
was set to 1 and then log2 transformed, which adjusts the variance so that it is the 
same for all intensities.  
 
Normalisation was performed to reduce non-biological variability (e.g. hybridisation 
efficiencies, washing etc.) and to allow between-array comparisons. The 
manufacturer’s advice is normalisation to the 75th percentile; i.e. for each microarray 
the value of the 75% percentile miRNA is subtracted from the value of each miRNA 
in that microarray. The use of the 75% percentile instead of the more normally used 
median normalisation is performed because a large fraction of miRNAs will not be 
detected in any given experiment. Two alternative methods to the normalisation to the 
75
th
 percentile were also considered (normalisation to the 90% percentile and 
normalisation to the 50% percentile after filtering of miRNAs which were flagged as 
absent). To test these alternative normalisation methods the coefficient of variation 
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was calculated across all samples from the 14 day PB study for four internal control 
spots (whose levels should be constant in the microarrays) which cover a range of 
intensity signals, for the three alternative normalisation methods. This analysis found 
the lowest coefficient of variation for all four control probes after normalisation to the 
75
th
 percentile, supporting that it is the most suitable normalisation for these samples 
(Figure 2.6)  
 
Figure 2.6 Comparison of normalisation methods of microRNA microarrays 
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Fig. 2.6 Coefficient of variation across all samples from 14 day PB study for four internal 
positive control spots present in the microarrays with three different normalisation methods. 
The Y-axis shows the coefficient of variation, while on the x-axis the names of the positive 
control probes are shown. 
 
 
Normalisation to the 75% percentile was performed in Genespring GX 10.0 (Agilent). 
Next, filtering of miRNAs with very low or undetected expression was required to 
reduce noise in the microarray data. Too stringent filtering could remove potentially 
interesting miRNAs from further analysis, while too relaxed filtering could result in 
high background noise in the data. Here it was decided to filter out from further 
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analysis all miRNAs which were not flagged as present in at least 50% of the samples 
in any one group. 
 
2.4 Polymerase chain reaction (PCR) 
2.4.1 Real-time Quantitative PCR (qPCR) 
 
In qPCR the generation and accumulation of PCR products occurs in real-time, with 
genes being quantified during the exponential phase of PCR, when the enzymatic 
process is first order and therefore at its most reliable and precise. To detect and 
quantify expression levels of selected miRNAs the widely used and reliable 
quantitative PCR (qPCR) pre-designed Taqman MicroRNA assays (Applied 
Biosystems) were used. This method relies on the use of stem-loop RT primers 
followed by Taqman PCR analysis (Chen et al., 2005). This methodology is specific 
for mature miRNAs (i.e. do not bind to pri-miRNA, pre-miRNA, or genomic DNA), 
can discriminate miRNAs that differ by a single base, and amplify them with high 
efficiencies. Taqman probes are oligonucleotides probes that anneal to sequences 
between the PCR primer sets. Attached to these probes are FAM dyes that only 
fluoresce- and hence can be measured- during PCR amplification, due to the 5’ 
nuclease activity of DNA polymerase; hence no signal is generated from non-specific 
PCR products.  
 
In the first step 10ng of total RNA was reverse transcribed using the reagents in the 
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). A MJ Research 
Peltier PTC-200 thermocycler (BioRad) was used to perform the reverse transcription. 
In the second step the generated cDNA was amplified using the Taqman MicroRNA 
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assays and the Taqman 2X Universal PCR master mix, No AmpErase UNG (Applied 
Biosystems). The PCR master mix also contained the passive reference dye ROX 
which was used to automatically correct for differences in reaction concentrations and 
volumes. The PCR was performed in 96-well plates in an ABI 7500 Fast Real-Time 
PCR machine (Applied Biosystems). The solutions were first heated at 95
o
C for 10 
minutes to activate the DNA polymerase. Then 40 cycles were performed of heating 
to 95
o
C for 15 seconds and 60
o
C for 1 minute. Each PCR reaction was performed in 
triplicate. Also included in triplicate in each run were no template control (i.e. PCR 
reactions in which DNA template is replaced with water) and no reverse transcription 
- controls (samples for which reverse transcription was performed in the absence of 
reverse transcriptase). PCR products in the no template control samples indicate the 
presence of nucleic acid contamination of the PCR reagents. PCR products in the no 
reverse transcriptase- samples indicate the amplification of genomic DNA instead of 
RNA.  
 
QPCR data were analysed in the ABI 7500 Sequence Detection System (Applied 
Biosystems). The comparative Ct Method (ΔΔCT Method) was used to quantify 
miRNA expression. Calibration was based on the expression of the 18s rRNA 
Taqman or snoRNA gene assay (Applied Biosystems). The 18S rRNA gene was 
reverse transcribed using the same reverse transcriptase used in the TaqMan 
MicroRNA Reverse Transcription Kit and random hexamers were used as primers. 
The snoRNA was processed with the same protocol as the miRNA assays. The 
baseline and threshold were manually chosen for each PCR plate run. Baseline was 
the initial phase of PCR reaction for which fluorescence is not detected. Threshold 
was a point above the baseline, but within the exponential phase of PCR 
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amplification. The threshold cycle (CT) was the fractional cycle number at which the 
fluorescence of a sample passed the set threshold value.  ΔCT for a miRNA was the 
difference in CT between the miRNA and the calibrator (in this case 18s rRNA).  
ΔΔCT was the difference in average value between the ΔCT of control and treated 
samples. The fold change in the expression of the examined miRNA between control 
and treated samples was 2
ΔΔCT
.  
 
2.4.2 Semi-quantitative PCR 
 
In traditional semi-quantitative PCR the process is performed for an appropriate 
number of cycles and then the PCR product is run and detected on an agarose gel. 
Semi-quantitative PCR offers a cheaper, but less precise method of quantifying 
changes in gene expression. A two-step RT-PCR protocol was used here to perform 
semi-quantitative PCR, with both reverse transcription and PCR performed with the 
MJ Research Peltier PTC-200 thermocycler. In the first step total RNA was reverse-
transcribed using M-MLV (Promega) reverse transcriptase to form cDNA. Two μg of 
total RNA was mixed with 0.5μg random hexamers (Qiagen) and heated at 70oC for 
five minutes to melt secondary structures and then placed immediately on ice. Next 
were added 200 units of M-MLV, 1.25μl of 10mM dNTP mixture (Invitrogen), 25 
units of RNase inhibitor (Applied Biosystems), 5μl of M-MLV reaction buffer,  and 
made up to 25μl with nuclease-free water. The mixture was heated at 370C for one 
hour and then to 75
o
C for 15 minutes to denature the enzyme.     
 
In the second step 1-2μl of the RT mix were amplified by PCR using the Tfi 
polymerase (Invitrogen) and custom PCR primers. First a 50μl mixture was made 
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containing 5x PCR reaction buffer, 200μM of each nucleotide, 1.5mM MgCl2, 0.2μm 
of each primer set, 1-2μl cDNA, and made up with nuclease-free water to 49μl. The 
solution was then heated at 94
o
C for two minutes. After the heating step 1μl of Tfi 
polymerase was added to the mixture. The late addition of the polymerase is termed 
“Hot start” PCR and it reduces the amplification of non-specific PCR products. Then 
30-35 cycles of PCR were performed at 94
o
C for 30 seconds, annealing temperature 
for 30 seconds, and extension for one minute. After the completion of the designated 
number of cycles the protocol was completed by ten minutes of extension at 70
o
C. 
The PCR primers used were either custom-designed using primer-Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) or were obtained from previously 
published papers (Table 2.1). 
 
Table 2.1 Primer sequences used for semi-quantitative PCR 
Primer Forward sequence 
(5’-3’) 
Reverse sequence 
(5’-3’) 
Annealing 
temperature 
Product 
size 
Reference 
cdh1 ACAGCAAGCATGCC
AGTGAA 
GCACCAACACACCCA
GCATA 
62
o 
C 326 bp Barth et al. 
2005 
cyp2b1/2 GGA GAG CGC TTT 
GAC TAC 
CTC GTG GAT AAC 
TGC ATC 
59
o 
C 514 bp Pustylnyak 
et. al. 2007 
gapdh CAT GGA CTG TGG 
TCA TGA G 
TTC AAC GGC ACA 
GTC AAG G 
59
o 
C 373 bp Pustylnyak 
et. al. 2007 
Primer A AGCGCCCCAAATCTC
CAGGATC 
AACACGGTCGTCACA
CCTGGTG 
55
0
C 249 bp Custom 
made 
Primer B ACCATCCCACCTCCC
TTTAAACCC 
TAGGCAGAGGTGGGT
TAGCACG 
55
o
C 260 bp Custom 
made 
 
PCR products were examined by electrophoresis through 1% agarose gels.  Gels were 
made by adding agarose powder to 1xTAE buffer (40mM Tris-acetate, 1mM EDTA), 
made up from 10x TAE stock (Sigma-Aldrich), and heating it to dissolve. Ethidium 
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bromide (0.5μg/ml) was added to the gels to allow visualisation of PCR products and 
the gels were then poured into agarose gel tanks and allowed to set.  A 20μl volume of 
PCR products was mixed with 5x loading buffer (Invitrogen) and loaded into the gel 
A DNA ladder (Sigma-Aldrich) was used to allow determination of the molecular 
sizes of the observed PCR products. Electrophoresis was setup at 100V for 30-60 
minutes and PCR products were visualised by exposure to UV light. Detected bands 
were quantified in the Aida image analyser v 3.52 (Raytest) and the expression of 
genes of interest were normalised to the expression of the gapdh gene. 
 
2.5 Immunoblotting 
2.5.1 Protein extraction from liver samples  
 
Protein was extracted from 50 mg of liver tissue. Livers were homogenised with a 
polytron machine in 500 μl of lysis buffer (50 mM Tris–HCl, pH 7.4; 1% IGEPAL 
(Sigma-Aldrich); 0.25% sodium deoxycholate (Sigma-Aldrich); 150 mM NaCl 
(Sigma-Aldrich); 1 mM EDTA (SIGMA-Aldrich); 100 X Halt Protease inhibitor 
(Pierce)).  Homogenisation was followed by sonication and incubation at 4 °C for 
30 min. The solutions were then centrifuged at maximum speed for 20 minutes to 
remove insoluble debris.  The protein extracts were quantified using the BCA 
(bicinchoninic acid) protein assay (Pierce).  This assay is based on the reduction of 
Cu
2+
 ions to Cu
1+
 by proteins. The BCA then reacts with the reduced Cu
1+
 ion to form 
a purple coloured complex. Absorbance at 562nm is proportional to the amount of 
protein present in the solution. 
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2.5.2 Protein detection and quantification 
Protein mixtures were separated according to size by electrophoresis through sodium 
dedocyl sulphate (SDS) 7.5-15% polyacrylamide gels at 100V for 1-2 hours. Equal 
amounts of protein (50μg), as determined by BCA quantification, were loaded into 
each lane mixed with 5x Laemmli loading buffer (Sigma-Aldrich) and made up to 2% 
SDS, 5% β-mercaptoethanol, 10% glycerol, 0.01% bromophenol blue, 60 mM Tris-Cl 
pH 6.8 equal volumes with water. Also loaded onto the gel was Novex Sharp pre-
stained protein standard (Invitrogen) to allow estimation of protein size. The proteins 
were then electrophoretically transferred from the gel onto a nitrocellulose membrane 
(400 Amps and 200V for 90 minutes) and the efficiency of the transfer was assessed 
by staining the membrane with Ponceau S (Sigma-Aldrich), a reversible non-specific 
protein stain. The nitrocellulose membrane was blocked for one hour at room 
temperature with 10% fat-free milk made up in PBS-Tween 0.1%  to reduce non-
specific binding and then incubated with the commercially available monoclonal 
primary antibodies, made up to the appropriate concentration in PBS-Tween 0.1%, 
overnight at 4
o
C. The next morning the blots were washed (PBS-Tween 0.1%) and 
incubated at room temperature for one hour with horseradish peroxidise (HRP)-
conjugated secondary antibodies which bound the primary antibody. The 
concentrations of antibodies used are shown in Table 2.2. 
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Table 2.2 Concentrations of primary/secondary antibodies used for immunoblotting 
Antibody Primary  Ab concentration Secondary Ab 
concentration 
Zeb1 (Santa Cruz) 1:200 1:2000 
Zeb2 (Santa Cruz) 1:200 1:2000 
β-actin (Sigma-
Aldrich) 
1:10000 1:10000 
 
After a final thorough washing of the membrane (with PBS-Tween 0.01%), bound 
antibodies were detected using SuperSignal West Dura Extended Duration 
Substrate (Pierce). Hyperfilm ECL (GE Healthcare) was overlaid for appropriate time 
over the blot and then exposed. Protein bands of the protein of interest were quantified 
in Aida image analyser v.3.52 and normalised to that of β-actin. 
 
2.6 Methylation analysis 
2.6.1 DNA extraction and quantification 
 
DNA was extracted from liver samples using the DNeasy Blood & Tissue kit 
(Qiagen) following the manufacturer’s protocol, and using the reagents and buffers 
included in the kit. Briefly, approximately 25mg of left lateral lobe liver tissue were 
lysed overnight using proteinase K at 56
o
C in ATL tissue lysis buffer. RNase A 
(Sigma-Aldrich) was added at 100mg/ml and left at room temperature for two minutes 
to digest RNAs present in the lysate. Equal amounts of buffer AW1 and ethanol (96-
100%) were added to the mix and vortexed. The mixture was centrifuged in mini-spin 
columns containing membranes which selectively bind DNA. The mini-spin column 
membrane was washed with buffer AW2 to remove contaminants and the sample 
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DNA was eluted from the membrane with water. Extracted DNA was quantified using 
the Nanodrop ND-1000 and used for subsequent experiments if its 260:280 ratio was 
higher than 1.6. 
 
2.6.2 Global DNA methylation analysis 
 
The levels of global DNA methylation for extracted DNA were determined using the 
Methylamp Global DNA Methylation Quantification Ultra Kit (Epigentek) following 
the manufacturer’s instructions. First 150ng of genomic DNA extracted from liver 
samples were immobilised onto a strip. The immobilised DNA was subsequently 
bound by an antibody that specifically recognises 5-methylcytosine, the methylated 
form of cytosine. This antibody includes a chromophore that has its maximum 
absorbance at 450nm, with the amount of methylated cytosine in the sample being 
proportional to the absorbance of the solution at that wavelength.  
 
2.7 RLM-RACE  
 
RNA ligase-mediated rapid amplification of 5´ cDNA ends (RLM-RACE) is a 
protocol that allows the identification of the 5’ end and the transcriptional start site 
(TSS) for genes which have part of their sequence known. In this method an oligo 
with a known sequence is attached to the 5’ end of the gene. Then PCR is performed 
using one primer that anneals to the attached oligo and a second primer that is 
designed to anneal to a known part of the gene that is downstream. The PCR product 
can then be sequenced to identify the 5’ end of the gene (Figure 2.7).  
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Figure 2.7 Overview of the methodology of Generacer kit 
 
Fig. 2.7 RNA from sample cell/tissue is reverse transcribed to form cDNA. RNA is 
enzymatically degraded and then the Generacer oligo is attached to the 5’ end of cDNAs. 
PCR amplification is performed using one primer specific for the Generacer primer and one 
primer that is specific for a region within the gene of interest. The PCR product is then 
purified and sequenced to identify the 5’ end of the cDNA. 
 
 
The Generacer kit (Invitrogen) was used here to perform RLM-RACE for miRNAs. 
Attachment of the Generacer RNA oligo to the 5’ end of the gene requires a prior 
modification of the RNA. First 5μg of total RNA was treated with calf intestinal 
phosphatase to remove 5’ terminal phosphate from non-capped RNAs and then 
treatment with tobacco acid pyrophosphatase removes the 5’-cap structure from 
capped RNAs. This allows the ligation of Generacer RNA oligo to the 5’ end of 
RNAs. The ligated RNA was then reverse transcribed using Superscript III reverse 
transcriptase using random hexamers as primers. Modified RNA was then amplified 
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using a Generacer RNA oligo-specific primer and a custom-primer. The whole 
protocol was also performed on RNA from Hela cells provided by manufacturer. The 
Beta-Actin  gene was then amplified as a positive control of the whole process. 
 
2.8 In silico analysis  
Genomic DNA sequences were obtained from the University of California Santa Cruz 
(UCSC) genome browser (Rhead et al., 2010) from the latest available rat genome 
assembly (Nov 2004 Baylor 3.4/rn4). The NUBISCAN (Podvinec et al., 2002) and 
the PROMO 3.0 software (Messeguer et al., 2002) was used to predict putative 
transcription factor binding sites within examined DNA sequences. The NUBISCAN 
software identifies nuclear receptor response elements in genomic sequences. The 
PROMO software uses known transcription factor binding sites deposited in 
TRANSFAC database to generate binding site weight matrixes. The CpG island 
searcher software (Takai & Jones, 2002) was used to scan selected genomic sequences 
for the presence of putative CpG islands. CpG islands were defined as those regions 
which were larger than 200 bases, with a greater than 55% percentage of cytosines 
and guanines, and a 0.65 ratio of observed to expected cytosine-guanine dimmers. The 
TargetScan v5.1 software (http://www.targetscan.org) was used to predict mRNA 
targets of specific miRNAs. TargetScan predicts targets by scanning for conserved 
7mer and 8mer sequences in the 3’ UTR of mRNAs that complement the seed region 
of miRNAs. The algorithm also allows for some mismatch of the seed region if extra 
binding exists at 3’ end of miRNA.  The IDs of predicted miRNA targets were 
uploaded to the PANTHER database (Mi et al., 2003, Thomas et al., 2006) and 
allocated to pathways. Comparisons of the distribution of the genes within the rat 
genome into pathways with the distribution of predicted targets of miRNAs allowed 
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the identification of enriched pathways. The FirstEF software was used to predict 
promoter regions (Davuluri et al., 2001) 
 
2.9 Clustering and classification of samples 
2.9.1 Hierarchical clustering 
 
Hierarchical clustering of the generated miRNA data was used to identify the 
treatments which had the most similar effects on the hepatic miRNA profiles at the 
tested times. Additionally this method allowed the identification of co-regulated 
miRNAs. Clustering of the miRNA data was performed in Gene Cluster 3.0 (Eisen et 
al., 1998) and the generated tree was viewed in Gene Treeview (Saldanha, 2004). 
Hierarchical clustering is unsupervised in that no information is supplied by the user 
besides the normalised expression data. The hierarchical clustering algorithm is 
termed “agglomerative” because it sequentially joins small clusters to bigger ones and 
“binary” due to the fact that it joins together two-clusters at a time. The hierarchical 
clustering algorithm initially considers each sample as an isolated cluster. The 
similarity between all clusters is then calculated using the chosen similarity metric 
(e.g. correlation centred correlation uncentred, Euclidian, etc.) and performing all 
possible pair-wise comparisons. The two most similar samples are then joined with 
the length of the branch proportional to their distance as calculated by the similarity 
metric (more similar samples are connected by shorter branches, less similar with 
longer branches). The two samples are then merged to a single cluster and the process 
is repeated until all samples are incorporated into the generated tree. To calculate the 
distance metric of clusters formed when two or more samples are joined together 
different options exist (simple linkage, complete linkage, average linkage, etc.). The 
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average linkage used here is the most robust to outliers. With this linkage the distance 
metric between two metrics is the average value of their members. The most 
commonly used distance metric is correlation. Correlation metrics group samples and 
genes together according to similar patterns of gene expression.  
 
2.9.2 Sample classification 
Prediction analysis of microarrays (PAM) is a class prediction tool that has been 
specifically developed for analysis of microarray data (Tibshirani et al., 2002). Given 
a predefined class it can identify the smallest group of genes that characterise that 
group of samples. The identification of this signature is achieved using the expression 
of genes and the nearest shrunken centroid method. This signature can subsequently 
be used to predict the class of new sets of samples, if there are any available.  PAM 
was performed as a function tool within the BRB Array tools v4.2 (BRB Array tools).  
 
 2.10 Statistical analysis 
Student’s t-test and ANOVA were used to test for significance of PCR, 
immunoblotting, and methylation data. One-way ANOVA with multiple testing 
correction were used to identify differentially expressed miRNAs after 90 days of 
chemical treatments. Parametric (Pearson’s) and non-parametric (Spearman’s) 
correlations analysis were performed in Graphpad Prism v5.0. Significance analysis 
of microarrays (SAM) (Tusher et al., 2001) was used to identify deregulated miRNAs 
from the 14 day PB dietary study. This statistical method was specifically developed 
for microarrays and determines which genes are statistically differentially expressed. 
This method has the advantage of being non-parametric and that it allows control over 
the false detection rate (FDR).   
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3.1. Introduction 
The Agilent miRNA microarray platform was used to profile the expression of 
miRNAs in control and treated animal’s livers generated by the Syngenta multiple 
compounds study (Dow, 2007b) as previously described (section 2.3) . Samples from 
animals treated for 90 days were chosen for microarray examination rather than 
earlier time-points, i.e. 28 or 7 days, as it was surmised that changes in miRNA 
expression relating to carcinogenesis would be more established at this later stage. 
Moreover, most acute toxicological responses irrelevant to carcinogenesis would have 
attenuated by that stage. The eight chemicals examined here represented a diversity of 
MOA, carcinogenic potentials, and effects on the liver: 
 
 2-AAF is an aromatic amide that is metabolised into electrophilic derivatives, 
which react with DNA. 2-AAF was the only confirmed GNTX compound 
included in this study. Besides being mutagenic 2-AAF is also a powerful 
complete carcinogen that can cause liver tumours by itself (Heflich & Neft, 
1994).   
 
 MP HCl is a NGTX hepatocarcinogen. The MOA of this compound is 
considered to be its cytotoxicity, coupled with increased hepatic cell 
proliferation (Lijinsky, 1984). 
 
 PB and BP are two “PB-type chemicals”, a structurally diverse family of 
chemicals characterised by their ability to pronouncedly induce cyp2b 
enzymes in the liver. Of the two chemicals only PB can cause hepatocellular 
adenomas in the male rat, even though both chemicals are mice 
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hepatocarcinogens (Whysner et al., 1996, Butler, 1978); (NTP TR-533, 2006). 
The MOA of PB hepatocarcinogenesis requires CAR activity, as the chemical 
does not cause tumours in CAR KO mice (Yamamoto et al., 2004). PB also 
acts as a strong promoter following initiation (Whysner et al., 1996).  
 
 DEHP is a phthalate widely used as a plasticiser. It is a rodent 
hepatocarcinogen and a peroxisome proliferator chemical (PPC) (NTP TR-
217, 1982). These structurally diverse chemicals (PPCs) are characterised by 
their induction of peroxisomal and fatty acid-oxidising enzymes, increase in 
both the size and number of peroxisomes, and hepatic hypertrophy and 
hyperplasia (Moody et al., 1991). DEHP brings about its PPC activities via its 
monoester metabolite mono-ethylhexyphthalate (MEHP) which activates 
PPARα (Lapinskas et al., 2005). DEHP does not have peroxisome 
proliferation effects in PPARα knockout mice (Ward et al., 1998), 
demonstrating the important role of the receptor in driving its liver effects.  
 
 Chl.Ac. and MON are two male rat NGTX hepatocarcinogens with unknown 
MOA. MON is a photosynthesis-inhibiting herbicide. It is weakly 
carcinogenic in male Fischer rats, but is not carcinogenic in mice or female 
Fischer rats (NTP TR-266, 1988). Chl.Ac. is a chlorinated hydrocarbon that is 
used for some chemical synthetic processes. It induces tumours in both mice 
and rats in oral studies (NTP TR-304, 1987).  
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 DETU is a NGTX compound which was chosen due to its lack of effects in 
the liver and because it is not hepatocarcinogenic in either mice or rat (NTP 
TR-149, 1979).  
 
The liver samples generated from this study therefore were a good starting point to 
examine the hypothesis that miRNAs are useful biomarkers of cancer-inducing 
chemicals. In total 48 samples were examined. Of these 42 were liver samples from 
the control and treated animals at 90 days. The other six samples examined were 
technical replicates- three control technical replicates (CTR) and three PB-treated 
technical replicates (PTR). 
 
Also available for these samples were data on the effects of each chemical on relevant 
parameters such as overall animal toxicity, liver size, hepatic proliferation, liver 
histopathology, etc. (Dow, 2007b), as well as transcriptomic profiling data (Richard 
A. Currie personal communication). These two datasets could then be compared to the 
generated hepatic miRNA profiles. 
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3.2. Effects of chemical treatments on animals 
Data relevant to liver carcinogenesis are presented in Tables 3.1-3.4 (Dow, 2007b).   
These data were not collected by myself and are shown here to facilitate the 
miRNA data obtained in my experiments. 
 
Table 3.1 Frequency of liver tumours in two-year bioassay in male Fischer rat 
 
Compound Dose (ppm) Number of neoplasias/carcinomas Reference 
DETU  250 0/50 (0%) (NTP TR-149, 
1979) 
BP 1250 0/50 (0%) (NTP TR-533, 
2006) 
MON 1500 9/50 (18%) (NTP TR-266, 
1988) 
DEHP 12000 12/49 (24%) (NTP TR-217, 
1982) 
PB 1000 11/33 (33%) (Butler, 1978) 
Chl.Ac. 1250 23/50 (46%) (NTP TR-304, 
1987) 
MP HCL 250 18/20 (90%) (Lijinsky, 1984) 
2-AAF 40 23/23 (100%) (Ogiso et al., 
1985) 
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Table 3.2 Liver weight adjusted to bodyweight for each treatment  
 
Compound Day 7 Day 28 Day 90 
CON 9.4 9.5 11.6 
DETU 10.3* 10.2 11.7 
BP 11.2* 9.5 14.7* 
MON 10.3* 10.7* 13.1* 
DEHP 14.6* 18.9* 19.9* 
PB 11.7* 13.7* 14.7* 
Chl.Ac. 8.7* 8.9 11.5 
MP HCL 9.5 9.7 11.9 
2-AAF 9.4 10.5* 12.2 
Values are the average ratio of liver weight to bodyweight; Analysis of covariance of 
organ weight to bodyweight * p<0.05 
 
Table 3.3 Percentage of Ki67-labelled hepatic cells for each treatment group  
 
Compound Day 7 Day 28 Day 90 
CON 5.68 2.47 0.81 
DETU 2.71* 1.69 2.71* 
BP 6.59 2.77 1.69* 
MON 5.68 2.49 2.24* 
DEHP 7.87 2.30 1.77* 
PB 6.32 3.26 2.23* 
Chl.Ac. 2.15* 3.95* 3.48* 
MP HCL 4.83 7.76* 7.66* 
2-AAF 5.37 3.32 4.94* 
ANOVA with double arcsine transformation * p<0.05 
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Table 3.4 Liver micropathology 
 
Treatment Hypertrophy Necrosis and/or 
apoptosis 
Vacuolation Biliary 
hyperplasia +/- 
inflammation 
DAY 7 28 90 7 28 90 7 28 90 7 28 90 
CON 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
DETU 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
BP 5/5 5/5 5/5 0/5 0/5 0/5 0/5 4/5 4/5 0/5 0/5 0/5 
MON 0/5 0/5 0/4 0/5 0/5 0/4 0/5 0/5 4/4 0/5 0/5 0/4 
DEHP 5/5 5/5 5/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
PB 5/5 5/5 4/4 0/5 0/5 0/4 0/5 4/5 4/4 0/5 0/5 0/4 
Chl. Ac. 0/5 0/5 0/4 0/5 0/5 0/4 0/5 0/5 0/4 0/5 0/5 0/4 
MP HCL 0/5 0/5 0/5 1/5 3/5 4/5 0/5 0/5 0/5 0/5 5/5 5/5 
2-AAF 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 5/5 5/5 
 
At the tested doses the chemicals causing the highest frequency of tumour formation 
in the two year bioassay were 2-AAF, MP HCl, and Chl. Ac. These were also the 
chemicals with the highest Ki67 LI at 90 days. Besides the induction of proliferation 
2-AAF, the most potent carcinogen of this study, also caused a transient increase in 
adjusted liver size at 28 days and biliary hyperplasia +/- inflammation at days 28 and 
90.   MP HCl caused the biggest increase in hepatic proliferation at days 28 and days 
90. It was also the only compound for which minimal necrosis/apoptosis were 
detected. These two observations are in accord with the MOA of MP HCL being 
hepatotoxicity followed by regenerative hyperplasia. MP HCL was also the only other 
compound besides 2-AAF to cause biliary hyperplasia +/- inflammation at days 28 
and 90. Chl. Ac caused a small transient decrease in liver weight at day 7. 
 
Chapter 3 
 - 110 - 
 
The nuclear receptor agonists PB, BP, and DEHP were the only ones to cause 
hypertrophy from day 7 onwards, centrilobular for the PB-type compounds and 
diffuse for the PPARα activator.  The three compounds also caused the biggest 
sustained increase in adjusted liver weight. DEHP caused the biggest increase (day 7- 
155%; day 28 198%; day 90 171%). PB and BP caused similar increases except for 
day 28 when no change was observed for BP-treated animals (Day 7- 124% and 
119%; day 28 144% and 100%; day 90 127% for both). These three compounds also 
caused minimal vacuolation from day 7 onwards. 
 
Besides the nuclear receptor activators, MON was the only compound to cause a 
sustained statistically significant increase in adjusted liver weight (110% day 7; 113% 
day 28; 113% day 90) and to cause minimal vacuolation on day 90. DETU had 
minimal effects on the liver, with a transient increase in liver weight being observed 
on day 7.  
 
3.3. Evaluation of quality and processing of microarray data  
3.3.1 PCA and Quality Control metrics of samples 
The first step after data extraction was to confirm that the biochemical and analytical 
manipulations had worked as expected and to identify any potential problematic 
samples. First a PCA was performed (Figure 3.1). Outlier samples can be indentified 
as those which are clearly separated from the other samples of their group. 
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Figure 3.1 PCA of pre-filtered normalised samples from 90 day dietary study 
 
 
Fig. 3.1 Each symbol represents an array, with its colour indicating the group to which it 
belongs and its shape indicating if the treatment is carcinogenic. The red circles highlight the 
four samples (DETU 5, DEHP 5, MON 4, and MP HCL 3) which are clearly outliers from 
their groups.   X-axis= principal component (PC) 1, Y-axis= PC2, Z-axis= PC3. 
 
The PCA analysis revealed four samples (DEHP 5, DETU 4, MON 4, and MP HCL 
3) as being clear outliers. Besides PCA an additional method to evaluate sample 
quality was based on the quality control (QC) metrics which were automatically 
generated for each sample by the Agilent FE software. These metrics were (1) 
“AnyColorPrcntFeatPopnOL”: this is the percentage of features on the array which 
are population outliers. A high value can indicate that regions on the array were 
problematic (2) “gTotalSignal75pctile”: the sum of the signal for all miRNAs at the 
75
th
 percentile. A very low value indicates that some part of the procedure was sub-
optimal resulting in low signal. A very high signal can indicate insufficient washing 
of the microarray (3) “AddErrorEstimateGreen” is an estimate of the total error on the 
microarray. Higher values indicate higher error on the arrays (4) 
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“gNonCtrlMedPrcntCVBGSubSig” which is the median covariance of inlier probes 
minus the background.  The values of these four QC metrics for each of the samples 
are tabulated in Table 3.5-3.6.       
 
Table 3.5 QC metrics for controls and non-carcinogen treated samples 
Sample Metric 1 Metric 2 Metric 3 Metric 4 
CON 1 2.4 22.4 3.3 43.8 
CON 2 4.4 30.4 3.2 37.4 
CON 3 2.1 39.5 3.5 6.7 
CON 4 2.9 49.4 3.9 6.9 
CON 5 3.2 42.7 3.1 6.1 
CTR 1 3.5 35.3 3.1 16.0 
CTR 2 2.2 37.2 2.9 6.7 
CTR 3 2.5 30.6 6.2 7.4 
BP 1 3.2 42.8 3.9 6.5 
BP 2 3.2 41.8 2.7 9.4 
BP 3 2.9 31.1 3.7 26.3 
BP 4 3.0 40.6 3.3 22.1 
BP 5 2.8 30.0 2.8 6.6 
DETU 1 2.4 42.0 3.0 7.1 
DETU 2 3.2 32.0 2.8 10.4 
DETU 3 6.4 37.3 4.6 7.1 
DETU 4 2.1 35.5 3.3 6.9 
DETU 5 2.7 1369.8 526.5 6.1 
Metric 1= AnyColorPrcntFeatPopnOL;    Metric 2= gTotalSignal75pctile 
Metric 3= AddErrorEstimateGreen;         Metric 4=gNonCtrlMedPrcntCVBGSubSig 
Marked in bold are outlier samples as identified by PCA. Coloured red are QC metric 
values that are outside normal range. 
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Table 3.6: QC metrics for carcinogen-treated samples 
Sample Metric 1 Metric 2 Metric 3 Metric 4 
2-AAF 1 3.9 40.7 3.3 7.1 
2-AAF 2 2.6 54.4 3.2 5.7 
2-AAF 3 3.3 38.0 3.0 25.8 
2-AAF 4 3.3 57.6 3.0 6.7 
2-AAF 5 2.6 29.4 4.1 6.7 
Chl. Ac. 1 2.0 51.1 3.8 6.2 
Chl. Ac. 2 3.1 44.3 2.6 6.6 
Chl. Ac. 3 2.7 45.0 3.0 6.7 
Chl. Ac. 4 3.0 49.8 3.3 11.3 
DEHP 1 3.0 41.4 3.0 5.3 
DEHP 2 2.8 32.8 4.2 6.2 
DEHP 3 2.6 45.5 3.2 9.0 
DEHP 4 2.2 40.0 3.4 8.6 
DEHP 5 5.0 9.3 5.0 90.5 
MON 1 2.8 59.6 3.3 7.1 
MON 2 4.0 44.3 3.1 6.3 
MON 3 5.9 21.4 4.4 19.2 
MON 4 2.5 4.9 3.9 9.1 
MON 5 4.0 38.9 2.7 9.3 
MP HCL 1 2.9 60.8 3.2 7.1 
MP HCL 2 3.6 32.9 3.4 48.0 
MP HCL 3 2.2 78.2 3.0 6.6 
MP HCL 4 3.5 62.6 3.2 8.4 
MP HCL 5 2.8 34.7 2.9 6.9 
PB 1 2.5 54.2 3.1 6.7 
PB 2 2.7 40.2 3.5 7.1 
PB 3 3.2 40.9 4.0 9.8 
PTR 1 3.7 33.1 3.4 16.6 
PTR 2 2.9 30.7 3.4 31.3 
PTR 3 2.5 49.6 3.3 7.5 
Metric 1= AnyColorPrcntFeatPopnOL;   Metric 2= gTotalSignal75pctile 
Metric 3= AddErrorEstimateGreen;         Metric 4= gNonCtrlMedPrcntCVBGSubSig 
Marked in bold are outlier samples as identified by PCA. Coloured red are QC metric values 
that are outside normal range 
 
Samples marked with bold in tables 3.1-3.2 are the four samples that were identified 
as outliers by PCA. Three of the four sample outliers identified by PCA had clearly 
unusual QC metrics. DETU 5 had a metric 2 value more than 20 times the next 
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sample, indicating that the sample was not washed sufficiently. Conversely, samples 
MON 4 and DEHP 5 had very low metric 2 values, indicating that for these samples 
RNA labelling or hybridisation failed. Based on the PCA and QC metric examination 
four samples (DETU 5, DEHP 5, MON 4, and MP HCL 3) were removed from 
further analysis as problematic outlier samples.  
 
3.3.2 Filtering of miRNA data  
The next step was to filter out miRNAs which were not expressed, or were expressed 
at very low levels in the samples. Of the 350 miRNAs represented in the microarrays 
192 were detected in at least one sample, 167 were detected in 50% of samples of 
control or any treatment, and 90 miRNAs were detected in all samples. The fact that 
so many of the miRNAs were not detected could be due to the fact that (a) the 
expression of many miRNAs is tissue-cell type dependent as well as varying 
according to developmental stage (b) The sensitivity of microarrays is lower than 
other techniques (e.g. PCR or deep-sequencing) so that miRNAs with very low 
expression may not be reliably detected. Further analysis was performed on the 167 
miRNAs that were detected in 50% of samples in any condition.  
 
Box plots allow a quick visual summarisation of median, distribution, and most 
extreme values of a given sample. Box plots for the normalised, filtered samples 
showed that the microarray samples had comparable distributions and intensities, 
supporting their reproducibility (Figure 3.2).  
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Figure 3.2 Box plots of normalised and filtered microarray samples 
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Fig. 3.2 Each box-plot on the x-axis represents a microarray sample. The lower end of the box 
is the 25
th
 percentile, while the highest end is the 75
th
 percentile. On the Y-axis is plotted the 
normalised log2 intensity from the microarrays. The black line in the middle of each box-plot 
is the median value for that sample. The open circle signifies the log2 value of the miRNA 
with the highest intensity in each sample. End of the whiskers contain 1.5 interquartile range. 
 
 
After filtering and normalisation the most widely expressed miRNAs in the untreated 
rat liver were determined. In Table 3.7 the twenty miRNAs with the highest 
expression in the control liver, as determined by microarrays, are shown.  
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Table 3.7: Top 20 abundantly expressed miRNAs in untreated rat liver 
miRNA Expression (Log2) Standard Deviation 
rno-miR-122 10.9 0.4 
rno-let-7f 7.3 0.4 
rno-miR-21 7.0 0.3 
rno-let-7a 6.9 0.4 
rno-miR-192 6.5 0.4 
rno-miR-29a 6.5 0.1 
rno-miR-22 6.5 0.2 
rno-miR-26a 6.3 0.1 
rno-let-7c 5.9 0.4 
rno-miR-26b 5.7 0.4 
rno-miR-23b 5.3 0.2 
rno-miR-125b-5p 5.3 0.4 
rno-miR-29c 5.1 0.2 
rno-let-7b 5.1 0.3 
rno-miR-126 5.0 0.2 
rno-miR-99a 5.0 0.1 
rno-miR-194 4.9 0.1 
rno-let-7d 4.9 0.3 
rno-miR-16 4.8 0.3 
- Expression shown is the average log2 hybridisation signal for the five control 
samples   
 
As can be seen there is a wide spread in the expressions of miRNAs. Especially high 
was the expression of miR-122 (~12 times higher than the next miRNA). The 
expression levels of all the 167 detected miRNAs can be seen in Appendix I. 
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3.3.3. Comparison of microarray technical replicates 
The process of miRNA profiling is a complicated protocol involving multiple intricate 
steps- labelling RNA, hybridising it onto arrays, washing and scanning the arrays, and 
finally normalising the extracted data. Each one of these steps can introduce error into 
the data. Moreover, the fact that for this study RNA was extracted from whole liver 
samples, a tissue composed of multiple cell types, added a further source of 
variability. Therefore, in order to assess the robustness of the acquired microarray 
data of this study, miRNA profiles were compared between two sets of technical 
replicates. For six liver samples RNA was extracted twice and the whole process of 
miRNA profiling was performed twice. Comparison of the miRNA profiles of these 
two sets of technical replicates would then allow an estimation of the total technical 
error in the microarray data. As can be seen the two sets of technical replicates 
showed high correlation (r=0.97 Pearson’s correlation), supporting the reproducibility 
of the miRNA data (Figure 3.3). A further observation was that technical variability 
started to increase for miRNAs with low intensity, corroborating the necessity of 
filtering out miRNAs with very low expression. 
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Figure 3.3 Comparison of technical replicates for microarrays. 
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Fig. 3.3 On each axis is plotted the mean log2 intensity of a given miRNA in one of the 
replicate sets. Each circle represents one of the 167 miRNAs detected in at least 50% of 
samples in any condition. On the top panel the technical replicates for the three control 
samples are compared and on the bottom panel the replicates for the three PB samples are 
compared.  
 
Evaluation of data quality performed here (PCA, quality control metrics, technical 
replicates) therefore supports the reliability and reproducibility of the acquired 
microarray data for 44/48 microarray samples. A few other observations also back this 
conclusion. First, the miRNA signals covered a wide range from negative to very high 
values. This observation shows that the microarrays had a large dynamic range. 
Second, the five positive control probes present in the arrays (hur 1,2,4,6 and mir-1) 
were detected on all arrays, while a number of negative controls were not detected in 
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any of the samples. Thirdly, the individual miRNAs that were flagged as being 
present or absent were consistent across the microarrays. Finally, for all samples the 
most abundant signal was miR-122, a hepatocyte-specific miRNA that makes up 70% 
of the liver miRNAome (Hou et al., 2011, Jopling et al., 2005).  
 
3.4 Deregulation of hepatic miRNAs by hepatocarcinogens 
3.4.1 MiRNA profiles are distinct for carcinogen-treated livers 
As a first step an unpaired t-test was performed to determine the hepatic miRNAs 
with statistically significant differential expression between animals treated with 
carcinogenic treatments (PB-DEHP-MON-MP HCL- Chl.Ac- and 2-AAF) and 
untreated animals at 90 days. Two miRNAs were identified as being statistically 
differentially expressed between the two groups, with the difference in expression 
being relatively modest in magnitude (Figure 3.4 and Table 3.8) 
 
Figure 3.4 Volcano plot of liver microRNAs  from carcinogen vs. untreated animals 
 
Fig. 3.4 Unpaired t-test was performed with Benjamin-Hochberg multiple testing. On 
Coloured red are miRNAs with p<0.05. On the Y-axis is plotted the corrected p value for each 
miRNA and on the x-axis the log2 fold change. 
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Table 3.8 Differentially expressed liver microRNA between carcinogen-treated and 
untreated animals 
 
miRNA Corrected p value Fold Change in carcinogen treated samples 
compared to untreated animals 
rno-miR-99a 0.002 -1.4 
rno-miR-429 0.03 2.1 
Unpaired T-Test with Benjamin-Hochberg multiple testing correction between 
untreated animals and animals exposed to carcinogenic treatments (2-AAF, MP HCL, 
Chl. Ac, PB, and DEHP) for 90 days. The miRNAs shown had corrected p<0.05 
 
Next the PAM class prediction software (Tibshirani et al., 2002)  was used to identify 
a signature entailing the smallest possible number of miRNAs that could predict 
whether a chemical treatment was hepatocarcinogenic (2-AAF, MP-HCl, Chl.Ac, PB, 
MON, or DEHP), or non-hepatocarcinogenic (DETU or BP), in this rat strain. Figure 
3.5 shows the misclassification error of the method as the number of miRNAs used 
for classification decreases. The success of the resultant miRNA classifier for each 
liver sample can be seen in Table 3.9. 
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Figure 3.5 PAM misclassification with decreasing  number of microRNAs 
 
 
 
 
Fig. 3.5 PAM analysis was performed within BRB-array tools software. Y-axis is the 
misclassification error; on the x-axis is the number of miRNAs used (a) Total 
misclassification error (b) Misclassification error for a sample as carcinogen (True) or non-
carcinogen (False) separately. The threshold was automatically set as 0.94. 
 
(b) 
(a) 
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Table 3.9: Performance of PAM classifier during cross-validation 
Sample  Classified correctly  Classified incorrectly  
DETU 5/5 samples 0/5 samples 
BP 3/5 samples 2/5 samples 
PB 1/3 samples 2/3 samples 
DEHP 4/4 samples 0/4 samples 
MON 4/4 samples 0/4 samples 
Chl. Ac 4/4 samples 0/4 samples 
MP HCL 5/5 samples 0/5 samples 
2-AAF 4/5 samples 1/5 samples 
Number of examined liver samples that were correctly or incorrectly classified as 
being exposed to hepatocarcinogenic treatment using PAM derived miRNA signature 
  
 
For 85% of the samples the PAM classifier correctly predicted whether the liver was 
treated with a carcinogen. Two out of the three PB-treated samples was falsely 
classified as non-carcinogenic, while two out of five BP-treated samples were falsely 
classified as carcinogenic. The miRNA profiles could therefore correctly identify 2-
AAF, MP HCL, Chl. Ac, MON, DEHP, and DETU. BP and PB are harder to 
discriminate due to their similar miRNA profiles. All the other carcinogenic 
treatments were correctly classified. The classifier consisted of 33 miRNAs, as shown 
in Table 3.10.  
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Table 3.10 PAM identified microRNA signature 
 
 Array id  Class label  Prediction  Prediction 
Correct?  
1  DETU1  False  False  YES  
2  DETU2  False  False  YES  
3  DETU3  False  False  YES  
4  DETU4  False  False  YES  
5  BP1  False  False  YES  
6  BP2  False  False  YES  
7  BP3  False  True  NO  
8  BP4  False  False  YES  
9  BP5  False  True  NO  
10  PB1  True  False  NO  
11  PB2  True  False  NO  
12  PB3  True  True  YES  
13  DEHP1  True  True  YES  
14  DEHP2  True  True  YES  
15  DEHP3  True  True  YES  
16  DEHP4  True  True  YES  
17  MON1  True  True  YES  
18  MON2  True  True  YES  
19  MON3  True  True  YES  
20  MON4  True  True  YES  
21  Chl Ac1  True  True  YES  
22  Chl Ac2  True  True  YES  
23  Chl Ac3  True  True  YES  
24  Chl Ac4  True  True  YES  
25  MP HCL1  True  True  YES  
26  MP HCL2  True  True  YES  
27  MP HCL3  True  True  YES  
28  MP HCL4  True  True  YES  
29  2-AAF1  True  True  YES  
30  2-AAF2  True  True  YES  
31  2-AAF3  True  True  YES  
32  2-AAF4  True  True  YES  
33  2-AAF5  True  False  NO  
 
-threshold for PAM equal to 0.94
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Previously, studies have reported that preneoplastic biochemical/morphological 
changes induced in the liver following chemical treatment can be early markers of 
carcinogenicity (Elcombe et al., 2002, Allen et al., 2004, Cohen, 2010).  These 
markers were increased relative liver weight, liver hypertrophy, and hepatic labelling 
index (LI). Importantly, for some of the chemicals examined here, their miRNA 
profiles were better at predicting carcinogenicity than the biochemical/morphological 
changes that they induced. MON and Chl.Ac are particularly hard to identify as 
carcinogens using biochemical/morphological changes. MON only caused an 
equivocal increase in relative liver weight as defined by Elcombe et al. 2002, whilst 
Chl. Ac only an increase in LI at 90 days. Hence their miRNA profiles could be a 
better marker of their eventual carcinogenicity in the rat. 
 
3.4.2 Identification of possible miRNA biomarkers of carcinogenicity 
MiRNA biomarkers of carcinogenicity are those whose expression is a good early 
indicator of the carcinogenicity of a chemical. Direct comparison of carcinogenic 
treatments Vs non-carcinogenic treatments overlooks the fact that the effects of 
carcinogens on liver miRNAs may be specific to a given MOA. Therefore, as an 
alternative method miRNA biomarkers of carcinogenicity were identified here as 
those which display a significant change in their expression from untreated animals by 
two or more carcinogens, in the same direction (i.e. induction or repression) for each 
treatment. One-way ANOVA was used to identify differentially expressed miRNAs. 
Coupled with the Benjamini-Hochberg multiple testing correction 70 of 167 miRNAs 
as being differentially expressed at p<0.05. This statistical test identifies a high 
proportion of miRNAs as being differentially expressed at 90 days (~40%). These 
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differentiated miRNAs can be seen in Appendix II. In order to generate a more 
manageable list one-way ANOVA was performed coupled with Bonferonni-Holm 
multiple testing correction, which is a more stringent statistical test. This test 
identified 21miRNAs as being significantly deregulated at 90 days (Table 3.11)  
 
Table 3.11: Differentially expressed microRNAs after 90 days of chemical treatment 
 
 
microRNA 
 
Corrected 
p.value 
 
DETU 
 
BP     
 
PB 
 
DEHP 
 
MON 
 
Chl. Ac 
 
MP 
HCL 
 
2-AAF 
miR-34a >0.01 -1.1 -1.3 1 -1.2 3.9 2.3 1.7 27.9 
miR-96 >0.01 1.3 2 3.6 1.6 1.6 -1.5 1 -1.3 
miR-221 >0.01 -1.5 -1.8 -1.1 3 -1.2 1.5 1 -1.1 
miR-200a >0.01 -1.2 2 3.7 1.7 1.1 2 1.7 2 
miR-107 >0.01 -1.1 1.1 -1.1 2.0 1 1.1 -1.2 -1.3 
miR-200b >0.01 -1 2.5 4.5 2.0 1.2 2.3 1.6 2 
miR-429 >0.01 -1.1 2.4 3.8 1.9 1.2 2.3 1.8 2.7 
miR-182 >0.01 2.4 4.3 6.3 3.1 3.3 1.1 1.3 1.4 
miR-375 >0.01 -2 -2.3 -2 1.8 2.2 1.7 -2.1 -1.5 
miR-193 >0.01 -1.3 -1.1 1.2 -1.7 -2.4 -4.9 -1.9 -1.3 
miR-17 >0.01 -1.1 1.1 -1.1 1.1 1 -1.6 -1.2 -1.2 
miR-497 >0.01 1 -1.1 -1.1 -1.2 -1.3 -1.7 -1.3 -1 
miR-203 0.01 -1.2 -1.1 -1.4 -1.4 -1.2 -2 -1.2 -1.6 
miR-31 0.01 1.1 1.1 -1 1.3 -1 1.3 -1.4 -1.5 
miR-29a 0.01 -1.1 -1 1.1 1.3 1 -1.2 -1.2 -1.2 
miR-29c 0.01 -1.1 1 1.2 1.3 -1 -1.3 -1.2 -1.2 
miR-99a 0.02 -1 -1.3 -1.3 -1.3 -1.5 -1.3 -1.5 -1.6 
miR-20a 0.03 -1 1 -1.1 1.1 -1 -1.6 -1.2 -1.3 
miR-139-5p 0.03 1.3 -1.1 1.1 1.3 1.3 3.2 1.3 -1.3 
miR-28 0.04 1.1 1 1.1 -1.1 1 1.4 1 -1.3 
miR-505 0.05 -1.1 1.1 1.5 1.5 1.1 2.8 1.2 -1.6 
 
Differentially regulated miRNAs were identified using one-way ANOVA with 
Bonferonni-Holm multiple testing correction and p<0.05 
 
Values shown are average absolute fold change from control in that treatment 
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The altered miRNAs included both downregulated and upregulated ones, indicating 
that both forms of deregulation can occur. In terms of magnitude, most altered 
miRNAs were changed between 1.5 to 5 fold from control, which is similar level to 
the changes observed between HCC and benign liver tissue (Jiang et al., 2008). The 
miRNAs deregulated in each treatment compared to control at 90 days can be seen in 
Table 3.12.  
 
Table 3.12 MicroRNAs differentially expressed from control for each chemical 
treatment at 90 days 
Compound miRNAs  significantly changed from control 
DETU None 
BP mir-200b(↑) +miR-200a(↑)+ miR-429 (↑) + miR-182(↑↑) + miR-96 (↑) + 
mir-221 (down)  
PB mir-200b(↑↑)+miR-200a(↑) + miR-429 (↑)  + miR-182(↑↑) + miR-96 (↑)  
DEHP miR-200b (↑)+ miR-200a + miR-429 + miR-182(↑)+ miR-96 +          
mir-221(↑) + miR-107(↑) + miR-29a 
MON miR-182(↑) + miR-96 + miR-34a(↑) +miR-193(↓) + miR-99a 
 
Chl. Ac 
miR-200b(↑) + miR-200a(↑) + miR-429(↑) + miR-34a(↑) + miR-203(↓) 
+ miR-193(↓↓) + miR-505(↑)+ miR-139-5p(↑) +  miR-17 + miR-20a +  
miR-96 (down) + miR-28 + miR-497 
MP HCL miR-200a + miR-99a + miR-34a 
 
2-AAF 
mir-200b(↑) + miR-200a(↑) + miR-429 (↑) + miR-34a(↑↑↑) + miR-203  
+ miR-99a  
MiRNAs were identified as differentially expressed using one-way ANOVA with 
Bonferonni-Holm multiple test correction and Tukey HSD post test p<0.05 
 
Underlined are miRNAs that fulfil biomarker criteria 
↑Upregulated >2-fold; ↑↑↑ Upregulated > 10-fold ↓ Downregulated >2-fold; ↓↓ 
Downregulated >4-fold ; Coloured are miRNAs that belong to same family 
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It is important to note that all carcinogens tested here resulted in altered miRNA 
expression at 90 days, long before the appearance of liver tumours. Moreover, 
there is a small set of miRNAs that are frequently affected by carcinogens, even 
though they have distinct MOA. Nine miRNAs fulfil the requirements set for 
biomarkers as defined previously (Table 3.13) 
 
Table 3.13 Set of potential biomarker microRNAs 
 
miRNA Locus in rat DNA strand Intragenic or intergenic 
miR-200a/200b/429 Chr. 5 (q36) - Intergenic 
miR-96/182 Chr. 4 (q22) - Intergenic 
miR-34a Chr. 5 (q36) + Intergenic 
miR-99a Chr. 11 (q11)  + Intergenic 
miR-203 Chr. 6 (q32) + Intergenic 
miR-193 Chr. 10 (q25) + Intergenic 
 
Large fractions (30-40%) of miRNAs are found within protein-coding genes and are 
transcribed together with their host genes (Chuang & Jones, 2007). Interestingly, all 
of the identified biomarker miRNAs were intergenic, being transcribed from 
independent promoters, suggesting that these miRNAs are more receptive to chemical 
treatments. Of the 9 identified miRNAs five belonged into one of two separate 
clusters (Figure 3.6) 
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Figure 3.6 Chromosomal organisation of the miR-200a/200b/429 and miR-
96/182/183 microRNAs in the rat. 
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MiR-200a, miR-200b and miR-429 are clustered together and transcribed from the 
same promoter as part of one long pre-miRNA (Gregory et al., 2008a, Burk et al., 
2008). In rats this cluster is located on chromosome 5. The miR-200a/200b/429 
cluster was induced at 90 days by 5/6 carcinogens, as well as non-carcinogenic BP. 
Similarly, miR-182 and miR-96 are transcribed from a common promoter together 
with another miRNA, miR-183 (Xu et al., 2007). The expression of miR-183 was too 
low to pass the filtering criteria (i.e. be detected in at least 50% of samples in any 
group), so was filtered out from further analysis. MiR-96 and miR-182 are located on 
rat chromosome 4 and were induced by three carcinogens, as well as the non-
carcinogenic BP. It is expected that the expressions of the miRNAs belonging to the 
same clusters (i.e. miR-200a with miR-200b/miR-429; and miR-96 with miR-182) 
should be correlated across treatments. Indeed, that was what was observed. The 
highly correlated expression of the clustered miRNAs suggests that their induction 
following chemical treatment is the result of altered transcriptional regulation of their 
promoter (Fig. 3.7).  
Chapter 3 
 - 129 - 
 
Figure 3.7 Correlated expression of clustered microRNAs miR-200a/200b/429 and 
miR-96/182 
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Fig. 3.7  Pearson’s correlation was used for calculation of correlation strength. Values plotted 
are log2 intensities. Each circle is the averaged expression of the miRNA in one treatment 
group. 
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The sensitivity and specificity of expressional changes of the identified miRNA 
biomarkers for chemical hepatocarcinogens are shown in Table 3.14 below.  
 
Table 3.14 Sensitivity and specificity of “biomarker” microRNAs 
miRNA Sensitivity Specificity 
miR-200a/200b/429 5/6 (83%) 1/2 (50%) 
miR-96/182 4/6 (67%) 1/2 (50%) 
miR-34a 4/6 (67%) 0/2 (0%) 
miR-99a 3/6 (50%) 0/2 (0%) 
miR-203 2/6 (33%) 0/2 (0%) 
miR-193 2/6 (33%) 0/2 (0%) 
Sensitivity= Percentage of carcinogenic-treatments in which the miRNA was 
deregulated from control by one-way ANOVA and Dunnett’s post-test 
Specificity= Percentage of non-carcinogenic treatments in which miRNA was 
deregulated from control by one-way ANOVA and Dunnett’s post-test 
 
The highest sensitivity was observed for the miR-200a/200b/429 cluster which was 
induced by 5/6 carcinogenic treatments (exception was MON). Among other miRNAs 
identified as commonly deregulated by carcinogen treatment, induction of miR-34a 
was observed specifically for 4/6 tested carcinogens. Significant downregulation of 
miR-99a was observed only for three carcinogens, while miR-203 and miR-193 were 
significantly deregulated by two carcinogenic treatments and were unaffected by the 
non-carcinogens. Importantly, all of the indentified miRNAs have been previously 
reported as being deregulated in various types of cancer, including HCC (Table 3.15).  
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Table 3.15 Reported deregulation of identified microRNA biomarkers in cancers 
miRNA Compound Cancers in which the miRNA 
is deregulated 
Known target genes 
 
miR-200a 
PB, BP, DEHP,    
2-AAF, Chl.Ac, 
MP HCL  
HCC (Murakami et al., 2006) 
breast (Shimono et al., 2009), 
ovarian (Bendoraite et al., 2010) 
b-catenin (Xia et al., 2010); 
Zeb1 and Zeb2 (Gregory et 
al., 2008a); Fog2 (Hyun et 
al., 2009)   
 
 
miR-200b 
 
PB, BP, DEHP, 
2-AAF, Chl.Ac 
HCC (Gramantieri et al., 2007) , 
breast (Shimono et al., 2009) , 
ovarian (Bendoraite et al., 2010) 
Zeb1 and Zeb2 (Gregory et 
al., 2008a); Fog2 (Hyun et 
al., 2009) 
 
miR-429 
PB, BP, DEHP, 
2-AAF, Chl.Ac 
Breast (Shimono et al., 2009), 
ovarian (Bendoraite et al., 2010) 
Zeb1 and Zeb2 (Gregory et 
al., 2008a); Fog2 (Hyun et 
al., 2009) 
 
miR-96 
PB, BP, DEHP, 
MON, Chl.Ac. 
(down) 
HCC (Pineau et al., 2010); 
breast (Shimono et al., 2009) 
Endometrial   
FOXO1 (Myatt et al., 2010) 
miR-182 PB, BP, DEHP, 
MON 
breast (Shimono et al., 2009) 
Endometrial (Myatt et al., 2010) 
FOXO1 (Myatt et al., 2010) 
miR-34a 2-AAF, MP 
HCL, MON, 
Chl.Ac. 
Neuroblastoma (Welch et al., 
2007) (Welsch et al 2007); 
Colon  (Tazawa et al., 2007); 
HCC (Pineau et al., 2010) 
- SIRT1, NOTCH1, 
E2F3, MET, Bcl-2 
(Chang et al., 2007) 
 miR-99a 2-AAF, MP 
HCL, MON 
HCC (Hou et al., 2011) Children 
Adenocarcinoma (Doghman et 
al., 2010); 
- IGF-IR 
- mTOR (Doghman et 
al., 2010); 
miR-203 2-AAF & 
Chl.Ac  
HCC  (Furuta et al., 2010); 
Ovarian (Iorio et al., 2007) 
- ABCE1 
- CDK6 (Furuta et al., 
2010) 
miR-193 Chl.Ac. & 
MON 
Oral cancer (Kozaki et al., 
2008); Squamous cell carcinoma 
(Dry et al., 2011) 
- E2F6 
 (Kozaki et al., 2008) 
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The literature was then scrutinised to determine whether these 10 miRNAs have been 
reported to be deregulated in the liver after sub-chronic chemical treatments. Indeed, 
other studies have reported changes in some of these miRNAs after sub-chronic 
chemical treatments. For example miR-34a and miR-203 have also been reported to 
be deregulated in rodent livers treated with Wy-14,643 and tamoxifen (Table 3.16). 
 
Table 3.16 Reported hepatocarcinogenic treatments affecting identified biomarker 
microRNAs 
 
Reference Treatment GNTX? Animal miRNAs affected 
Shah et al., 
2007 
 
0.1 %Wy,14,643 two 
weeks 
 
NO 
 
mice 
miR-34a; miR-203; miR-
99a; miR-182 
Pogribny et 
al., 2007 
420 ppm Tamoxifen 24 
weeks 
 
YES 
Female 
F344 
miR-34a; miR-193; miR-
203 
 
 
Pogribny et 
al., 2009 
 
 
0.02% 2-AAF 12 and 24 
weeks 
 
 
YES 
 
Male 
Sprague-
Dawley 
miR-34a at 12 and 24 
weeks;         miR-
200a/200b/429 
(progressive increase from 
12 to 24 weeks); 
miR-99a , miR-182, and 
miR-96 (at 24 weeks) 
 
Wang et al., 
2009 
choline-deficient and 
amino acid–defined 
(CDAA) diet 6,18,32, 
and 65 weeks 
 
NO 
 
C57BL/6 
mice 
 
miR-200b 
 
Li et al., 
2010b 
N-ethyl-N-nitrosourea 
(ENU) 
120 mg/Kg for 
1,7,15,30, and 120 days 
 
YES 
Big-blue 
female 
mice 
 
miR-34a from day 1 
onwards 
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3.4.3 MiRNA profiles are associated with the MOA of chemicals 
It has been reported that the mRNA profile of livers reflects the MOA of chemicals 
with which they are treated (Ellinger-Ziegelbauer et al., 2008, Nie et al., 2006). 
Clustering analysis could clarify whether the same is true for miRNA hepatic profiles 
as well. The clustering tree was constructed using the 21 miRNAs identified as 
differentially regulated. For easier interpretation of the resulting tree the miRNA 
expression was averaged for the samples in each group of treatments. Besides the 
information regarding the grouping of chemical treatments, the clustering analysis 
also allowed the identification of miRNAs which undergo coordinated regulation 
(Figure 3.8).  
Figure 3.8 Clustering analysis of control and treated liver samples at 90 days 
 
Fig. 3.8 The tree was constructed using Average linkage with correlation uncentred as the 
similarity metric using the 21 deregulated miRNAs (Table 3.11). MiRNAs were median 
centred and normalised in Cluster 3.0. Red colour indicates higher expression than the 
median; the green colour indicated lower expression, and the black colour similar expression. 
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Importantly, the clustering of the samples based on the differentially expressed 
miRNAs appears to follow a logical order. DETU, the chemical with the least effects 
on the liver, associated with the control animals. In a second node the two PB-type 
compounds, PB and BP, clustered together. On a third node the three most potent 
carcinogens (2-AAF, MP HCL, and Chl.Ac) were also clustered together. Therefore, 
the clustering analysis performed here indicates that liver miRNAs profiles 
reflect the MOA of a chemical.   
 
Clustering of miRNAs demonstrated that several of them exhibited correlated changes 
in expression as a result of the chemical treatments. MiRNA members of the miR-
200a/200b/429 and miR-96/182 clusters, which were shown previously to be highly 
correlated (Figure 3.7), grouped together. MiR-17 and miR-20a which are part of the 
miR-17-92 oncogenic cluster also showed very high correlation (r=0.98, Pearson’s 
correlation). Grouped together were miRNAs miR-29c and miR-29a which belong to 
the same family but are found in different chromosomes (r=0.95 Pearson’s 
correlation).  
 
3.4.4 Comparison of chemical effects on mRNAs and miRNAs 
Deregulated mRNAs for the same liver samples at 90 days were previously identified 
(Richard Currie, personal communication). The number of deregulated mRNAs and 
miRNAs per treatment at 90 days were compared to determine how the two profiles 
relate to each other (Figure 3.9). 
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Figure 3.9 Comparison of chemical effects on mRNAs and miRNAs after 90 days of 
treatment 
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Fig. 3.9 Deregulated mRNAs were identified as those with p<0.05 (t-test from control) and 
more than 1.5-fold change from control. Deregulate miRNAs were those with p<0.05 by one-
way ANOVA with Benjamini-Hochberg and Dunnett’s HSD post-test. Correlation shown is 
Spearman’s correlation. 
 
For both mRNAs and miRNAs the chemical with the least effects on their expression 
at 90 days compared to control was DETU. The biggest divergence between the two 
datasets could be seen for DEHP (which had a much more pronounced effects relative 
to the other compounds on mRNAs compared to miRNAs) and Chl. Ac (with a much 
more pronounced effect relative to other compounds on miRNAs than mRNAs). The 
correlation between the two categories of genes was significant with Spearman’s 
correlation.  
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3.4.5 Correlation of “biomarker” miRNAs with hepatic parameters 
The correlation between the expression of the identified “biomarker” miRNAs and 
selected hepatic parameters was then examined (Table 3.17).  
 
Table 3.17 Correlation of biomarker miRNAs with hepatic parameters 
 
Correlation value shown is for the average expression of each miRNA in control and treated 
samples as determined by miRNA microarrays with the average frequency of liver tumours, 
adjusted liver weight, and Ki67 LI for the same liver samples (Table 3.1-3.3). Correlation 
used was Pearson’s correlation. * p<0.05 correlation was significant 
 
A significant correlation was only observed between the expression of miR-34a and 
miR-99a with the frequency of liver tumours.  MiR-34a and miR-99a also showed the 
strongest correlation with the Ki67 LI even though it was not significant. MiR-96 and 
miR-182 showed the strongest correlation with adjusted body weight. 
 
microRNA % liver tumours Adjusted liver weight Ki67 LI 
miR-200a r=0.41 r=0.29 r=0.03 
miR-200b r=0.25 r=0.38 r=0.18 
miR-429 r=0.47 r=0.29 r=0.21 
miR-96 r=-0.43 r=0.54 r=-0.42 
miR-182 r=-0.38 r=0.58 r=-0.39 
miR-193 r=-0.25 r=0.18 r=-0.30 
miR-203 r=-0.51 r=-0.06 r=-027 
miR-99a r=-0.74 * p<0.05 r=-0.17 r=-0.60 
miR-34a r=0.71 * p<0.05 r=-0.34 r=0.45 
Chapter 3 
 - 137 - 
 
3.5 Chemical-specific miRNA profiles 
3.5.1 PB-type compounds have characteristic miRNA profiles 
This was the first study to examine the effect of PB-like compounds on the liver 
miRNAome. The main effect of both compounds at 90 days was the induction of two 
miRNA clusters, the miR-200a/200b/429 (Figure 3.10) and miR-182/96 (Figure 
3.11).  
 
Figure 3.10 Effects of chemical treatments on the expression of miR-200a/200b/429             
at 90 days 
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Fig. 3.10 On the Y-axis is displayed the averaged hybridisation signal normalised to control 
for each of the three miRNAs. On the x-axis are plotted the eight chemical treatments. Error 
bars are the S.D. and * signifies statistically significant expression as determined by one-way 
ANOVA with Tukey HSD test and corrected p<0.05. 
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Figure 3.11 Effects of chemical treatments on the expression of miR-96/182 at 90 
days 
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Fig. 3.11 On the Y-axis is displayed the averaged hybridisation signal normalised to control 
for the two miRNAs. On the x-axis are plotted the eight chemical treatments. Error bars are 
the S.D. and * signifies statistically significant expression as determined by one-way ANOVA 
with Tukey HSD test and corrected p<0.05. 
 
Both of these clusters were induced by other compounds as well, although PB had the 
biggest effect. The level of expression of these five miRNAs were also compared for 
the six PB and the six control technical replicates In support of the veracity of the 
induction of these two clusters, the expressions of these miRNAs were very similar 
between the technical replicates (Figure 3.12). 
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Figure 3.12 Expression of selected microRNAs in two sets of technical replicates 
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Fig. 3.12 .Y-axis is the normalised log2 hybridisation intensity, n=3 for each group. Error 
bars are S.D.  
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3.5.2. Effects of genotoxic 2-AAF on microRNAs 
A previously reported study looked at the effect of 2-AAF treatment on liver miRNAs 
(Pogribny et al 2009). 2-AAF was the only compound used in the present study for 
which published data existed on its effects on the liver miRNAome. Albeit the 
Pogribny et al study used a lower dose of 2-AAF (20 vs. 40 ppm in the present study) 
and was performed in a different rat strain (Sprague Dawley vs. Fischer). An 
additional source of variability between this study and the (Pogribny et al., 2009a) 
study was the use of different microarray platforms (Agilent Vs. mirVana miRNA 
Bioarrays (Ambion)). Nevertheless, for both studies the main effect of 2-AAF was the 
induction of miR-34a and the miR-200b/200a/429 cluster (Table 3.18).  
 
Table 3.18 Comparison of reported effects of 2-AAF on liver microRNAs 
 
miRNA Pogribny et al 2009 This study 
miR-34a 3.0 27.9 
miR-200a 2.8 2.0 
miR-200b 2.7 2.0 
miR-429 2.0 2.7 
Values are average fold change from control at 12 weeks (Pogribny et al 2009) and 90 
days (this study) as determined using microarrays. N=4 for Pogribny et al 2009 and 
n=5 for this study. 
 
The main effect of GNTX 2-AAF treatment on hepatic miRNA expression that 
differentiated it from the NGTX carcinogens was the much more pronounced 
induction of miR-34a (Figure 3.13). 
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Figure 3.13 Effects of chemical treatments on the expression of miR-34a at 90 days 
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Fig. 3.13 Values are average fold change in expression from control as determined by 
microarrays. * Statistically significant one-way ANOVA Tukey HSD test p<0.05. 
n=3-5 animals per group. Error bars are S.D. 
 
On the other hand 2-AAF resulted in some similar deregulations of miRNAs as 
NGTX carcinogens such as the induction of the miR-200a/200b/429 cluster (Figure 
3.10) and the downregulation of miR-99a and miR-203 (Figure 3.14). 
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Figure 3.14 Effects of chemical treatments on the expression of miR-99a and miR-203 
at 90 days 
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Fig. 3.14 Y-axis is fold change from control as determined by microarrays, bars are S.D. * 
significantly different one-way ANOVA Tukey HSD test p<0.05. n=3-5 animals per group. 
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3.5.3 DEHP shows some similarities to PB-type compounds 
 
The effect of a PPC, Wy-14,643, on hepatic miRNAs has been examined and reported 
(Shah et al., 2007).  Their study showed that Wy-14,643 treatment, just like DEHP 
(another PPC) here, causes deregulation of miRNA expression. When comparing the 
results of the Wy-14,643 study with the DEHP data generated here it is important to 
note that, besides the difference in chemicals, they were performed in different 
species and for different durations. Nevertheless, two miRNAs that were deregulated 
in both studies were miR-182 and miR-107 (for miR-182 18.2-fold for Shah et al. 
2007 vs. 3.1 for this study; for miR-107 2.3 Vs 2.0). Induction of miR-107 was 
similar for both compounds, but miR-182 was much more pronounced for the Wy-
14,643 study.  
 
One important difference between the effects of Wy-14,643 and DEHP was the lack 
of repression of let-7c by DEHP. The downregulation of let-7c by Wy-14,643 was 
observed from 4 hours through to two weeks, and up to 11 months when liver tumours 
are prominent.  
 
Another interesting observation was a high correlation between two miRNA clusters 
miR-200a/200b/429 with miR-182/96 specifically for the livers treated with DEHP, 
BP, and PB (Figure 3.15).  
 
 
 
 
Chapter 3 
 - 144 - 
 
Figure 3.15 Correlation of miR-200b and miR-96 at 90 days. 
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Fig. 3.15 (a) the correlation of the two miRNAs across all 90 day treatments can be seen (b) 
the correlation of the two miRNAs in PB, BP, and DEHP samples only can be seen. Pearson’s 
correlation is used 
 
This high correlation between the two miRNA clusters for DEHP, BP, and PB 
suggests that these two clusters are very likely under common regulation after 
treatment with these three compounds. It is important to note that DEHP also activates 
the CAR receptor (Ren et al., 2010, Eveillard et al., 2009a, Eveillard et al., 2009b). 
Therefore, it is possible that a common CAR-dependent factor is involved in the 
correlated induction of these two miRNA clusters by DEHP, BP, and PB. 
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3.5.4. MiRNA profiles of MP HCL, MON, and Chl.Ac. 
MP HCl had unexpectedly few effects on the liver miRNAs, given its carcinogenic 
potency (90% liver tumour formation (Lijinsky, 1984). The three miRNAs with 
significantly altered expression due to MP HCl treatment were changed less than 2-
fold from control. These miRNAs were miR-99a, miR-34a, and miR-200a; all three 
are potential biomarkers of carcinogenicity. MON and Chl.Ac were the two 
carcinogenic chemicals used in this study which had an unknown MOA. Both 
treatments caused downregulation of miR-193 (Figure 3.16) as well as other of the 
biomarker miRNAs.   
 
Figure 3.16 Effects of chemical treatments on the expression of miR-193 at 90 days 
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Fig. 3.16 Y-axis is fold change from control, bars are S.E. * significantly different from 
control one-way ANOVA with Tukey HSD p<0.05. n=3-5 animals per group. 
 
MON induced the miR-96/182 cluster, miR-34a, and miR-99a. Chl.Ac induced miR-
200a/200b/429, miR-34a, and repressed miR-203. Chl.Ac also had several chemical-
specific effects on miRNAs (e.g. miR-497, miR-505, and miR-139-3p). 
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3.6 qPCR validation of miRNA changes 
The change in expression for miR-200b was also quantified in samples from the 90 
day dietary study by qPCR and supported the veracity of the 90 day study microarray 
data (Figure 3.17). 
 
Figure 3.17 Correlation of microRNA fold changes calculated by qPCR and 
microarrays.          
 
0 1 2 3 4 5
0
1
2
3
4
5
25 26 27 28 29 30
25
30
35
40
miR-96-BP
miR-96-PB
miR-96-DEHP
miR-96-MON
miR-203-Chl Ac
miR-203-2-AAF
miR-34a-MON
miR-34a-MP HCL
miR-34a- Chl Ac
miR-34a- 2-AAFr=0.99 p<0.001
Fold change from control (microarrays)
F
o
ld
 c
h
a
n
g
e
 f
ro
m
 c
o
n
tr
o
l(
q
P
C
R
)
 
Fig. 3.17 The same liver samples were examined by qPCR and microarrays; n=3-5 animals 
per group.  On the Y-axis the mean fold change for a miRNA calculated by the ΔΔCT method 
is shown. On the x-axis the fold change as calculated from the hybridisation data. The 
correlation shown is Pearson’s correlation. 
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3.7 Discussion  
 
MiRNA expression profiles were determined for the liver samples from the Syngenta 
multiple compound study using the Agilent miRNA microarray platform. A number 
of observations concurred on the reliability and reproducibility of the generated 
microarray data (e.g. reproducibility of the technical replicates). MiRNA profiling 
using microarrays has become more reliable and reproducible in recent years as the 
involved technologies have been further developed and optimised. Nevertheless, the 
confirmation of miRNA deregulations detected by microarrays is still a required step. 
Microarrays and qPCR rely on alternative methodologies to quantify gene expression 
(Hybridisation of extracted RNA onto predesigned probes vs. PCR amplification of 
specific sequences respectively).  Therefore, qPCR is often used as an independent 
method of validating the gene deregulations identified by microarrays. The 
quantifications of selected miRNAs by qPCR performed here were in agreement with 
the microarray data. These data hence were a further confirmation that the observed 
changes in the expression of miRNAs were real events.  
 
A first conclusion from this study was that all the carcinogens tested affected hepatic 
miRNAs at 90 days. Other studies have previously reported perturbation in liver 
miRNA profiles after sub-chronic treatment with chemical carcinogens (e.g. 
(Pogribny et al., 2007, Shah et al., 2007, Pogribny et al., 2009a)). However this study 
(a) examined a wider variety of chemicals with both known and unknown MOA (b) 
also examined chemicals which were less powerful carcinogens (PB, DEHP, and 
MON), while previous studies focused on highly potent carcinogens. Therefore, this 
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study has verified that alterations in the expression of hepatic miRNAs from the early 
stages of tumourgenesis are a common effect of chemical carcinogens. 
 
A second key finding was that the miRNA profile of a given compound can give 
insights into its MOA. This was most clearly demonstrated by the two PB-type 
compounds, PB and BP. These two structurally diverse chemicals resulted in a 
characteristic “miRNA signature”. Hence chemicals of this class of compounds 
appear to have distinguishing miRNA profiles.  
 
Interestingly, the miRNA profile of 2-AAF suggested that besides its genotoxic 
activities it also potentially has epigenetic activities as well. Even though DNA 
damage and adduct formation is an important step in 2-AAF induced carcinogenicity, 
evidence suggests the requirement of subsequent epigenetic events to drive tumour 
formation following initiation (Williams et al., 2000, Williams et al., 1998). For 
example two chemicals closely related to 2-AAF, 2-acetylaminophenanthrene and 
trans-4-acetylaminostilbene, have similar genotoxic potencies but are unable to cause 
tumours without the action of a promoter such as PB (Bitsch et al., 1993). This fact 
suggests that 2-AAF has properties similar to promoters. The similarities of the 
miRNA profile of 2-AAF to that of NGTX carcinogens used in the present study 
supports the epigenetic MOA of this chemical. 
 
Additionally, the miRNA profile of DEHP shows some differences to that reported for 
Wy-14,643 and similarities to that of the PB-type compounds. Both Wy-14,643 and 
DEHP are PPC and activators of PPARα. However, unlike Wy-14,643 treatment in 
mice, DEHP did not downregulate let-7c in rats. Importantly, repression of let-7c by 
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Wy-14,643 was PPARa dependent as it did not occur in PPARα-null mice (Shah et 
al., 2007).  One difference between the two chemicals is that Wy-14,643 is a much 
more potent carcinogen, resulting in 100% hepatic tumours at a dose of 0.1%.  Since 
let-7c is a suppressor of hepatic proliferation (Shah et al., 2007), increased hepatic 
proliferation induced by let-7c repression may be part of the reason why Wy-14,643 is 
a much more potent rat hepatocarcinogen than DEHP. 
 
Recent studies have demonstrated that besides activating PPARα, DEHP can also 
induce activity of the CAR receptor (Ren et al., 2010, Eveillard et al., 2009a, 
Eveillard et al., 2009b). Nevertheless, transcriptomic analysis has shown that most 
genes affected by DEHP in the mouse liver are PPARα-dependent (94%), with only a 
small group regulated via CAR instead (Ren et al., 2010). Until recently it was 
considered that the carcinogenicity of DEHP is wholly dependent on PPARα activity 
(Klaunig et al., 2003). Unlike Wy-14,643 though, DEHP can also induce low levels of 
tumours in PPARα-null mice (Ito et al., 2007). This has led to suggestions that DEHP 
can cause tumour formation through different pathways compared to Wy-14,643 
(Guyton et al., 2009). The precise nature of the MOA of phthalates is an important 
factor in the risk assessment of these common environmental contaminants. The 
highly correlated effect of PB, BP, and DEHP on the miR-200a/200b/429 and miR-
96/182 clusters adds further support to the DEHP-mediated activation of CAR. It 
seems a possibility that miRNAs regulated by DEHP via CAR may be an alternative 
method by which phthalates may drive carcinogenesis in PPARα-null mice. 
 
A final key finding was the identification of a set of potential miRNA biomarkers of 
carcinogenesis. In order for any identified miRNA signatures to be useful, they must 
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possess both high sensitivities (ability to detect carcinogens) and specificities (ability 
to discriminate carcinogens from non-carcinogens). Indeed, for the chemical 
treatments examined in this study, candidate miRNA signatures did show good 
specificities and sensitivities (Section 3.4). It is important to note however that a 
relatively small set of chemicals –six carcinogens and two non-carcinogens- were 
examined in this study. The determination of the specificity of the identified miRNA 
signatures was particularly worrisome, due to the fact that only two non-carcinogens 
were available for this study. Whilst the set of chemicals that were tested here were 
deliberately chosen to represent diverse MOA, the calculated sensitivities and 
specificities determined in this study must be confirmed in a larger study.  
 
It is noteworthy that not included in this list are miRNAs which have been previously 
strongly associated with HCC (such as miR-122, miR-21, let-7a, miR-221, and 17-92 
cluster). For example the hepatocyte specific miRNA miR-122 is downregulated in 
50-70% of HCC (Gramantieri et al., 2007, Kutay et al., 2006, Hou et al., 2011), while 
miR-21 is frequently upregulated in HCC and is a regulator of PTEN (Meng et al., 
2007).  
 
Since carcinogenesis is a multistep process one possibility is that changes in the 
expression of these miRNAs do not occur until the later stages of tumour formation. 
Indeed, evidence supporting the gradual deregulation of miRNAs has been collected 
from rodent models of carcinogenesis. Unlike in humans were examination can occur 
only after the appearance of disease, in rodents the livers can be examined from the 
earliest stages of carcinogenesis. Kutay et al. 2006 examined male Fischer rat fed a 
folic acid, methionine and choline-deficient diet FMD. These animals develop 
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preneoplastic nodules at 36 weeks and tumours at 54 weeks. Downregulation of miR-
122 was observed in the tumours of these animals at 54 weeks, but not in the 
preneoplastic tissue. Wang et al 2009 studied mice fed CDAA diet for 6, 18, 32, and 
65 weeks. By 65 weeks mice livers will show signs of steatosis and preneoplastic 
nodules, while tumours appear at 85 weeks.  MiR-122 levels were not altered in the 
livers of these mice until 65 weeks of treatment. Thus miRNAs that have been 
found to be deregulated in HCC may not be useful for predicting carcinogenicity 
of chemicals following short-term exposures. 
 
In conclusion the study here has allowed a more thorough examination of the 
hypothesis that miRNAs can contribute to toxicological assessments than has been 
previously possible. Overall, the findings of this study support the potential usefulness 
of miRNAs as biomarkers of hepatocarcinogenicity. It has been shown that by 90 
days all carcinogens affect expression of hepatic miRNAs. Additionally, it seems 
possible that information regarding the MOA of carcinogens can be extracted from 
their miRNA profiles. Finally a set of frequently deregulated miRNAs has been 
identified which could potentially assist toxicological assessments. 
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profiling of rats treated with 
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4.1 Introduction 
The doses used for the PB dietary study (Dow, 2007a) were chosen from the 
literature, based on their reported short-term and long-term effects on the liver. 
(Kolaja et al., 1996) examined the effect of treatment with 10, 50, 100, and 500 ppm 
PB on male B6C3F1 mice and male F344 rats over 90 days. In the rat only the 100 
and the 500 ppm doses caused an increased liver weight and DNA synthesis. 
(Hagiwara et al., 1999) tested the administration of 8, 30, 125, and 500 ppm PB in a 
two year animal bioassay of male Fischer rats. None of the doses caused adenomas or 
carcinomas of the liver, with only the 125 and 500 ppm doses causing liver 
enlargement and appearance of GST-P
+
 foci. Uniquely for the 500 ppm dose, nodules 
of regenerative hyperplasia were detected.  (Butler, 1978) tested a 1000 ppm dose in a 
two-year bioassay on male Fischer rats. It was found that 11 out of 33 animals 
surviving to that point had developed adenomas. The reported data therefore support a 
threshold in the ability of PB doses to induce hepatic tumours in the two-year 
bioassay with the male Fischer rat, as well as for the induction of hyperplasia and 
hepatomegaly. Research on PB promotion also supports the presence of thresholds for 
tumour promotion following initiation, although at lower levels. Following DEN 
initiation, 300 and 1200 ppm PB could promote liver cancers in male Fischer rats, but 
not 75 ppm or lower doses of PB (Maekawa et al., 1992). 
 
For the conducted animal study, nine-week old male Fischer rats were treated with 50, 
500 and 1000 ppm doses of PB through their diet. By 14 days the transient induction 
of hepatocyte proliferation and the maximum increase in liver weight will have 
occurred (Kolaja et al., 1996). Hence, the tested doses included one dose which has 
been reported to be hepatocarcinogenic in two-year bioassay (1000 ppm), one dose 
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which is non-hepatocarcinogenic, but is mitogenic and causes liver enlargement (500 
ppm), and one dose which is not hepatocarcinogenic and does not affect liver weight 
or cell proliferation (50 ppm). Throughout the conduction of the animal study 
parameters such as overt toxicity, P450 activity, liver weight, cytotoxicity, 
hypertrophy, hepatic cell proliferation, and apoptosis were measured in order to 
confirm that the PB doses caused the expected changes on the liver.  
 
Transcriptomic and metabonomic studies on the livers of this animal study have been 
already published (Waterman et al., 2010). Here the hepatic miRNA profiles of 
control and PB-treated animals were determined at 1, 3, 7, and 14 days using three 
animals per group, by the same methodology as that used in chapter 3. It is well 
known that miRNAs regulate cell proliferation and apoptosis.  
 
The aims of this study were:  (1) to examine whether changes in miRNA expression 
are involved in PB-induced proliferation (2) determine whether the carcinogenic PB 
dose had different effects on the hepatic miRNAome from these early stages than the 
non-carcinogenic PB dose.   
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4.2 Effects of chemical treatments on animals 
The effects of the three PB doses on the whole animal and in the liver in particular 
over the 14 days of the study have been reported previously (Waterman et al., 2010; 
Dow, 2007a). The data shown in tables 4.1-4.5 summarise the previously 
published findings with these rat samples. These data were not collected by 
myself and are shown here to facilitate the interpretation of the miRNA data 
obtained in my experiments. 
 
Table 4.1 Microsomal PROD activity 
 Control(n=5) 50 ppm(n=5) 500 ppm (n=5) 1000 ppm (n=5) 
Day 1 4.45±0.30 7.33±1.48** 179.72** 193.33** 
Day 3 2.88±0.82 100.24±30.69** 569.07±97.83** 753.99±157.45** 
Day 7 3.42±0.33 192.52±56.85** 1370.84±359.09** 1757.24±243.79** 
Day 14 4.70±2.37 210.58±16.29** 861.36±140.50** 958.37±148.91** 
PROD activity (pmol/min/mg protein); Error shown is SD; p<0.01 
 
Table 4.2 Effect of phenobarbital on relative liver weight 
 Control(n=5) 50 ppm(n=5) 500 ppm (n=5) 1000 ppm (n=5) 
Day 1 4.6±0.2 4.7±0.1 4.9±0.1** 4.6±0.1 
Day 3 4.7±0.3 5.0±0.2 5.2±0.3* 5.6±0.2** 
Day 7 4.3±0.1 4.7±0.1** 5.4±0.2** 5.7±0.1** 
Day 14 4.2±0.2 4.4±0.2 5.4±0.2** 5.7±0.2** 
Liver to bodyweight ratio (%); Error shown is SD; * p<0.05 ** p<0.01 
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Table 4.3 Incidence of centrilobular hypertrophy 
 Control(n=5) 50 ppm(n=5) 500 ppm (n=5) 1000 ppm (n=5) 
Day 1 0 0 3 1 
Day 3 0 1 3 4 
Day 7 0 3 4 5 
Day 14 0 3 5 5 
Animals displaying centrilobular hypertrophy (%); Error shown is SD 
 
Table 4.4 Ki67 hepatic labelling index  
 Control(n=5) 50 ppm(n=5) 500 ppm (n=5) 1000 ppm (n=5) 
Day 1 6.77 ±2.55 8.63 ±2.55 7.94 ±2.41 9.88 ±2.87 
Day 3 6.92 ±0.73 6.14 ±0.74 9.65 ±0.58
** 
11.13 ±1.73
** 
Day 7 5.08 ±0.33 4.32 ±1.12 4.63 ±1.13 4.35 ±1.21 
Day 14 2.03 ±1.04 1.10 ±0.26 1.38 ±0.49 1.83 ±0.63 
Percentage of nuclei staining positive for Ki67; Error shown is SD ** p<0.01 
 
Table 4.5 Incidence of apoptotic bodies  
 Control(n=5) 50 ppm(n=5) 500 ppm (n=5) 1000 ppm (n=5) 
Day 1 0.05±0.04 0.06±0.03 0.06±0.06 0.05±0.05 
Day 3 0.06±0.04 0.03±0.03 0.07±0.04 0.04±0.03 
Day 7 0.05±0.06 0.06±0.07 0.05±0.03 0.03±0.03 
Day 14 0.08±0.06 0.07±0.07 0.11±0.04 0.08±0.10 
Number of apoptotic bodies/mm
2
; Error shown is SD 
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CYP2B1 is the main enzyme that mediates the dealkylation of 7-pentoxyresorufin 
(PROD) into resorufin, a process that can be measured fluorometrically. CYP2B1 is 
the major cyp enzyme induced by PB via CAR activation. The microsomal PROD 
levels (Table 4.1) hence support a consistent moderate induction of CYP2B1/2 by the 
50 ppm dose and a much more pronounced induction by the 500 and the 1000 ppm 
doses. The adjusted liver weights of animals were consistently increased by the 500 
and the 1000 ppm doses (Table 4.2). The maximum weight was reached by 7 or 14 
days. Centrilobular hypertrophy was detected in the liver samples microscopically. By 
the 14
th
 day all animals treated with 500 and 1000 ppm PB displayed centrilobular 
hypertrophy, as well as 3/5 treated with 50 ppm PB. Ki67 hepatic labelling index (LI) 
showed a transient statistically significant increase in the livers of animals at 3 days 
(increase 1.4-fold in rats treated with 500 ppm and 1.6-fold for animals treated with 
1000 ppm). By the 7
th
 day the Ki67 Li returned to normal. The terminal 
deoxynucleotidyl transferase mediated dUTP nick end labelling (TUNEL) method 
was used to stain apoptotic cells. The incidence of apoptotic bodies per unit area was 
unaffected across the study.  
 
The above data collected and reported by others (Waterman et al., 2010) and 
Syngenta project report, personal communication) demonstrate that overall, the effects 
of PB on the liver during this 14 day period were as expected i.e. induction of 
CYP2B, transient induction of proliferation, and sustained increase in liver size. 
Based on this information, the liver samples harvested in the study were used for my 
experiments. Microarrays were used to profile liver samples of controls and animals 
treated with three PB doses after 1, 3, 7, and 14 days. 
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4.3. Quality control of microarray data 
The quality control metrics of the microarray samples were examined, as described in 
chapter 3, in order to evaluate the quality of the microarray samples (Tables 4.6-4.9). 
 
Table 4.6 quality control metrics of day 1 microarray samples 
Sample Metric 1 Metric 2 Metric 3 Metric 4 
CONTROL- 1 4.7 0.5 13.1 5.3 
CONTROL- 2 5.0 0.0 8.9 6.8 
CONTROL- 3 8.6 0.0 11.6 9.5 
50 ppm- 1 3.3 4.2 8.8 6.2 
50 ppm- 2 5.7 2.1 12.2 6.8 
50 ppm- 3 4.2 2.1 10.9 7.2 
500 ppm- 1 2.0 2.4 7.5 6.1 
500 ppm- 2 1.9 1.1 9.3 6.6 
500 ppm- 3 2.7 0.0 10.3 7.1 
1000 ppm- 1 3.9 1.2 11.8 6.4 
1000 ppm- 2 5.2 3.8 10.8 6.7 
1000 ppm- 3 4.8 1.0 8.9 27.6 
 
Metric 1= AnyColorPrcntFeatPopnOL;     Metric 2= gTotalSignal75pctile 
Metric 3= AddErrorEstimateGreen;          Metric 4= gNonCtrlMedPrcntCVBGSubSig 
(See Section 3.3.1 for explanation of the metrics)  
Samples refer to individual animals and values are arbitrary units
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Table 4.7 quality control metrics of day 3 microarray samples 
Sample Metric 1 Metric 2 Metric 3 Metric 4 
CONTROL- 1         3.33 4.37 12.61 7.40 
CONTROL- 2 4.06 2.98 9.49 7.17 
CONTROL- 3 2.88 1.27 8.01 5.19 
50 ppm- 1 3.65 5.20 11.57 7.72 
50 ppm- 2 3.46 2.33 10.00 7.54 
50 ppm- 3 4.72 2.25 13.23 6.25 
500 ppm- 1 6.25 6.80 11.50 17.35 
500 ppm- 2 5.73 3.84 9.43 7.39 
500 ppm- 3 3.08 4.16 9.67 5.64 
1000 ppm- 1 3.07 2.49 6.53 6.47 
1000 ppm- 2 2.45 4.33 8.62 6.86 
1000 ppm- 3 3.53 3.59 11.45 6.35 
 
Metric 1= AnyColorPrcntFeatPopnOL;     Metric 2= gTotalSignal75pctile 
Metric 3= AddErrorEstimateGreen;          Metric 4= gNonCtrlMedPrcntCVBGSubSig 
(See Section 3.3.1 for explanation of the metrics)  
Samples refer to individual animals and values are arbitrary units
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Table 4.8 quality control metrics of day 7 microarray samples 
Sample Metric 1 Metric 2 Metric 3 Metric 4 
CONTROL- 1 3.07 0.34 9.33 6.03 
CONTROL- 2 3.43 7.11 10.40 6.26 
CONTROL- 3 1.84 5.10 7.11 5.87 
50 ppm- 1 2.65 3.70 9.33 6.80 
50 ppm- 2 4.17 1.25 9.82 5.95 
50 ppm- 3 4.60 1.42 9.76 5.82 
500 ppm- 1 6.39 11.45 15.83 10.55 
500 ppm- 2 2.90 2.98 9.18 7.00 
500 ppm- 3 3.51 0.13 7.51 31.53 
1000 ppm- 1 3.55 1.35 7.91 44.06 
1000 ppm- 2 4.72 3.15 9.78 6.03 
1000 ppm- 3 5.72 1.78 16.59 6.88 
 
Metric 1= AnyColorPrcntFeatPopnOL;     Metric 2= gTotalSignal75pctile 
Metric 3= AddErrorEstimateGreen;          Metric 4= gNonCtrlMedPrcntCVBGSubSig 
(See Section 3.3.1 for explanation of the metrics)  
Samples refer to individual animals and values are arbitrary units
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Table 4.9 quality control metrics of day 14 microarray 
Sample Metric 1 Metric 2 Metric 3 Metric 4 
CONTROL- 1 3.33 2.98 7.14 6.66 
CONTROL- 2 2.40 2.68 14.66 6.55 
CONTROL- 3 1.77 3.37 7.42 6.02 
50 ppm- 1 3.61 4.51 10.06 6.08 
50 ppm- 2 1.42 0.00 12.32 6.46 
50 ppm- 3 8.00 3.35 13.89 8.23 
500 ppm- 1 4.31 0.00 10.21 9.08 
500 ppm- 2 5.17 3.13 10.59 5.80 
500 ppm- 3 1.35 5.66 8.28 5.87 
1000 ppm- 1 3.53 2.76 10.81 6.11 
1000 ppm- 2 4.24 0.40 8.03 6.35 
1000 ppm- 3 1.58 1.89 10.11 5.26 
Metric 1= AnyColorPrcntFeatPopnOL;     Metric 2= gTotalSignal75pctile 
Metric 3= AddErrorEstimateGreen;          Metric 4= gNonCtrlMedPrcntCVBGSubSig 
(See Section 3.3.1 for explanation of the metrics); Samples refer to individual animals and 
values are arbitrary units 
 
As can be seen the values of the four metrics were consistent for the 48 microarray 
samples, with no obvious sample outliers. Another observation was the much lower 
values of metric 2, the gTotalgenesignal75pctilem, in these microarray samples 
compared to that for the samples from the multicompound study of chapter 3. This 
fact indicates that the hybridisation signal was generally lower for this set of 
microarrays. In accordance to this, 95 miRNAs were detected in the 14 day study 
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compared to 167 miRNAs in the 90 day multicompound study, using the same 
filtering criteria. The 72 miRNAs not detected in the present 14 day PB study were 
those with the lowest expression which were detected in the 90 day multicompound 
study. Consequently, some miRNAs which were found to be significant in the 90 day 
study were not detected in the 14 day study e.g. miR-182, miR-429, miR-203, etc. 
The difference between the hybridisation intensity of the two microarray studies was 
probably the result of variability in the efficiencies of hybridisation, ligation etc. 
 
Boxplots were plotted for the 12 samples at each of the four timepoints after 
normalisation and filtration of the miRNAs that were not detected. The boxplots 
showed that the distribution of miRNAs were comparable for all the microarray 
samples of a given day (Figure 4.1). 
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Figure 4.1 Boxplots for normalised, filtered microarray samples for 14 day 
phenobarbital study 
N
o
rm
a
lis
e
d
 L
o
g
2
 in
te
n
si
ty
Control 1000 ppm 50 ppm 500 ppm
N
o
rm
a
lis
e
d
 L
o
g
2
 in
te
n
si
ty
DAY 1
N
o
rm
a
lis
e
d
 L
o
g
2
 in
te
n
si
ty
Control 1000 ppm 50 ppm 500 ppm
N
o
rm
a
lis
e
d
 L
o
g
2
 in
te
n
si
ty
DAY 3
N
o
rm
a
li
s
e
d
 L
o
g
2
 i
n
te
n
s
it
y
Control 1000 ppm 50 ppm 500 ppm
N
o
rm
a
li
s
e
d
 L
o
g
2
 i
n
te
n
s
it
y
DAY 7
N
o
rm
a
li
s
e
d
 L
o
g
2
 i
n
te
n
s
it
y
Control 1000 ppm 50 ppm 500 ppm
DAY 14
N
o
rm
a
li
s
e
d
 L
o
g
2
 in
te
n
s
it
y
N
o
rm
a
li
s
e
d
 L
o
g
2
 in
te
n
s
it
y
N
o
rm
a
li
s
e
d
 L
o
g
2
 in
te
n
s
it
y
N
o
rm
a
li
s
e
d
 L
o
g
2
 in
te
n
s
it
y
N
o
rm
a
lis
e
d
 L
o
g
2
 in
te
n
si
ty
N
o
rm
a
lis
e
d
 L
o
g
2
 in
te
n
si
ty
N
o
rm
a
lis
e
d
 L
o
g
2
 in
te
n
si
ty
N
o
rm
a
lis
e
d
 L
o
g
2
 in
te
n
si
ty
N
o
rm
a
li
s
e
d
 L
o
g
2
 i
n
te
n
s
it
y
N
o
rm
a
li
s
e
d
 L
o
g
2
 i
n
te
n
s
it
y
N
o
rm
a
li
s
e
d
 L
o
g
2
 i
n
te
n
s
it
y
N
o
rm
a
li
s
e
d
 L
o
g
2
 in
te
n
s
it
y
N
o
rm
a
li
s
e
d
 L
o
g
2
 in
te
n
s
it
y
N
o
rm
a
li
s
e
d
 L
o
g
2
 in
te
n
s
it
y
N
o
rm
a
li
s
e
d
 L
o
g
2
 in
te
n
s
it
y
 
Fig. 4.1 Plot displays the 25
th
 percentile (bottom end of box), 75
th
 percentile (top of box), and 
median (line in the middle of box). Whiskers contain the 1.5 interquartile. Plotted as red 
circles are miRNAs with expression outside the 1.5 interquartile. 
 
Besides the quality control metrics and the boxplots, other factors supported the 
reliability of the microarray data (a high miR-122 expression, expression of positive 
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and negative control probes of samples, the dynamic range of the microarrays, and the 
consistency of miRNA expression across replicates). In conclusion, the quality control 
analysis supports the reliability of the microarray data acquired for the 14 day PB 
study liver samples. 
 
4.4 Clustering Analysis of samples 
Hierarchical clustering analysis was used to study the dose and temporal patterns of 
PB effects on the liver miRNAome. Clustering was performed using the 95 miRNAs that 
were detected in at least 50% of liver samples in any condition. For each treatment the 
expression of miRNAs was averaged and its fold change from its day control samples was 
determined. It would be expected that if the dose effects of PB were consistent through 
time, the averaged samples would cluster according to their dose treatments e.g. the 
1000 ppm doses from the different days clustering together. Instead, treatments 
clustered according to length of exposure, suggesting that the temporal aspects of PB 
effects on hepatic miRNAs are prominent. A second observation was the clustering of 
the treatments into early (day 1 and day 3) and late (day 7 and day 14) stages of PB 
treatment, indicating a distinction between the earlier and later responses (Figure 
4.2).  
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Figure 4.2 Clustering analysis of samples from 14 day phenobarbital study. 
 
 
(Figure legend in the next page) 
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Fig. 4.2 For each treatment group the fold change of each miRNA from the day control were 
calculated. The calculated values were then median centred and normalised in Cluster 3.0. 
Samples and miRNAs were clustered using Correlation centred similarity metric and average 
linkage. Red colour indicates high expression and green indicated low expression 
 
 
From Figure 4.2 it can be seen that miRNAs did not show consistent repression or 
induction as a result of PB treatments, but instead varied over time. To examine 
further the temporal aspects of PB on hepatic miRNAs clustering was then performed 
for the control and treated samples at each of the four timepoints of the study (Figure 
4.3).       
 
Figure 4.3 Clustering of samples at individual timepoints of 14 day phenobarbital 
study. 
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Fig. 4.3 Trees were constructed using the 95 miRNAs which were expressed in at least 50% 
of samples in any condition. Expressions of miRNAs were median centred and normalised in 
Cluster 3.0. Correlation centred was used as the similarity metric and clusters were linked by 
average linkage. For clarity heat maps of miRNA expression for each sample are not shown.  
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Interestingly, the control and PB-treated liver samples clustered at a more or less 
random fashion after 1, 3, and 7 days. In contrast, a clearly non-random association of 
samples could be seen for samples after 14 days. One cluster contained the control 
and 50 ppm PB dosed samples, while the high 500 and 1000 ppm PB doses were part 
of a distinct branch.  Moreover, at 14 days of PB exposure liver samples from animals 
exposed to the carcinogenic 1000 ppm dose of PB clustered separately from those 
treated with the 50 and 500 ppm dose. This is despite the fact that up to 14 days the 
500 and the 1000 ppm doses had similar effects on hepatic proliferation, CYP450 
induction, and liver weight. Therefore, hierarchical clustering analysis supports 
the effects of PB on the hepatic miRNAome are time and dose dependent.  
 
The expression and clustering of miRNAs for the day 14 samples can be seen below 
(Figure 4.4).  
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Figure 4.4 Clustering analysis after 14 days of phenobarbital treatment. 
CON 50 500 1000
 
 
Fig. 4.4 Tree was constructed using 95 miRNAs that were detected in at least 50% of samples 
in any group. MiRNAs were median centred and normalised. Tree was constructed using 
Correlation metric and average linkage. Red indicates high expression, green low expression, 
and black no difference compared to median. 
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It can be seen that the expression of miRNAs after 14 days was more similar for the 
two higher PB doses. Additionally, clustering revealed one group of miRNAs which 
were strongly induced by the 1000 ppm PB dose at 14 days (miR-200a, miR-200b, 
miR-324-3p, miR-96, and miR-494).  Importantly, miR-200a, miR-200b, and miR-96 
were also found to be induced by 1000 ppm PB after 90 days of treatment (section 
3.5.1). Just as in the 90 day samples, a significant correlation was observed for the 
clustered miRNAs miR-200a and miR-200b (Figure 4.5).   
 
Figure 4.5 Correlation of miR-200a with miR-200b across 14 day phenobarbital 
study. 
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Fig. 4.5 Mean log2 hybridisation signal for miR-200b and miR-200a for each of the 16 
treatment groups of 14 day PB study is plotted on each axis. Pearson’s correlation analysis 
was performed. 
 
 
 
In the 90 day samples a very strong correlation was also observed between the 
expression of miR-200b and miR-96 for the PB, BP, and DEHP treated samples. To 
determine whether that relationship holds true from early on, the correlation of miR-
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200b with miR-96 was also determined for the 14 day PB study samples and again 
found to be significant (Figure 4.6).  
 
Figure 4.6 Correlation of miR-96 with miR-200b across 14 day phenobarbital study. 
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Fig. 4.6 Mean log2 hybridisation signal of each treatment is plotted on each axis. Pearson’s 
correlation analysis was used. On the top panel all points were plotted. Circled is outlier point, 
day 1 control. The day 1 control sample was removed in the lower panel. 
 
It was found that the expression of miR-96 in the day one control was an outlier and 
for that reasons was removed from further analysis.
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4.5 Identifying differentially expressed miRNAs 
4.5.1 MiRNAs deregulated by mitogenic PB doses 
 
SAM was used to distinguish miRNAs that were differentially expressed between the 
mitogenic treatments (500 and 1000 ppm) and the non-mitogenic treatments (50 ppm 
and control) at the different time points (Figure 4.7).  
 
Figure 4.7 Common effects of mitogenic phenobarbital doses on microRNAs. 
Day 3
Day 14Day 7
miR-221
miR-199a-3p
miR-96miR-200a miR-200b miR-494
miR-139-3pmiR-93
miR-365
miR-324-3p
miR-22*miR-196a
 
Fig. 4.7 The Venn diagram shows the miRNAs which were differentially expressed between 
hepatic non-proliferating (control and 50 ppm PB) and proliferating (500 and 1000 ppm PB) 
treatments. SAM was used with an FDR<0.001. Indicated as red are miRNAs with increased 
expression in the 1000 ppm treated animals, while coloured black are miRNAs with decreased 
expression in the 1000 ppm animals. No altered miRNAs were found on the first day of 
treatment. 
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The Ki67 data support a transient induction of hepatic turnover on the third day of 
exposure by the 500 and the 1000 ppm PB doses. A reasonable assumption to make 
was that miRNAs which were involved in PB-induced proliferation should also show 
a transient deregulation at the early timepoints (days 1-3) by the two mitogenic doses, 
but not by the 50 ppm PB dose. Only two miRNAs were found to be statistically 
significant between the mitogenic and mitogenic treatments at either 1 or 3 days. One 
was miR-199a-3p which was downregulated by the 500 ppm (0.74±0.03 fold) and 
1000 ppm (0.81±0.08 fold) doses at day 3. The other was miR-221 which was 
downregulated by the 500 ppm (0.90±0.10) and 1000 ppm (0.63±0.13) at the same 
time. Their expression across all doses and timepoints can be seen in Figure 4.8.  
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Figure 4.8 Fold Changes in expression of miR-199a-3p and miR-221 across doses 
and time. 
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Fig. 4.8 Values shown are average fold change from control per treatment; n=3 and error bars 
are S.D. Significance tested by SAM analysis of control + 50 ppm Vs 500 and 1000 ppm).  
 
The changes in the expressions of both miRNAs after 3 days were relatively modest.  
However, since the changes in expression were calculated for the whole liver, while 
only a small fraction of hepatic cells are induced to proliferate in response to PB 
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treatment (Table 4.4), it is possible that  the magnitude of change for these miRNAs 
was underestimated. A number of miRNAs have been previously associated with 
hepatocyte proliferation. After 2/3 partial hepatectomy, induction of miR-21 and loss 
of miR-378 has been linked to the transition of hepatocytes from G1 to S phase (Song 
et al., 2010).  Let-7c is a miRNA that suppresses cell growth and is repressed in the 
liver of mice following Wy-14,643 treatment (Shah et al., 2007). Another miRNA 
that has been linked to hepatocyte proliferation is miR-26a. This miRNA targets 
cyclins D2 and E2 in liver cells and can repress cancer cell proliferation in vivo (Kota 
et al., 2009). The expressions of these miRNAs were examined at the early timepoints 
(Table 4.10), but were not affected by PB treatment. 
 
Table 4.10 Changes in expression of selected microRNAs involved in proliferation 
DAY 1 3 
Dose(ppm) 50 500 1000 50 500 1000 
miR-21 0.99±0.01 0.85±0.10 1.1±0.23 0.95±0.33 0.81±0.08 0.93±0.24 
miR-378 0.84±0.21 1.02±0.05 0.84±0.06 1.01±0.04 0.91±0.13 0.98±0.17 
Let-7c 0.92±0.2 0.93±0.01 0.91±0.11 0.85±0.09 0.82±0.10 0.96±0.16 
miR-26a 0.86±0.13 0.97±0.02 0.94±0.03 0.87±0.12 0.84±0.04 0.94±0.08 
Fold change from control; ± S.D. n=3 animals per group 
 
 
4.5.2 MiRNAs deregulated by carcinogenic 1000 ppm PB dose 
 
After 14 days of PB treatment the carcinogenic 1000 ppm dose results in a 
characteristic miRNA hepatic profile.  In order to identify the miRNAs which 
discriminate the carcinogenic dose, a SAM analysis was performed of 1000 ppm Vs 
control; 1000 ppm Vs 50 ppm; and 1000 ppm Vs 500 ppm (Figure 4.9).  
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Figure 4.9 Specific effects of a carcinogenic phenobarbital dose on microRNAs. 
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Fig. 4.9 The Venn diagram showing the miRNAs differentially expressed between 
1000 ppm treated animals and other groups at 14 days.  SAM was used with an 
FDR<0.001. Indicated as red are miRNAs with increased expression in the 1000 ppm 
treated animals, while coloured black are miRNAs with decreased expression in the 
1000 ppm animals.  
 
 
 
One interesting miRNA was miR-29b, which was downregulated to similar levels by 
all three PB doses at 14 days (Figure 4.10).  
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Figure 4.10 Effect of phenobarbital doses on expression of miR-29b at 14 days 
 
CON 50 500 1000
0.0
0.5
1.0
1.5
Dose of PB in diet (ppm)
* *
F
o
ld
 C
h
a
n
g
e
 f
ro
m
 c
o
n
tr
o
l
 
 
Fig. 4.10 Values shown are mean fold change; error bars are S.D.; n=3 animals per group. * 
Significant by SAM analysis of treatment Vs control, q<0.0001. 
 
 
This miRNA has been shown previously to target DNA methyltransferases (DNMT) 
3A and 3B (Garzon et al., 2009), hence could be involved in regulation of methylation 
patterns of the liver. The two miRNAs that were significantly induced by the 1000 
ppm dose compared to all other treatments at day 14 were miR-200b and miR-96 
(Figure 4.11). 
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Figure 4.11 Dose dependent effect of phenobarbital on miR-200b and miR-96 
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Fig. 4.11 Values are mean fold change; error bars are S.D.; n=3 animals per group. * 
Significant by SAM analysis of treatment Vs control, q<0.0001. 
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4.5.3 Progressive induction of miR-200b and miR-96 from 14 to 90 days 
 
Six hepatic miRNAs were significantly differentially expressed between control and 
1000 ppm treated animals at 14 days at FDR<0.01. The change in their expression 
from control animals was then compared at 14 and 90 days to determine whether the 
deregulation of these miRNAs was a consistent or transient event (Table 4.11)   
 
 
Table 4.11 Comparison of effects of phenobarbital at 14 and 90 days 
 
miRNA Id Fold change from 
control day 14 
Fold change from 
control day 90 
miR-200b 2.7±0.2 4.5±0.4 
miR-96 2.1±0.1 3.6±0.1 
miR-494 1.7±0.05 0.6±0.2 
miR-324-3p 1.5±0.2 0.8±0.4 
miR-93 1.4±0.1 1.1±0.1 
miR-29b 0.7±0.04 1.1±0.2 
Fold change from control; values are mean fold change ± S.D. n=3 
 
 
MiR-200b and miR-96 are the only miRNAs displaying progressive deregulation by 
miRNA treatment between 14 and 90 days.  The other four miRNAs (miR-93, miR-
324-3p, miR-93, and miR-29b) were expressed at similar levels as in the control 
animals at 90 days. The progressive inductions of miR-200a/miR-200b and miR-96 
over the 90 days of PB treatment can be clearly seen in Figure 4.12 and Figure 4.13 
below.   
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Figure 4.12 progressive inductions of miR-200a and miR-200b with 1000 ppm 
phenobarbital treatment 
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Fig. 4.12 Values shown are mean fold change from day control for that treatment; 
error bars are S.D. n=3 except for control samples at 90 days were n=5. Statistics 
performed were one-way ANOVA with Dunnett’s post-test comparison against 
expression at day 1. * p<0.05 ** p<0.01 *** p<0.0001. 
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Figure 4.13 Progressive induction of miR-96 with 1000 ppm phenobarbital treatment. 
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Fig. 4.13 Values are mean fold change from day control for that treatment; error bars 
are S.D; n=3. Statistics performed were one-way ANOVA with Dunnett’s post-test 
comparison against day 3. Day 1 data were removed because they were clear outliers. 
  
 
 
4.6 Correlations of miR-200b and miR-96 with hepatic parameters 
 
The availability of data on the effect of PB doses on the liver allowed an examination 
of the association between these hepatic parameters and the expression of PB-induced 
miRNAs miR-200a, miR-200b and miR-96. In Table 4.12 the non-parametric 
correlation between the microsomal PROD activity (Table 4.1), relative liver weight 
(Table 4.2), and Ki67 hepatic labelling index (Table 4.3) and the expressions of these 
three miRNAs are tabulated. 
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Table 4.12 Correlation between CAR-induced microRNAs and liver parameters 
 
 miR-200a miR-200b miR-96 
Relative liver 
weight 
r=0.58, *p<0.05 r=0.67, **p<0.01 r= 0.63, **p<0.01 
PROD activity r=0.73, **p<0.01 r=0.67, **p<0.01 r= 0.67, **p<0.01 
Ki67 LI r=-0.51, *p<0.05 r=-0.51, *p<0.05. r=-0.18, n.s. 
r is Spearman correlation; n=3 for microarrays and n=5 for hepatic parameters 
 
 
A significant correlation was observed for relative liver weight and PROD activity 
with the levels of the three PB-induced miRNAs.  On the other hand, the correlation 
between the expression of these miRNAs and the Ki 67 hepatic LI was not significant.  
 
 
4.7 qPCR validation of observed changes 
 
 
MiR-200b was the miRNA showing the biggest significant fold-change in expression 
at 14 days. The dose and temporal nature of miR-200b induction by PB in the day 14 
PB study was examined by qPCR (Figure 4.13).  
 
 
 
 
 
 
 
 
Chapter 4 
 - 182 - 
 
 
Figure 4.14 QPCR analysis of miR-200b in 14 day PB study. 
Dose response on Day 14
co
nt
ro
l
50 50
0
10
00
0.0
0.5
1.0
1.5
2.0
2.5
*
Dose of PB in diet (ppm)
F
o
ld
 C
h
a
n
g
e
 f
ro
m
 c
o
n
tr
o
l
 
Temporal response across 14 days
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Fig. 4.14 Plotted on the Y-axis are mean fold-changes from day 14 control samples as 
calculated by qPCR. N=3 animals per group; errors bars signify S.D. One way ANOVA with 
Dunnett’s post-test, * p<0.05. 
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The qPCR data agreed with the microarray data in showing a significant induction of 
miR-200b specifically by the carcinogenic PB dose at 14 days. The correlation 
between the microarrays and qPCR for the expression of miR-200b in the examined 
samples was highly significant (Figure 4.15) 
 
Figure 4.15 Correlation of microRNA fold changes calculated by qPCR and 
microarrays for miR-200b 
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Fig. 4.15 On the y-axis the fold change in expression from day 14 control (calculated by 
comparative CT method) and on the x-axis the fold change in expression from day 14 control 
calculated by microarrays. Expression plotted is the average of three animals; Pearson’s 
correlation was used to measure correlation of the two methods. Next to each plotted sample 
the label identifies the dose and time of exposure to PB.  
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4.8 Discussion 
 
The importance of both the dose and temporal parameters of chemical treatments is a 
fundamental tenet of toxicology. Indeed, the data generated here indicate that the 
effects of PB on the hepatic miRNAome are dependent on both the dose and temporal 
aspects of the chemical treatment (for example the distinct miRNA profiles of PB 
doses and the progressive induction of the miR-200a/200b/429 and miR-96/182 
clusters). Unfortunately, for the other compounds examined in this study miRNA 
profiles were only generated for a single dose and timepoint (Chapter 3).  Profiling of 
livers from animals exposed to multiple dose levels would also allow an evaluation of 
whether the observed effects of chemicals are restricted to the very high doses used 
here or are also relevant at lower doses. Temporal information would be important for 
the determination of the optimal timepoint at which miRNA profiles are the most 
informative. Together, the availability of dose and temporal data would also greatly 
facilitate the investigation of the functional effects of miRNA deregulations.     
 
Waterman et al. (2010) previously performed transcriptomic profiling of the same 
PB-treated liver samples that were examined here. Their analysis revealed that 
protein-coding genes affected by PB displayed three major patterns: consistent 
induction or repression; transient early induction (days 1-3); and genes deregulated at 
later stages (days 7-14). Many miRNAs are embedded within protein-coding genes 
and are co-transcribed with them. In addition, transcription factors and cellular 
signalling pathways regulate both mRNAs and miRNAs. A reasonable assumption 
then would be that the effects of PB on miRNAs would follow similar patterns to that 
of protein-coding genes. However, in fact miRNAs displayed a different profile of 
response. Minimal changes in the miRNA profile were determined after 1, 3, and 7 
days. The biggest changes could be seen at 14 days of treatment by which point 
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carcinogenic and non-carcinogenic doses of PB could be discriminated based on their 
hepatic miRNA profiles. 
 
The results of the miRNA profiling indicate that hepatic miRNAs are initially (1-3 
days of treatment) more resistant to deregulation by chemical treatment than protein-
coding genes. The reason behind this discrepancy between miRNAs and mRNAs 
responses is currently not clear. However, after continual chemical treatment (>one 
week) miRNA deregulations are also prominent. In confirmation of this finding, it has 
been recently reported that the genotoxic hepatocarcinogen N-ethyl-N-nitrosourea 
(ENU) also displays progressive deregulation of miRNAs, with minimal changes at 1 
and 3 days, with maximum changes after 7 and 14 days (Li et al., 2010b).  It is 
important to note that the two reported studies of carcinogens which did not affect 
hepatic miRNAs looked at acute effects i.e. Benzo[a]pyrene and TCDD caused 
minimal effects in the liver after three and four days of treatment respectively (Moffat 
et al., 2007, Yauk et al., 2010). Therefore, the currently available data indicates that 
it is important that the effect of chemicals on hepatic liver miRNAome must take into 
consideration both dose and temporal aspects.  
 
The mitogenic properties of PB are considered a key event in its carcinogenic 
mechanism (Holsapple et al., 2006). It is well established that miRNAs can regulate 
cellular proliferation. Nevertheless, studies of conditional Dicer1-knockout in 
hepatocytes have shown that liver cells can proliferate even in the absence of 
functional miRNAs (Sekine et al., 2009, Song et al., 2010). Hence, it is possible that 
PB can induce proliferation without affecting miRNAs. Two miRNAs were 
deregulated by the two mitogenic PB doses at day 3, miR-199a-3p and miR-221. 
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Interestingly, downregulation of miR-199a-3p in HCC has been recently linked to 
activation of the PAK4/Raf/MEK/ERK pathway that facilitates tumour growth (Hou 
et al., 2011). It will be interesting to examine in future studies whether the 
downregulation of this miRNA is involved in the mitogenic stimulation of PB. Other 
miRNAs which have been previously linked to hepatocyte proliferation (miR-21, 
miR-378, and let-7c) were not changed by mitogenic PB exposure.  
 
Treatment with CAR activators for 90 days (PB, BP, and possibly DEHP) had the 
common effect of the coordinated induction of the two miRNA clusters, miR-
200a/200b/429 and miR-182/96. Examination of the 14 day PB treated samples 
revealed that the induction of these miRNA clusters (a) occurs after one-two weeks of 
treatment (b) is progressive in nature (c) is dose-dependant. These PB-induced effects 
were also confirmed by qPCR. A progressive induction of these two miRNA clusters 
between 12 and 24 weeks was also reported for 2-AAF (Pogribny et al., 2009a). It 
was found here that the induction of these miRNA clusters occurs after the transient 
induction of proliferation has ceased. In the present study, a significant correlation 
was found between the expression of these miRNA clusters with both the relative 
liver weight and microsomal PROD activity. Both of these parameters are mediated 
by activation of CAR, suggesting a potential link.   
 
Besides its other effects, CAR also affects hepatic metabolism. Activation of CAR in 
ob/ob mice attenuated diabetes progression, increases insulin-induced repression of 
gluconeogenesis, and decreased hepatic lipid content (Dong et al., 2009). Similar 
beneficial results of CAR activation on hepatic glucose and lipid metabolism were 
also reported for mice fed high fat diets (Gao et al., 2009). CAR can block FOXO1 by 
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directly binding to it (Kodama et al., 2004). CAR also antagonises HNF-4 by 
competing for its coactivators and binding sites (Miao et al., 2006). It is possible that 
the induction of the miR-200a/200b/429 and of the miR-96/182 clusters by CAR 
activators may be another way by which such chemicals can affect hepatic 
metabolism. MiR-182 and miR-96 have been shown to repress expression of FOXO 
proteins in T-cells (Stittrich et al., 2010), ovarian (Myatt et al., 2010), and breast 
cancer (Guttilla & White, 2009). A recent paper has shown that members of the miR-
200 family cooperate in targeting FOG-2, resulting in greater activity of the PI3K 
pathway (Hyun et al., 2009). Therefore inductions of these two clusters are predicted 
to target gluconeogenesis by repressing FOXO directly (miR-182/miR-96) and 
indirectly (miR-200) (Figure 4.16). 
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Figure 4.16 Proposed model for metabolic regulation of gluconeogenesis by CAR 
activators 
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Fig. 4.16 FOXO promotes gluconeogenesis by binding to the insulin response sequence (IRS) 
of genes. Insulin causes the phosphorylation of FOXO by activating the PI3K-Akt pathway. 
The phosphorylation of FOXO represses gluconeogenesis by causing the localisation of 
FOXO outside the nucleus reducing its ability to bind IRS. FOG2 is a recently discovered 
inhibitor of the PI3K pathway. PB treatment results in translocation of CAR to the nucleus 
and the induction of the miR-200a/200b/429 and miR-182/96 miRNA clusters. Within the 
nucleus CAR inhibits FOXO by direct binding onto it. MiR-96 and miR-182 target and 
repress FOXO protein. The miR-200a/miR-200b, and miR-429 target FOG2 releasing the 
PI3K-Akt pathway. The dashed arrows indicate an associated but undefined linkage. 
 
 
 
Clearly more work is needed to examine whether these miRNAs are involved in 
metabolic effects of CAR activation on the liver.
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5.1 Introduction 
 
In chapter 3 a set of liver miRNAs that were commonly deregulated after short-term 
treatment with chemical hepatocarcinogens are described. In chapter 4 the time and 
dose dependent effects of PB on the liver miRNAome were revealed. The work 
presented so far therefore had focused on profiling the liver miRNAome and on the 
identification of altered miRNAs. The studies reported in this chapter used this 
information and focused on investigating (1) the mechanisms underlying miRNA 
deregulation (2) the consequences of the observed miRNA deregulation. Particular 
emphasis was placed on the investigation of cause/effect associated with miRNAs 
affected by PB treatment.  
 
Altered DNA methylation patterns are frequently associated with deregulated gene 
expression in disease, including cancers (Sharma et al., 2010). Interestingly, among 
the identified “biomarker” miRNAs affected by hepatocarcinogens (see Table 3.12) 
almost all have been reported to be dysregulated in cancers due to altered 
methylation- miR-203 (Kozaki et al., 2008, Furuta et al., 2010, Lodygin et al., 2008), 
miR-200a/200b/429 cluster (Li et al., 2010), and miR-193 (Kozaki et al., 2008)]. 
Moreover, hepatocarcinogens can affect both gene-specific and global DNA 
methylation in the liver (Pogribny et al., 2008). Disruption of the normal methylation 
pattern is hence a mechanism by which chemical treatments can potentially affect the 
expression of liver miRNAs. CpG islands are guanine-cytosine rich genomic regions 
containing clusters of CpG dinucleotides whose methylation represses gene 
expression. The identification of “CpG islands” in the promoters of miRNAs indicates 
that methylation could potentially be involved in their regulation. The methylation of 
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CpG sites within the CpG islands can then be compared to the expression of the 
miRNA to determine if there is a relationship between the two. 
 
Just as methylation patterns can affect expression of miRNAs, so too some miRNAs 
themselves regulate the epigenetic machinery. Three known enzymes are involved in 
methylation of CpG sites in mammals: DNMT1, DNMT3A, and DNMT3B. DNMT1 
is the enzyme that is responsible for maintaining existing methylation patterns, while 
DNMT3A and DNMT3B perform de novo methylation (Jones, 2002). The members 
of the miR-29 family of miRNAs (miR-29a, miR-29b, and miR-29c) repress the 
expression of DNMT3A and DNMT3B (Fabbri et al., 2007, Filkowski et al., 2010, 
Takada et al., 2009). It has also been shown that miR-29b can indirectly repress 
DNMT1 through the DNMT1-regulator Sp1 (Garzon et al., 2009). In acute amyloid 
leukaemia (AML) cells, overexpression of miR-29b results in global DNA 
hypomethylation (Garzon et al., 2009). Interestingly the expression of miR-29b was 
found to be transiently repressed at 14 days of PB treatment (Figure 4.10). Based on 
this observation the global hepatic DNA methylation was examined to determine 
whether an association exists between the deregulation of this miRNA and global 
hepatic DNA methylation. 
 
Besides methylation patterns, the expression of miRNAs can also be regulated by the 
binding of transcription factors (e.g. (Shah et al., 2007, Chang et al., 2007, Fazi et al., 
2005, Bracken et al., 2008). The research here has shown diverse chemicals affect a 
common set of miRNAs. This finding suggests that these miRNAs may be regulated 
by important cellular pathways that are disrupted by chemical treatments. Several 
computational tools have been developed for the purpose of identifying transcription 
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factor binding motifs within DNA sequences. The identification of transcription factor 
binding motifs in the promoter sequences of a miRNA is an indication that the protein 
may regulate the expression of that miRNA.  
 
Ultimately, the functional significance of the deregulation of a miRNA depends on the 
proteins, which are regulated by it. Each miRNA can potentially affect hundreds or 
even thousands of proteins (Selbach et al., 2008, Baek et al., 2008). Unfortunately, a 
very small fraction of the predicted targets of miRNAs have been experimentally 
verified so far. Consequently, the use of computational methods is necessary to 
predict the genes regulated by miRNAs. Although imperfect, several in silico methods 
have been developed that can predict miRNA targets with moderate success (Bartel, 
2009). The phenotypic consequences of the observed deregulation of miRNAs can 
then be explored through the proteins that they affect. Particularly important for most 
computational methods of predicting miRNA-targets, is the strength of the Watson-
Crick complementarity between the miRNA seed region (nucleotides 2-8 from 5’ end) 
and sites within mRNAs, especially within their 3’ UTR. Hence, the seed regions of 
miRNAs are the most significant aspect in the prediction of their regulated genes. The 
phenotypic consequences of miRNA deregulation can then be investigated by 
consideration of the proteins/pathways that they are predicted to regulate.  
 
An important confounding factor in determining the functional consequences of the 
observed miRNA deregulations was the lack of information regarding the identity of 
the cells in which these deregulations were taking place. In this project miRNA 
profiles were determined for liver segments removed from treated animals. This was a 
reasonable approach to start this study, allowing a determination of whether effects of 
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chemicals on the liver miRNAome could be detected. An obvious weakness of this 
methodology was its treatment of the liver as a uniform organ, ignoring the complex 
architecture and multiple cell types that constitute the liver (see Section 1.3.1). It is 
well established that the effects of chemicals are often restricted to a small fraction of 
hepatic cells. Consequently, the magnitude of miRNA deregulations determined here 
are expected to be underestimated, perhaps considerably so. Additionally, recently 
studies have shown that deregulations of miRNAs within specific hepatic cells can 
have important phenotypic consequences. One study reported that chronic alcohol 
treatment results in the induction of miR-155 in KC in vivo, which subsequently 
regulates TNFα production (Bala et al., 2011), whilst activation of HSCs alters their 
miRNA profiles (Guo et al., 2009). Hence potentially useful information on the 
hepatic cell types with affected miRNAome after chemical treatment could not be 
deduced from the microarray data generated here.  
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5.2. Analysis of miRNA promoters  
5.2.1 Identification of CpG islands within the promoters of miRNAs 
 
At present the definition of what parameters constitute a “true” CpG islands is 
somewhat arbitrary. Here a formal definition of CpG island was used (regions bigger 
than 500 base pairs; G/C content greater than 55%; expected/observed ratio of CpG 
dinucleotides greater than 0.65) which has the benefit of excluding GC-rich units, 
such as Alu repeats (Takai & Jones, 2002). The presence of CpG islands in the 
promoter regions of the identified biomarker miRNAs (Table 3.12) was examined 
using the CpG island searcher (http://cpgislands.usc.edu/, Takai & Jones, 2002) with 
the parameters set as described above. Besides rats, the bioinformatic search was also 
performed for the promoter region of their mouse and human homologs, to determine 
whether the detected CpG islands were conserved across species.  
 
Given the fact that pri-miRNAs can be tens of kilobases in length (Chang et al., 2007, 
Ozsolak et al., 2008) it was decided to examine regions from 30 kilobases upstream to 
1 kilobase downstream of each miRNA for the presence of CpG islands. DNA 
sequences were extracted from the UCSC genome browser (http://genome.ucsc.edu/) 
for the regions of interest. Using the criteria mentioned above CpG islands were 
identified in the promoters of most of the biomarker miRNAs (Table 5.1).  
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Table 5.1 CpG islands in the promoters of “biomarker” miRNAs. 
MiRNA Rat CpG 
islands? 
Mouse 
CpG 
islands? 
Human 
CpG 
islands? 
Location of CpG islands 
miR-203 YES YES YES Overlapping miRNA 
miR-34a YES YES YES ~22Kb upstream (rodents) ; 
~30Kb (Human) 
miR-96/182/183 YES  YES  YES  ~3.5-7 Kb upstream ; mice 
and humans also at  9-11 
Kb 
miR-193 YES  YES YES One overlapping miRNA 
and one at 7-10 Kb 
upstream 
miR-200b/200a/429 NONE NONE YES ~3-5 Kb upstream in 
humans 
miR-99a NONE NONE NONE NONE 
Genomic regions up to 30 kilobases upstream of pre-miRNA and up to 1 kilobase 
downstream were examined; in humans the promoter of miR-193a was examined as it is more 
similar to the rat homolog miR-193 
 
Only for miR-99a was a CpG island not detected in any of the three examined species.  
Conserved CpG islands were detected in all three species for miR-203, miR-34a, 
miR-193, and the miR-96/182 cluster.  Interestingly, for the miR-200a/200b/429 
cluster CpG islands were identified in the human promoter, but not for mice or 
rodents within the examined region. The CpG islands identified here show that 
methylation could potentially be involved in the regulation of several of the miRNAs 
identified in the present study. 
 
5.2.2 P53 binding sites are located in the promoter of miR-34a 
 
MiR-34a is a miRNA whose expression is directly activated by binding of p53 to a 
consensus p53 binding site (GGGCTTGCCTGGGCTTGTT) close to the 
transcriptional start site (TSS) of the miRNA (Chang et al., 2007, He et al., 2007). 
Examination of the genomic sequence up to 30Kb upstream of miR-34a in the rat 
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identified a single instance of this p53 binding site, which was located within the 
identified CpG island. Examination of the DNA sequences of the other biomarker 
miRNAs did not identify this p53 binding site in regions up to 30 kilobases upstream. 
Hence miR-34a is expected to be particularly responsive to p53 activity. 2-AAF, 
which was the only GNTX chemical used in this study, would be predicted to cause 
activation of the p53 signalling pathway. Examination of transcriptomic data from the 
liver samples at 90 days (Richard Currie personal communication) revealed an 
induction of p53 associated genes (e.g. Bax, cdkn1a, ccng1, and mdm2) specifically 
for 2-AAF treated rat liver samples. In accordance with these observations, the 
induction of hepatic miR-34a by 2-AAF treatment is much more pronounced than for 
other treatments (Figure 3.13).  
 
5.2.3 Analysis of miR-200a/200b/429 cluster proximal promoter 
 
The human promoter of the miR-200a/200b/429 cluster has been studied extensively 
(Bracken et al., 2008). The authors identified a putative TSS at 4277 bases upstream 
of miR-200b, with the proximal miR-200a/200b/429 promoter being located within 
the region of -320/+120 of the TSS. The expression of the miR-200a/200b/429 cluster 
was shown to be induced by five out of six tested carcinogens at 90 days, with the 
biggest effect observed following carcinogenic PB treatment (Figure 3.10).  
 
ZEB1 and ZEB2 transcription factor proteins, characterised by widely separated 
regions containing zinc-finger clusters, are the best established regulators of the miR-
200 family (Burk et al., 2008, Bracken et al., 2008). They repress the expression of 
the miR-200a/200b/429 cluster by direct binding to paired E-box sequences which are 
conserved within the human, rat, mouse, and canine genomes proximal miR-
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200a/200b/429 promoters. Besides transcriptionally regulating the expression of the 
miR-200a/200b/429 these transcription factors are also the best established targets of 
the miRNA members of the miR-200a/200b/429 cluster (Gregory et al., 2008a, 
Christoffersen et al., 2007, Korpal & Kang, 2008, Park et al., 2008). Therefore a 
negative feedback loop relationship between the miR-200 family and the ZEB1/ZEB2 
proteins exist (Burk et al., 2008, Bracken et al., 2008) (Figure 5.1).  
 
Figure 5.1 Negative feedback loop regulating the expression of the miR-
200a/200b/429 cluster and the ZEB1/ZEB2 transcription factors. 
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Fig. 5.1 ZEB1 and ZEB2 bind onto E-box sites found in the promoter region of the miR-
200a/200b/429 cluster and repress the transcription of the unit. At the same time, all three 
miRNA target and post-transcriptionally regulate ZEB1 and ZEB2. 
 
However, neither zeb1 nor zeb2 displayed altered expression in the rat liver 
transcriptomic data (R.A. Currie, personal communication). This finding indicated 
that these proteins are not involved in the observed induction of miR-200a, miR-200b, 
and miR-429 in the rat liver after chemical treatment. Since the biggest induction of 
the hepatic miR-200a/200b/429 cluster was caused by PB treatment, transcription 
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factors that are affected by the chemical were examined as potential mediators of that 
effect. Activation of CAR is a main mechanism by which PB propagates its cellular 
effects (Ueda et al., 2002). Two other transcription factors that are known to be 
affected by PB treatment or CAR activation are the hepatic nuclear factor 4 alpha 
(hnf4α) (Bell & Michalopoulos, 2006) and c-myc (Blanco-Bose et al., 2008). The 
genomic region up to 5 kilobases upstream of the miR-200b was examined for 
HNF4α, CAR, and c-myc binding sites.  
 
DNA sequences recognised by nuclear receptors are repeats of distinct hexamers at 
particular orientations to each other. These orientations include inverted repeats (IR), 
direct repeats (DR), and everted repeats (ER). NUBISCAN, a computational tool that 
was developed specifically to identify binding sites of nuclear receptors (Podvinec et 
al., 2002), was used to identify potential HNF4α binding sites within the promoter of 
miR-200b (Table 5.2).  
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Table 5.2 Putative HNF4α a binding sites up to 5000 bases upstream of rat miR-200b 
Position  upstream 
of miR-200b 
p. value Strand Score Repeat SEQUENCE 
4292 0.01 + 0.98 IR3 AGGCCAcacTGTCCT  
4225 0.01 + 0.94 ER5 TGACCTgtgccAGTTCA  
3870 0.01 + 0.93 DR10 GGGGCAggcaggagggAGGCCA  
142 0.02 + 0.93 ER9 TGCCCTccagaatgaAGGGCT  
4220 0.02 - 0.92 DR8 AGGTCAacaactcgGGGACA  
3854 0.03 + 0.92 IR3 AGGCCAgacAGGCCT  
3854 0.03 + 0.92 DR3 AGGCCAgacAGGCCT  
345 0.03 + 0.92 DR8 AGGCCAggtttggcTGGACA  
1865 0.04 + 0.88 IR6 TGGGCAcctaccTGCCCC  
4552 0.04 - 0.92 DR0 AGGCCCAGGCCA  
3880 0.04 + 0.88 DR4 GGGGCAggtaGGGGCA  
1335 0.04 + 0.87 ER5 TGCCCTtttctGGTGCA  
1702 0.05 + 0.91 DR2 AGGACAcaGGGACA  
Putative HNf4α binding sites within 5000 base pairs upstream of the rat miR-200b, with a 
calculated p<0.05 were identified using NUBISCAN. Scores were calculated by the 
NUBISCAN algorithm, with the highest scores indicating a better match. Also shown is the 
identified repeat element. Under the sequence heading are shown the genomic sequences 
containing putative HNF4α binding sequence, with the hexamer sequences shown in capitals. 
 
Interestingly, the top two predicted HNF4α binding sites were located at 4225 (IR3 
elements) and 4292 bases (ER5 element) upstream of miR-200b, within the identified 
proximal promoter of the miRNA cluster. Next, the PROMO tool for prediction of 
putative transcription factor binding sites (Messeguer et al., 2002)  was used to 
identify c-myc and CAR/RXR binding sites in the same genomic region by comparing 
the genomic DNA sequences to known transcription factor binding sites (Table 5.3).   
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Table 5.3 Putative c-myc and CAR/RXR binding sites upstream of miR-200b  
Transcription factor Putative binding sites 
c-myc 40, 620, 670, 830, 1430, 2780, 3630, 
3990, 4110, 4240, 4840 
CAR/RXR 50, 790, 2170, 3610 
Putative binding sites were predicted in region up to 5000 bases upstream of the pre-miR-
200b using the PROMO software. Threshold was set as 15% dissimilarity between genomic 
sequence and transcription factor matrix. 
 
Therefore potential HNF4α and c-myc binding sites are present close to the proximal 
promoter of the miR-200a/200b/429 cluster and could regulate its expression. 
 
5.2.4 Examination of genomic region upstream of miR-96/182 
A very strong correlation was observed for the miR-200a/200b/429 cluster and the 
miR-96/182 cluster in liver samples treated with PB, BP, and DEHP at 90 days 
(Figure 3.15). A similar association between these two miRNA clusters has also been 
reported in the literature to occur in breast and pancreatic cells (Shimono et al., 2009, 
Wellner et al., 2009). These findings suggest the activity of a common factor in the 
induction of these two miRNA clusters. It was decided to examine the genomic region 
upstream of the miR-96/182 cluster for the presence of binding sites that could also 
regulate the miR-200a/200b/429 cluster (i.e. CAR/RXR, ZEB1/ZEB2, HNF4α, and c-
myc). 
 
In order to narrow down the genomic area to be examined, the FirstEF software was 
used, a computational tool developed with the aim of predicting gene promoters by 
taking into account structural and functional elements of DNA sequences (Davuluri et 
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al., 2001). Examination of the region 30 kilobases upstream of the rat miR-96 
identified two possible promoter regions in the anti-sense strand: at 6156-6725 
upstream of miR-96 with a high probability (with p of 0.9979) and at 27699 to 28268 
with a much lower probability (p 0.4966). The first putative promoter, and the one 
with the highest probability, was localised within the area (3.5-7.5 kilobases) 
upstream of miR-96 that contains large CpG islands. CpG islands upstream of 
eukaryotic genes often indicate the presence of regulatory elements (Fickett & 
Hatzigeorgiou, 1997). RNA from rat liver samples could be amplified by RT-PCR 
using PCR primers designed to anneal to sequences 4478-5336 upstream of miR-96, 
demonstrating that this region is indeed transcribed in the rat liver (Figure 5.2). 
 
Figure 5.2 RT-PCR amplification upstream of miR-96 
 
Fig. 5.2 Genomic region amplified was 3426-3519 bases upstream of miR-96. 
Expected product is 93 bases in size. In lane 1 the DNA ladder can be seen with molecular 
weights of 1500, 1000, and incremental decreases of 100 bases for each band from then on. In 
lane 2 and lane 3 cDNA is amplified at 55
o
C and 60
o
C. In lane 4 PCR amplification was 
performed on no reverse transcriptase control and in lane 5 PCR amplification was performed 
on a no template control sample. PCR amplification was performed for 35 cycles for each 
sample. 
 
100 
200 
500 
1000 
1500 
1 2 3 4 5 
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Based on these observations the genomic region that contained the evolutionary 
conserved CpG islands (3.5-7.5 kilobases upstream of miR-96) was considered to be 
potentially important for the regulation of this miRNA cluster, and was chosen to be 
examined for potential ZEB1/ZEB2, CAR/RXR, HNF4α, and c-myc binding sites. 
This analysis identified a number of putative binding sites for these transcription 
factors within the CpG-containing genomic area upstream of miR-96 (Table 5.4)  
 
Table 5.4 selected binding motifs in CpG islands upstream of miR-96 
Binding Motiff Position upstream of miR-96 
CAR/RXR 5760 bases 
E-boxes (zeb1/zeb2 binding) 4343, 4645, and 4876 bases 
c-myc 3910, 4140, 4440, 4530, 4670, 5190, 
6280 
HNF4α 5420 
Transcription factor binding motifs were detected using PROMO and NUBISCAN 
computational tools. 
 
In an attempt to better define the promoter region of the miR-96/182 cluster, rapid 
amplification of cDNA ends (RACE) was performed using the Generacer kit as 
described in materials & methods (Section 2.6). This method allows the identification 
of TSS of genes, and has been used previously for analysis of pri-miRNA transcripts 
(Chang et al., 2007). As a positive control Hela RNA template was processed 
simultaneously with sample RNA. PCR primers were then used to specifically 
amplify β-ACTIN modified by the attachment at the 5’ end of the Generacer RNA 
oligo from the generated Hela cDNA template (Figure 5.3).  
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Figure 5.3 PCR amplification of positive control for Generacer
  
Fig. 5.3 Control Hela RNA was processed simultaneously with sample RNA using the 
Generacer kit. On lane 1 from left the same ladder was used as in figure 5.2. In lane 2 
amplification of β-actin, modified by the addition to its 5’ end of Generacer oligo, was 
performed using manufacturer’s primers and 30 PCR cycles. The expected product was 872 
base pairs (828 of β-actin + 44 bases of attached RNA oligo). In lane 3 the same PCR reaction 
was performed on a no template control sample.  For PCR amplification 5 PCR cycles were 
performed at 72
o
C, 5 PCR cycles at 70
o
C, and 20 PCR cycles at 68
o
C. 
 
 
The positive control reaction demonstrated that the processing of the RNA 
(dephosphorylation, decapping, attachment of RNA oligo, and reverse transcription) 
worked as expected. For RLM-RACE PCR amplification is performed on modified 
RNA using one fixed primer that anneals to the attached oligo, and one custom primer 
that anneals at some known region further downstream. PCR amplification was 
performed using the reverse primer used in Figure 5.2. Unfortunately the 
identification of the TSS of this miRNA cluster using the Generacer kit was not 
successful. Despite repeated attempts at optimising the PCR process (e.g. different set 
of primers, range of temperatures and PCR cycles, amount of starting cDNA, normal 
and touchdown PCR) a RACE PCR product could not be generated for the pri-
miRNA containing miR-182 and miR-96. The reason for difficulty in the 
amplification of the pri-miRNA was not clear.  It is possible that a rapid turnover of 
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the pri-miRNA to a pre-miRNA renders its detection by RACE more difficult than for 
other genes. 
 
Interestingly, a publicly available cloned cDNA (AK044240) (Carninci & 
Hayashizaki, 1999) ((Jan 2010) has been isolated from the CpG island containing 
genomic region from the mouse retina, an organ known to have high expression of the 
miR-182/96 cluster (Xu et al., 2007). This clone corresponds to the region that is 
3342-5562 bases upstream of the pre-miR-96, within the CpG island region, but 
corresponds to the opposite strand to that on which the pre-miR-96 is located. It has 
been reported that for some miRNA loci both strands can be transcribed (Tyler et al., 
2008). Amplification by RT-PCR using two distinct primer sets could amplify cDNA 
corresponding to this region (Figure 5.4).   
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Figure 5.4 RT-PCR amplification of complementary strand to miR-96 
 
Fig. 5.4 Amplification of sequences within the cloned cDNA (AK044240) corresponding to 
the opposite strand to miR-96. On the first lane from the left the DNA ladder can be seen with 
molecular weights of 1500, 1000, and incremental decreases of 100 bases for each band from 
then on. Primer A (4478-4727 upstream of miR-96) and primer B (5117-5336 upstream of 
miR-96) were custom designed. The expected size of the PCR product was 249 bases for 
primer A and 260 bases for primer B. For each primer three PCRs were performed: Normal 
PCR (RT+), no reverse transcriptase control (RT-), and a no template control (NTC). For each 
PCR reaction 35 cycles at 55
o
C were performed. 
 
  
5.3 Consequences of miRNA deregulation 
5.3.1 Correlation between miR-29b and global DNA Methylation  
 
The microarray data for the PB treatment over 90 days indicated a transient repression 
in the expression of miR-29b, but not of miR-29a or miR-29c, specifically at 14 days 
(Figure 5.5).  
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Figure 5.5 Expression of hepatic miR-29b in control and 1000 ppm PB-treated 
animals after 7, 14, and 90 days 
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Fig. 5.5 The expression of miR-29b was quantified with microarrays and for each treated 
group the mean fold change from the control samples was calculated. SAM analysis was 
performed at each time between control and 1000 ppm PB treated animals ** q<0.01 and 
error bars indicate S.D. n=3 except for 90 day control samples were n=5. 
 
 
This miRNA was not affected at 90 days by any other chemical treatment studied 
here. It has been reported that this miRNA can regulate global DNA methylation 
(Garzon et al., 2009, Takada et al., 2009, Blum et al., 2010). The Methylamp Global 
DNA Methylation Quantification Ultra Kit (Epigentek) was used to evaluate whether 
the observed repression of miR-29b by PB affected the methylation status of the liver. 
This kit quantifies the amount of methylated DNA based on the binding of an 
antibody to methylated cytosine. A standard curve showed that this kit could be used 
to quantify the amount of methylated DNA reliably (Figure 5.6).  
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Figure 5.6 Standard curve for Methylamp kit. 
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Fig. 5.6 Control DNA supplied by manufacturer (synthesized polynucleotide methylated at 
every 5-cytosine) was diluted to known concentrations and was measured using the 
methylamp kit. Line was automatically drawn using least squares. 
 
The methylation of genomic DNA from samples treated with the 1000 ppm PB dose 
after 7, 14, and 90 days was then examined. This analysis found that global DNA 
methylation was the inverse to the expression of miR-29b, being transiently induced 
only at 14 days of PB treatment (Figure 5.7). 
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Figure 5.7 Global DNA methylation in 1000 ppm PB-treated samples at days 7, 14, 
and 90. 
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Fig. 5.7 Methylation was measured using the Methylamp kit. The values for all treatments 
was normalised to their respective day control. Three animal liver DNA samples were 
examined per group, error bars represent S.D. T-test was performed between samples treated 
with 1000 ppm PB and their respective day control samples, * signifies p<0.05. 
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5.3.2 Effect of miR-200a/200b/429 dose-dependent induction on the 
expression of zeb1/zeb2 and epithelial markers 
 
Immunoblotting was used to quantify the expression of the zeb1 and zeb2 proteins in 
the control and PB-treated samples at 14 days of treatment (Figures 5.8).   
 
 
Figure 5.8 Immunoblotting of zeb1, zeb2, and b-actin in control and phenobarbital-
treated samples at 14 days. 
 
 
 
 
 
N=3 animals per group. 
 
 
Quantification of the immunoblots then confirmed the specific downregulation of 
zeb1 and zeb2 by the carcinogenic dose of PB at 14 days (Figure 5.9). 
 
 
 
 
 
 
Control 50 ppm 500 ppm 1000 ppm 
Zeb1 
β-actin 
Zeb2 
    
Control 50 ppm 500 ppm 1000 ppm 
β-actin 
Chapter 5 
 - 210 - 
 
 
Figure 5.9 Quantification of zeb1 and zeb2 proteins in livers treated with 
phenobarbital doses for 14 days. 
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Fig. 5.9 Shown is the mean fold change from control. Protein expression was normalised to b-
actin. N=3 per group, * p<0.05 one-way ANOVA with Dunnett’s post-test. Error bars are 
S.D. 
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Zeb1 and zeb2, targets of the miR-200 family of miRNAs, are major regulators of 
epithelial to mesenchymal transition (EMT), a complex process whereby epithelial 
cells are reorganised into more motile mesenchymal ones (Berx et al., 2007) . The 
proteins repress the expression E-cadherin gene (CDH1), a cell adhesion protein that 
is found on the plasma membrane of normal epithelial cells, and also induce the 
upregulation of the mesenchymal markers vimentin and N-cadherin (Vandewalle et 
al., 2009). However, examination of the transcriptomic data (personal communication 
R.A. Currie) did not reveal an association between induction of the miR-
200a/200b/429 cluster and deregulation of these three EMT marker genes (cdh1, vim, 
cdh2). At 90 days the only one of these genes showing a significant deregulation more 
than 1.5-fold was N-cadherin, and that was only observed in one treatment (-1.6 fold 
in DEHP treated animals). 
 
To confirm the microarray data the expression of E-cadherin was examined in control 
and 1000 ppm PB treated samples at 90 days by semi-quantitative PCR.  This 
timepoint was chosen as the maximum induction of the miR-200a/200b/429 cluster 
was observed at that stage. As a positive control the expression of cyp2b1/2 was 
examined in the same samples by end-point PCR (Figure 5.10). 
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Figure 5.10 PCR amplifications of cyp2b1/2, cdh1, and gapdh in control and 
phenobarbital-treated samples at 90 days 
e-cadherin
gapdh
cyp2b1/2
CONTROL 1000 ppm PB
 
 
N=3, 30 PCR cycles were performed 
 
 
 
Quantification of the PCR gels showed a pronounced induction of cyp2b1/2 (as 
expected), but no change in the levels of cdh1 (Figure 5.11). 
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Figure 5.11 Quantification of E-cadherin and cyp2b1/2 genes in livers treated with 
1000 ppm phenobarbital at 90 days 
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Fig. 5.11 Expression of genes was normalised to that of gapdh.  N=3 per group, error bars 
indicate S.D. * p<0.05 T-test. 
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Hence examination by end-point PCR agreed with the microarray data in that the 
expression of the E-cadherin gene was not changed at 90 days, despite the 
downregulation of zeb1 and zeb2. 
 
5.3.3 Pathways enriched for predicted gene targets of biomarker miRNAs 
 
As an alternative approach to focusing on candidate protein targets of miRNAs, their 
regulatory roles can be investigated through a consideration of the multiple proteins 
that they can regulate. The first step in such an analysis is the use of computational 
methods for prediction of potential gene targets. Most of these methods rely heavily 
on the sequence of the mature miRNAs, which can be seen in Table 5.5. 
 
Table 5.5 Mature sequence of biomarker microRNAs 
 
microRNA  sequence (5’ to 3’) 
miR-200a uaacacugucugguaacgaugu 
miR-200b uaauacugccugguaaugaugac 
miR-429 uaauacugucugguaaugccgu 
miR-96 uuuggcacuagcacauuuuugcu 
miR-182 uuuggcaaugguagaacucacaccg 
miR-34a uggcagugucuuagcugguugu 
miR-203 gugaaauguuuaggaccacuag 
miR-99a aacccguagauccgaucuugug 
miR-193 aacuggccuacaaagucccagu 
Mature sequences were obtained from miRBase (http://www.mirbase.org/). Highlighted in red 
is the seed region (nucleotides 2-8) for each miRNA. MiRNAs belonging to the same family 
are coloured the same colour and grouped in brackets. 
 
 
As can be seen miRNAs belonging to the same families have very similar mature 
sequences, supporting their overlapping regulatory roles. MiR-200b and miR-429 in 
particular have exactly the same seed sequence (aauacug), while they differ from 
{ 
{ 
} 
} 
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miR-200a by a single base. Similarly, the seed regions of miR-96 and miR-182 differ 
by only one base.  
 
TargetScan is a widely used in silico tool for the prediction of miRNA targets which 
takes into account a number of parameters (the strength of the seed pairing, the 
number of complementary sites between the miRNA and the mRNA, the location of 
complementary sites,  etc.) (Bartel, 2009). Although imperfect, this computational 
method can identify most regulatory targets of miRNAs. It has been experimentally 
shown to be more successful than other miRNA target-prediction tools (Baek et al., 
2008).  
 
Here the latest release of TargetScan (5.1) was used to predict the genes that are 
regulated by the biomarker miRNAs. For miR-200b and miR-429 the same genes are 
predicted gene targets due to the fact that the miRNAs have the same seed sequence. 
The generated lists of predicted gene targets were then analysed within the 
PANTHER database (Thomas et al., 2006). This classification system groups genes 
according to their known functions, families, pathway etc. Binomial statistics were 
used to compare the classification of the predicted miRNA-target genes with that of 
genes within the reference rat genome. Pathways for which there was an over-
representation of predicted miRNA gene targets could then be highlighted. The full 
list of the allocation of predicted miRNA targets to pathways can be viewed in the 
Appendix III section. In Table 5.6 the numbers of genes and the top five over-
represented pathways within the TargetScan generated lists for the biomarker 
miRNAs are shown. 
 
Chapter 5 
 - 216 - 
 
Table 5.6 Top pathways enriched with predicted targets of biomarker microRNAs 
 
 
miRNA # of predicted 
targets 
Top five over-represented pathways ranked by p 
value 
miR-96 672 PI3K (18, p<0.0001); EGF receptor (16, p<0.0001), 
Integrin (18, p<0.0001); insulin/IGF (12, p<0.0001), 
FGF (14, p<0.0001) 
miR-182 659 PI3K (15, p<0.0001); EGF (16, p<0.0001), FGF (13, 
p<0.0001); TGF-beta (13, p=0.0001), metabotropic 
glutamate receptor III (9,p=0.0001) 
miR-
200b/429 
637 PDGF (20, p<0.0001); Ras (14, p<0.0001); PI3K (16, 
p<0.0001); EGF (16, p<0.0001); FGF (15, p<0.0001) 
miR-200a 438 Insulin/IGF (11, p<0.0001); PI3K (12, p<0.0001); 
TGF-beta (12, p<0.0001); EGF (11, p<0.0001); 
interleukin (11, p=0.0001) 
miR-203 415 Integrin (12, p<0.0001); angiogenesis (11, p<0.0001); 
p53 pathway feedback loops 2 (6, p<0.0001); 
insulin/IGF (7, p<0.0001); PI3K (6, p<0.0001) 
miR-34a 376 TGF-beta (12, p<0.0001); PI3K (9, p<0.0001); 
metabotropic glutamate receptor III (7, p<0.0001); 
metabotropic glutamate receptor II (6, p=0.0002); 
insulin/IGF (7, p=0.0003) 
miR-193 99 EGF (6, p<0.0001); FGF (5, p=0.0001); Ras (4, 
p=0.0003); PDGF (5, p=0.0003); Inflammation 
mediated by cytokine and chemokine signalling (4, 
p=0.004)  
miR-99a 36 WNT(4, p=0.0004), Angiogenesis (3, p=0.002), 
presenilin (2, 0.01), Cadherin signalling (2, p=0.02); 
p53 pathway by glucose deprivation (1, p=0.03)  
MiRNA targets were predicted using TargetScan v5.1 and allocated to pathways using the 
PANTHER database. Top five pathways per miRNA are shown as ranked by p. value. Within 
brackets are shown the number of predicted miRNA-target genes that belong to that pathway 
and the calculated p. value.   
 
 
As can be seen there is a considerable variability in the number of proteins that are 
predicted to be regulated by miRNAs (from several hundreds to only 36 for miR-99a, 
see Appendix III). Interestingly, the analysis above clearly shows that the predicted 
miRNA target genes are enriched for genes belonging to the same signalling 
pathways. These pathways are thought to be important in the development of HCC 
e.g. PI3K, TGF-beta, WNT, Ras (Llovet & Bruix, 2008).  
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5.3.4 Synergistic activities of PB-induced miRNAs 
 
Next the focus was placed on examining the predicted effects of PB deregulated 
miRNAs on cellular pathways. Often individual miRNAs have a relatively modest 
effect on the levels of protein expression (Selbach et al., 2008, Baek et al., 2008). 
However, it is reasonable to assume that even small effects of miRNAs on protein 
expression can be additive when miRNAs target several proteins of the same 
signalling pathway. Moreover, a protein will be much more effectively silenced when 
it is targeted by several miRNAs at the same time. Since the main effect of PB on the 
liver miRNAome is the coordinated progressive induction of the two miRNA clusters 
(miR-96/182 and miR-200a/200b/429), the possibility of overlap in their regulatory 
roles was examined. Indeed, analysis showed that miRNA members of the two 
clusters are predicted to target several targets within the PI3K, TGF-beta, Ras, and 
EGF pathways (Tables 5.7-5.10).  
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Table 5.7 Predicted gene targets of phenobarbital-induced microRNAs in the PI3K 
pathway 
 miR-200a miR-200b/429 miR-96 miR-182 
AKT2 - X - - 
CCND2 - - X X 
FOXA1 X - - - 
FOXA2 X - - - 
FOXF2 - - X X 
FOXG1 - X - - 
FOXJ3 X - - - 
FOXK1 - X - - 
FOXK2 - X X X 
FOXN2 X X - - 
FOXN3 X X X X 
FOXO1 - - X (Verified) X (Verified) 
FOXO3  X X (Verified) X (Verified) 
FOXO4 - - X - 
FOXP1 X X - - 
FOXP2 X X X X 
FOXQ1 - - X X 
GNAI3 - X X X 
GNAQ - - X X 
GRB2 X - X (Verified) X (Verified) 
INPP5A - - X X 
IRS1 - - X (Verified) - 
IRS2 X - - - 
KRAS - X X (Verified) - 
PDPK1 - X - - 
PIK3R1 - - X X 
PTEN X X - - 
RPS6KB1 - X - - 
SOS1 - - X X 
YWHAB - X - - 
YWHAG X X X X 
YWHAZ X - - - 
 
Genes are marked with “X” if they were predicted to be regulated by that miRNA by 
TargetScan. “Verified” signifies that the miRNA has been reported to regulate that gene by 
luciferase assays. 
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Table 5.8 Predicted gene target of phenobarbital-induced microRNAs in the TGF-
beta pathway 
 
miR-200a miR-200b/429 miR-96 miR-182 
ACVR1 - - X X 
ACVR2A X X - - 
ACVR2B - X - - 
BMP1 X - - - 
CITED2 X - - X 
CREBBP X - - - 
FOXA1 X - - - 
FOXA2 X - - - 
FOXF2 - - X X 
FOXG1 - X - - 
FOXJ3 X - - - 
FOXK1 - X - - 
FOXK2 - X X X 
FOXN2 X X - - 
FOXN3 X X X X 
FOXO1 - - X (Verified) X (Verified) 
FOXO3  X X (Verified) X (Verified) 
FOXO4 - - X - 
FOXP1 X X - - 
FOXP2 X X X X 
FOXQ1 - - X X 
GDF6 X - - X 
JUN - X - - 
KRAS  X X (Verified)  
MAPK1 - - - X 
SMAD1 - - - X 
SMAD7 - - X X 
SMURF2  X   
TGFB2 X (Verified) - - - 
TGFBR1 X - - - 
TLL1 - - X - 
 
Genes are marked with “X” if they were predicted to be regulated by that miRNA by 
TargetScan. “Verified” signifies that the miRNA has been reported to regulate that 
gene by luciferase assays. 
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Table 5.9 Predicted gene target of phenobarbital-induced microRNAs in the Ras 
pathway 
 
miR-200a miR-200b/429 miR-96 miR-182 
AKT2 - X - - 
CDC42 X - - - 
ETS1 - X (Verified) - - 
GRB2 X - X (Verified) X (Verified) 
JUN - X - - 
KRAS - X X (Verified) - 
MAPK1 - - - X 
MAP2K1 - - X X 
MAP2K3 - - X - 
MAP2K4 X - - - 
PAK1 - - X - 
PAK6 - X - - 
PAK7 - X - - 
PDPK1 - X - - 
PLD1 - - - X 
RAC1 - X X X 
RALGDS - - - X 
RGL1 - X - - 
RHOA - X - - 
RPS6KA2 - X - - 
RPS6KA3 - X - - 
SHC1 - X X - 
SOS1 - - X X 
SRF - X - - 
TIAM1 X - - - 
 
Genes are marked with “X” if they were predicted to be regulated by that miRNA by 
TargetScan. “Verified” signifies that the miRNA has been reported to regulate that 
gene by luciferase assays. 
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Table 5.10 Predicted gene target of phenobarbital-induced microRNAs in the EGF 
pathway 
 
miR-200a miR-200b/429 miR-96 miR-182 
AKT2 - X - - 
CBL X X - - 
CDC42 X - - - 
GAB2 - - X X 
GAB4 - - - X 
GRB2 X  X (Verified) X (Verified) 
HBEGF - - X - 
KRAS - X X (Verified) - 
MAPK1 - - - X 
MAP2K1 - - X X 
MAP2K3 - - X - 
MAP2K4 X - - - 
MAP3K3 X - X X 
MAP3K5 - X - - 
MRAS - - X X 
NF1 - - X X 
PI3K2CA - - X - 
PLCG1 - X (Verified) X X 
PPP2CA X X - - 
PPP2R5C - X - - 
PPP2R5E - X - - 
PRKCA - X - - 
PRKCE X - X X 
PRKD1 - X - X 
RAC1 - X X X 
RAP1B - X - - 
RAP2C - X - - 
RASA1 - - - X (Verified) 
SHC1 - X X - 
SOS1 - - X X 
SPRY4 X - - X 
STAT5B X - - - 
YWHAB - X - - 
YWHAG X X X X 
YWHAZ X - - - 
 
Genes are marked with “X” if they were predicted to be regulated by that miRNA by 
TargetScan. “Verified” signifies that the miRNA has reported to regulate that gene by 
luciferase assays. 
 
This observation suggests that the induction of these miRNAs can have significant 
effects on the functioning of these signalling pathways which are important for the 
regulation of cell proliferation and apoptosis. 
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5.4 Discussion 
 
Given the important roles of miRNAs in physiology and disease it is expected that 
they will be under strict transcriptional regulation. Altered methylation patterns are 
one possible mechanism that could drive the observed hepatic miRNA deregulations 
observed after chemical treatments. It has been estimated that CpG islands are found 
in the promoter regions of 40% of mammalian genes (Larsen et al., 1992). CpG 
islands were also identified upstream of all the potential biomarker miRNAs, with the 
exceptions of miR-99a and miR-200a/200b/429. The presence of CpG islands in their 
promoters is an indication that methylation could be an important factor regulating 
their expression. For the miR-200a/200b/429 cluster a CpG island was only identified 
in the human promoter, but not for its rodent counterparts. It should be noted that 
methylation of this CpG island has been shown to be important for the regulation of 
this cluster in humans (Li et al., 2010).  Future research should examine whether the 
absence of a CpG island in rodents compared to humans is an important aspect of the 
regulation of these miRNAs.  
 
Chemical carcinogens could also deregulate miRNAs by affecting the activities of 
transcription factors that regulate them. Amongst the biomarker miRNAs, a conserved 
consensus p53 binding motif was found only in the promoter of miR-34a. It seems 
probable that its pronounced activation observed in 2-AAF treated samples is due to 
the DNA damage caused by the chemical stimulating miR-34a via p53 activation. 
Toxicogenomic studies have previously shown that GNTX and NGTX carcinogens 
have different gene expression profiles (Ellinger-Ziegelbauer et al., 2005). The 
distinctive characteristic of GNTX carcinogens was that they affected cellular 
pathways involved in DNA damage response, proliferation, and survival. The 
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profound 2-AAF-induced upregulation of miR-34a can then be interpreted as part of 
the DNA damage response.  
 
Since the miR-200a/200b/429 cluster was induced at 90 days by several chemical 
treatments (PB, BP, DEHP, 2-AAF, and Chl. Ac), it was reasonable to assume that the 
factor mediating the induction of this miRNA cluster would be a common target of 
these chemicals. The biggest induction of this cluster was clearly observed after PB 
treatment. Moreover, a more modest induction of the cluster was also observed in the 
livers of BP-treated animals. Given that BP appears to be a weaker inducer of PB-type 
responses in the liver (e.g. smaller induction of cyp2b1 gene) it is probable that the 
miRNA cluster is induced as a consequence of the deregulation of a gene pathway 
that is strongly affected by PB. Activation of CAR is a main mechanism by which PB 
propagates its effects (Ueda et al., 2002). However a number of observations 
indicated that CAR is not the mediator of the activation of these miRNAs: (1) the 
other chemical treatments which affected the miR-200a/200b/429 cluster in this study 
(i.e. 2-AAF, MP HCL, Chl.Ac) are not thought to activate CAR (2) PB treatment 
activates CAR activity immediately, while miR-200a/200b/429 only become induced 
after 1-2 weeks.  
 
Hence, the two other transcription factors that are affected by PB (c-myc and HNF4α) 
were considered as better candidates for factors regulating the expression of the miR-
200a/200b/429 cluster. C-myc is commonly activated in the liver by treatments with 
NGTX carcinogens (Nie et al., 2006, Lee & Edwards, 2003).  C-myc has also been 
reported to regulate the miR-200a/miR-200b/429 cluster in murine embryonic stem 
cells (Lin et al., 2009). A potential link between HNF4α and the expression of the 
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miR-200 family is suggested by the fact that HNF4α is a regulator of EMT in the liver 
(Ning et al., 2010, Yue et al., 2010, Parviz et al., 2003).  Interestingly, binding motifs 
for both c-myc and HNF4α were identified within the proximal promoter region of the 
miR-200a/200b/429 cluster. It is important to note that identification of putative 
transcription factor binding sites is not proof that the miRNAs are regulated by the 
transcription factors. Experimental validation is required to verify the proposed sites 
of regulation (e.g. chromosomal immunoprecipitation and electrophoretic mobility 
shift assay). However, the identification of the putative binding sites is a starting point 
indicating that these transcription factors could regulate these miRNAs. 
 
For many miRNAs it has been shown that they can have pronounced effects through 
their regulation of a single or a few protein targets. One of them is miR-29b which by 
repressing DNA methyltransferases can affect global DNA methylation. Here an 
inverse relationship was found between the expression of miR-29b in PB-treated liver 
and the global hepatic DNA methylation. What is the functional significance of the 
altered methylation observed in PB-treated livers? One possibility is that the increased 
activity of DNMT enzymes results in the aberrant methylation of tumour suppressor 
genes, which persists after global DNA levels return back to normal. A second 
possibility however, is that the transient induction of global DNA methylation may be 
an adaptive mechanism protecting the organ from excessive demethylation. A recent 
study found an association between the downregulation of members of miR-29c, a 
miRNA that also regulates DNMT enzymes, and resistance to disruption of global 
hepatic methylation (Pogribny et al., 2010). Older studies had shown that global 
hypomethylation is more pronounced in PB-treated livers of mice strains susceptible 
to PB-treated carcinogenesis (Counts et al., 1996).  The repression of miR-29b in PB-
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treated rats, and the resultant increase in the activity of DNMT enzymes, may protect 
the animal from excessive demethylation and be part of the reason that rats are 
relatively resistant (compared to some mice strains) to PB-induced tumours. 
 
In a similar vein it has also been shown that members of the miR-200 family of 
miRNAs are master-regulators of EMT in various cell types via regulation of the 
Zeb1/Zeb2 proteins (Korpal & Kang, 2008, Gregory et al., 2008b). EMT is a very 
important event during embryonic development, as well as for wound healing. 
Evidence accumulated in recent years supports that EMT could be an important step 
in the acquisition of more invasive and malignant properties by neoplastic hepatocytes 
(van Zijl et al., 2009, Choi & Diehl, 2009). A reciprocal association between the 
expression of miRNA members of the miR-200 family and the expression of the 
zeb1/zeb2 proteins in the rat liver has been reported previously (Pogribny et al., 
2009a, Pogribny et al., 2010, Tryndyak et al., 2009). Moreover, overexpression of 
miR-200b in primary mouse hepatocytes induces a higher expression of the E-
cadherin protein (Pogribny et al., 2010). Therefore, the induction of the hepatic miR-
200a/200b/429 cluster by PB treatment would be expected to elevate the expression of 
epithelial genes in the liver. It is interesting to note the Phillips et al., 2009 study, 
which treated CAR WT and CAR KO mice with a carcinogenic PB dose for 23 weeks 
(precancerous tissue) and 32 weeks (100% liver tumours). They found that at 23 
weeks of PB treatment hepatic cdh1 was induced only in the CAR WT mice.  This 
was reversed at 32 weeks in liver tumours. This finding is in agreement with an early 
induction of the miR-200 family of miRNAs.   
 
Here it was found that, as expected, the induction of miR-200a/200b/429 was 
inversely correlated to the expression of the zeb1/zeb2 proteins. However, despite the 
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observed repression of the Zeb1/Zeb2 proteins, no evidence was found that the 
observed induction of miR-200a/200b/429 cluster affected the expression of hepatic 
epithelial or mesenchymal markers. It is possible that downregulation of zeb1/zeb2 is 
not sufficient by itself to cause a stable induction of hepatic cdh1 because other 
regulatory factors are important e.g. methylation of E-cadherin promoter and activity 
of other transcription factors such as snail, twist, etc. Alternatively, the induction of 
miR-200a/200b/429 may act to protect the epithelial status of hepatic cells from other 
signalling pathways that promote EMT.  
 
Computational tools were then used to identify pathways that were enriched amongst 
proteins that are predicted to be regulated by the biomarker miRNAs. Of course any 
prediction tool that is used is imperfect, resulting in the misprediction of some 
miRNA-targets and overlooking some real targets of miRNAs. Nevertheless, since 
target-prediction tools (such as TargetScan) can pick up multiple true targets of 
miRNAs (Baek et al., 2008), they can be used to elicit the regulatory roles of 
miRNAs. Examination of the targets predicted for the biomarker miRNAs that are 
altered by the carcinogens in the present study revealed that they target pathways that 
are important in HCC e.g. PI3K, EGF, etc. 
 
Intriguingly, examination of the predicted targets of the PB-induced miRNAs 
indicated that they could be involved in a long known observation about PB: its 
biphasic effect on the liver. Many liver tumour promoters (such as PB or TCDD) 
stimulate a transient hepatic cell proliferation, followed by a sustained induction of a 
mitoinhibitory state (Andersen et al., 1995). It was first shown that inclusion of PB in 
the diet resulted in the suppression of hepatic proliferation in mice fed a choline-
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deficient diet (Abanobi et al., 1982). Shortly after a second study found that long term 
PB treatment (four weeks and 12 months) inhibited the mitogenic response in rat liver 
after 2/3 partial hepatectomy. This effect was progressive, with a stronger inhibitory 
effect at 12 months than at four weeks, and no effect of short term PB treatment 
(Barbason et al., 1983). It has also been shown that hepatocytes isolated from livers 
after chronic PB treatment are less responsive to mitogenic factors (Fletcher et al., 
1999, Fletcher et al., 1997, Tsai et al., 1991). In addition, chronic PB administration 
(1000 ppm PB) for eight weeks resulted in a decreased activation of PKC by 
treatment with Phorbol ester (Brockenbrough et al., 1991).  
 
EGF is a prosurvival and mitogenic pathway that frequently displays aberrant 
activation in HCC (Llovet & Bruix, 2008, Liu et al., 2006). In accordance with the 
mitoinhibitory effects of long-term PB treatment, members of the two miRNA 
clusters induced by the chemical target several key proteins which are involved in the 
transmission of EGF signalling (Figure 5.12).  
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Figure 5.12: Predicted targets of the miR-200a/200b/429 and miR-96/182 cluster 
found in EGF signalling pathway 
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Fig. 5.12 Red boxes are verified miRNA targets from literature, green boxes are predicted 
targets by TargetScan. * Within red or green boxes signify how many of the screened 
miRNAs (miR-200a/200b/429/182/96) are predicted to regulate that gene. EGF signalling 
pathway is initiated by the binding of a growth factor (EGF, TGF-α, HB-EGF) onto the EGF 
receptor, resulting in activation of the tyrosine kinase activity of the receptor. Intracellular 
signalling eventually affects cellular proliferation, survival, invasion etc. 
 
Some of these predicted targets have been experimentally confirmed in previously 
reported studies e.g. that GRB2 is regulated by miR-96 and miR-182 (Xu & Wong, 
2008); KRAS by miR-96 (Yu et al., 2010); PLCG1 by the miR-200b and miR-429 
miRNAs (Uhlmann et al., 2010). Importantly, several of the predicted targets are 
important upstream and/or linkage parts of the pathway. GRB2, SOS1, and SHC link 
growth factors to the activation of the RAS/RAF/MEK/ERK pathway 
(Dharmawardana et al., 2006). It has also been known for some time that PB 
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promotion acts to negatively select Ha-ras mutations (Aydinlik et al., 2001). PLC 
gamma is important for the activation of PI3K and PKC by the EGF pathway (Wells, 
1999).  
 
The induction of the two miRNA clusters by PB also agrees temporally with the 
initiation of the shift in PB-treated liver from a proliferating to a mitoinhibitory state. 
Ki67 data suggest that the PB-stimulated entrance of quiescent hepatic cells into the 
cell cycle occur in day 3 and is completed by day 7 (Table 4.4).  The two clusters are 
induced after one week of PB treatment, when the transient hyperplastic effect of PB 
ceases. Therefore, examination of the predicted targets of the PB-induced 
miRNAs suggests that they are involved in the shift of the liver to a 
mitoinhibitory state.  
 
In conclusion, the work performed here suggests that altered methylation or 
deregulation of transcription factors could underlie the observed changes in the 
expression of hepatic miRNAs. An inverse association was shown here between the 
expression of miR-200a/200b/429 and zeb1/zeb2, important protein regulators of 
EMT, as well as between the expression of miR-29b and global DNA methylation. 
Moreover, computational analysis suggests that the miRNAs that were found here to 
be targeted by chemical hepatocarcinogens regulate the activity of key cellular 
pathways. 
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6.1 MiRNA signatures are a promising approach to facilitate 
chemical risk assessment 
 
As was described in the Introduction (Section 1.4), there is a growing need for the 
development of alternative strategies for the assessment of chemical compounds. The 
principal hypothesis of this project was that hepatic miRNA profiles can contribute to 
the development of such alternative strategies. This project generated several 
important findings concerning the hypothesis of this project. These results were 
extensively discussed previously (see Discussions Chapters 3-5). Briefly, among the 
key findings were: 
 
(a) That all the tested carcinogenic treatments -which included chemicals with 
diverse MOA and carcinogenic potencies- resulted in the deregulation of 
hepatic miRNAs after 90 days in the pre-neoplastic liver tissue.  
 
(b) That there is possibly a link between hepatic miRNA profiles and the MOA of 
the chemical treatments -as indicated by the very similar hepatic miRNA 
profiles of PB and BP.  
 
(c) That although some miRNA perturbations were chemical-specific, the most 
significant effects of chemical treatments could be seen on a small set of 
“biomarker” miRNAs.  These miRNAs are predicted to affect pathways that 
are important in the development of HCC. 
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(d) That dose and temporal parameters greatly affect the hepatic miRNAome 
responses to the chemical treatment.  Carcinogenic dose of PB had distinct 
hepatic miRNA profiles from non-carcinogenic doses. It was also found that 
effects of continuous PB treatment on the hepatic miRNAome were becoming 
progressively more pronounced through 90 days of treatment.   
 
 
To the best of my knowledge this was the first study that has investigated in 
depth the effects of treatments with chemical hepatocarcinogens on the liver 
miRNAome. The data generated support the hypothesis that hepatic miRNA 
profiles can facilitate the earlier prediction and an improved mechanistic 
understanding of chemical hepatocarcinogens. Therefore, the utilisation of 
hepatic miRNAs profiles for the risk assessment of chemicals is a promising 
strategy that qualifies for further investigation.   
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6.2 MiRNA deregulations in the pre-neoplastic liver treated with 
hepatocarcinogens: Extraneous, adaptive or adverse? 
 
Given that chemical treatments affect the liver miRNAome, what is the phenotypic 
importance of these changes? There are three possible answers to this question:  
 
 (1) The miRNA changes are an extraneous response to chemical treatments.  
One possibility is that the observed changes in miRNA expressions are functionally 
irrelevant, not affecting the activity of proteins that are important for HCC 
development. In such a case the deregulation of miRNAs may be occurring passively 
due to the perturbation of upstream cellular pathways or as side-effects of the 
histopathological effects induced by the chemical treatments. It should be noted that 
even if that were the case, miRNA signatures would still be highly useful, so long as 
they possess sufficient specificities and sensitivities. However, in that case the 
mechanistic insight that could be gained from the study of these miRNAs would be 
more limited.  
 
(2) The miRNA changes contribute to the adaption of the liver to the chemical 
treatments. Adaptive liver responses to xenobiotic exposure are those which do not 
affect organ or animal viability, are reversible, maintain homeostasis, and enhance the 
ability of the organ to respond to the xenobiotic stress (Williams & Iatropoulos, 
2002). The livers which were examined here had been exposed to the chemical 
treatments for considerable time (up to 90 days), hence it is reasonable to expect that 
liver should have adapted to the chemical treatments by that point. Given the known 
regulatory role of miRNAs over key toxicological events (e.g. proliferation and 
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apoptosis), the changes in miRNA expressions could contribute to the eventual 
adaptation of the liver to the chemical responses. 
 
(3) The miRNA changes are adverse responses to the chemical treatments that 
contribute to the eventual carcinogenesis. Ample evidence supports the important 
role of miRNAs in HCC (see section 1.3.5). Hence the deregulated miRNAs in the rat 
liver could contribute to the eventual development of HCC by the disruption of key 
cellular pathways. These changes could facilitate the eventual development of 
mutations or offer a selective advantage to initiated pre-malignant cells. In addition, 
there is some evidence that disruptions of cellular pathways can occur firstly by 
epigenetic defects, followed later on by genetic mutations (Baylin & Ohm, 2006), 
hence early deregulations of miRNAs can possibly lead to an “addiction” of the 
incipient cancer cells to dysregulated pathways.   
 
It is certainly possible that all three cases may be true at the same time, with some of 
the observed miRNA deregulations being adaptive responses, some having adverse 
consequences, while others could be extraneous events. Clarifying which of the three 
possibilities is the case for individual miRNAs is a challenging task, since several 
important aspects of miRNA functioning have still not been elucidated. For example, 
it is still uncertain whether the main effects of miRNAs are mediated by the regulation 
of a few key proteins or through the totality of their effects on the proteome. A second 
uncertainty is whether effects have a threshold. There is evidence to support the latter 
suggestion (Brown et al., 2007, Sarasin-Filipowicz et al., 2009). Therefore, it is still 
vague whether the observed hepatic miRNA deregulations after chemical treatment in 
the rat have to exceed certain threshold (1.5-fold? 5-fold? 10-fold?) before they have 
significant effects. Closely related to this issue is the question of whether modest 
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deregulation of highly expressed miRNAs or considerable deregulations of miRNAs 
with lower expression are more important functionally. It is known that there is wide 
diversity in the expression levels of hepatic miRNAs (Hou et al., 2011). For instance, 
the hybridisation signal for miR-99a determined in this study was 45 times higher 
than that for miR-34a. Yet, for miR-99a the maximum deregulation by chemical 
treatment in the rat liver was measured at 1.6-fold, while for miR-34a that value was 
27.9 fold. At present it is not clear which of the two deregulated miRNAs would have 
the most important phenotypic significance.   
 
A further confusing factor is that the effects of miRNAs vary in different cellular 
contexts. This is a reasonable consequence of the fact that miRNAs propagate their 
cellular effects through the proteins that they regulate, while the protein milieu varies 
between cell types, developmental stage, and according to environmental conditions. 
For example in pancreatic cancers a tumour suppressive role has been suggested for 
miR-96 through regulation of KRAS (Yu et al., 2010), whilst in ovarian cancers miR-
96 is thought to act as an oncogene by suppressing the expression of FOXO proteins 
(Myatt et al., 2010). Hence, extrapolation of miRNA effects determined in one cell 
type to effects in a different cell type can be misleading. This is an uncertainty in the 
current study. 
 
Despite all these confounding factors, cautionary examination of the phenotypic 
consequences of miRNA deregulation has been attempted (Chapter 5). For the set of 
“biomarker” miRNAs (Table 3.13), the most probable interpretation is that their 
deregulation has some functional importance. This conclusion is based on their 
frequent deregulation by chemical carcinogens, their deregulation in various cancers 
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including HCC (Table 3.15), and the bioinformatic prediction that they regulate 
pathways which are important in cancer development (Table 5.6).  
 
Two of the proposed biomarker miRNAs were miR-99a and miR-203, which had 
been previously reported to be downregulated in HCC compared to normal liver 
(Furuta et al., 2010, Hou et al., 2011). MiR-99a is a miRNA with relatively high 
expression in normal liver (sixth highest in normal human liver according to Hou et 
al., 2011, who used a deep sequencing approach). This miRNA showed the biggest 
downregulation trend following treatment with the two most potent carcinogens, 2-
AAF and MP HCl. It has been reported that downregulation of this miRNA can 
induce mTOR signalling (Doghman et al., 2010).  Interestingly, few targets are 
predicted for miR-99a using TargetScan (Table 5.6). Among its targets were FZD5 
and FZD8, two receptors of WNT ligands, suggesting that this miRNA may also be 
involved in the dysregulation of β-catenin signalling in HCC. Importantly, both the 
mTOR and beta-catenin pathways are important in HCC development (Whittaker et 
al., 2010). MiR-203 has been reported to be downregulated by aberrant methylation in 
HCC (Furuta et al., 2010) as well as in several other cancers (Kozaki et al., 2008, 
Bueno et al., 2008, Bo et al., 2011, Chiang et al., 2011). In different cellular contexts, 
miR-203 has been reported to repress cellular proliferation and to promote 
differentiation (Furuta et al., 2010, Bueno et al., 2008, Yi et al., 2008). Hence a 
logical explanation is that the deregulation of these two miRNAs contributes to the 
development of chemical-induced HCC. 
 
Another miRNA that was frequently found to be affected by chemical carcinogens 
was miR-34a. In various cell types miR-34a has been shown to induce apoptosis and 
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senescence (Chang et al., 2007, He et al., 2007). This fact suggests a tumour-
suppressive role for miR-34a. In accordance with this, expression of this miRNA is 
often lost in various tumours due to either chromosomal deletions or epigenetic 
silencing (Hermeking, 2010, Hermeking, 2007).  As has been discussed previously 
(section 5.4), the potent induction of miR-34a by 2-AAF is most probably the result of 
DNA damage. However, miR-34a was also induced- though much more modestly- by 
three presumed NGTX carcinogens (MON, Chl.Ac, MP HCL). For these carcinogens 
transcriptomic data did not indicate activation of the p53 or apoptotic pathway (R.A 
Currie, personal communication). It will be interesting to establish whether the 
induction of this miRNA by the three NGTX carcinogens is associated with DNA 
damage.  
 
Despite the fact that miR-34a has been reported to be a tumour-suppressor miRNA in 
several types of cancers, there is also a possibility that it can have oncogenic effects 
during HCC development. In the liver miR-34a has been reported to be progressively 
upregulated between normal to cirrhotic and cirrhotic to HCC (Pineau et al., 2010). 
Interestingly, it has been reported that in the livers of rat treated with 2-AAF the miR-
34a-p53 feedback loop is disrupted (Pogribny et al., 2009a). The effects of miR-34a 
on cellular proliferation have been reported to be cell-type and context dependent 
(Dutta et al., 2007). A recent study suggests that in conditions of myc overexpression 
miR-34a can be anti-apoptotic (Sotillo et al., 2011). Recently it has also been reported 
that miR-34a targets HNF4α (Takagi et al., 2010) which is a tumour suppressor in 
HCC (Ning et al., 2010). Hence the role of miR-34a in HCC development needs to be 
examined further. 
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The most common effect of chemical treatments on the liver miRNAome though was 
the induction of the miR-200a/200b/429 cluster. It is interesting to note that members 
of the miR-200 family are expressed predominantly in epithelial cells. Of the most 
abundant hepatic cells, hepatocytes and the SECs are epithelial, while KC and HSCs 
are mesenchymal (Bhunchet & Wake, 1992). This suggests that the induction of miR-
200a/200b/429 occurs within hepatic epithelial cell populations. The miR-200 family 
has been one of the most extensively studied in recent years due to its central role in 
the regulation of several key signalling pathways (Figure 6.1). 
 
Figure 6.1 Central regulatory role of the miR-200 family 
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Fig. 6.1 In recent years this miRNA family has been shown to be involved in the regulation of 
key signalling pathways: EMT (Burk et al., 2008, Gregory et al., 2008b); PI3K (Hyun et al., 
2009); EGF (Uhlmann et al., 2010, Adam et al., 2009); Notch (Brabletz et al., 2011, Vallejo 
et al., 2011); Stemness (Shimono et al., 2009, Wellner et al., 2009); Beta-catenin (Xia et al., 
2010); Angiogenesis (Chan et al., 2011); and TGF-beta (Wang et al., 2011) 
 
These regulatory roles suggest that the early induction of the miR-200a/200b/429 may 
be an adaptive response of the liver, regulating hepatocyte proliferation, invasion, 
survival, and angiogenesis (through the regulation of EGF pathway, beta-catenin, 
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notch etc.) after continued treatment with chemical carcinogens. This regulatory role 
is in agreement with the fact that five out of six hepatocarcinogenic treatments 
induced this miRNA cluster in the liver. In addition, expression of these miRNAs is 
downregulated in HCC compared to normal liver (Gramantieri et al., 2007, Jiang et 
al., 2008, Ladeiro et al., 2008, Ura et al., 2009). It was also hypothesised that 
members of the miR-200a/200b/429 and miR-96/182 clusters can cooperate to more 
effectively regulate cellular pathways (Tables 5.7-5.10; Figure 5.12) 
 
6.3 Future work  
Reflection on the main findings of this project, points to several further research 
avenues that can be pursued. A first obvious line of research to be followed would be 
the examination of hepatic miRNA profiles of animals treated with more chemicals, at 
different timepoints, and with various doses. Examination of larger sets of liver 
samples would address several of the limitations discussed previously (for example a 
more accurate estimation of sensitivities and specificities of miRNA signatures or the 
optimal timepoint to use these signatures to predict carcinogenicity).  
 
The most complete dataset on chemical-induced hepatic miRNA expressions was 
generated here for PB, a prototype of NGTX carcinogens (Chapter 3 and 4). The 
main effect of the chemical on the hepatic miRNAome was found to be the 
progressive induction of the miR-200a/200b/429 and miR-96/182 clusters. It will be 
important to examine further the effects of PB on the liver miRNAome. This could 
include examining the miRNAome of hepatic foci and tumours generated by chronic 
PB treatment. This would allow determination of whether the effects of PB treatment 
on miRNAs, and the miR-200a/220b/429 and miR-96/182 clusters specifically, 
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continue until tumour development or whether they reverse at later stages.  
Examination of the miRNAome of livers from animals in which PB treatment was 
terminated some time before animal sacrifice will also demonstrate whether the 
miRNA deregulations are stable or reversible. In view of the reversible nature of 
chemical-induced NGTX carcinogenesis, such studies will be important 
 
As discussed previously, it is important to determine the identity of the hepatic 
cellular populations in which miRNA deregulation take place to assess cell 
specificity. Several different methodologies are currently available which attempt to 
localise changes in gene expressions within selective tissues. One such methodology 
is in situ hybridisation, which is based on the binding of labelled probes onto target 
sequences. For example, the localisation of miRNA deregulation of miR-21 in cardiac 
disease occurs within cardiac fibroblasts (Thum et al., 2008).  A second possible 
method is to examine directly the expression of miRNAs in purified hepatic cell 
fractions. Protocols are available that allow the isolation of specific cell types from 
whole liver tissues (e.g. hepatocytes, HSCs, KC). Hence, the examination of hepatic 
miRNAs in isolated cell fractions from chemically-treated livers could inform the 
localisation of miRNA deregulation.  It is also important to note that in this project 
most probably only a small fraction of the complete rat miRNAome examined. In 
January 2010, 350 rat miRNAs were known compared to 700 mouse and 1000 human 
miRNAs. No fundamental reason is known for why the number of miRNAs should 
vary between species by such a degree; hence it is expected that a large number of rat 
miRNAs remain to be identified. Indeed, a single recent study identified 61 new rat 
miRNAs (Linsen et al., 2010). Therefore, it is probable that this project overlooked a 
large fraction of hepatic miRNAs. However, it is important to note that the first 
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miRNAs to be identified in rats, and which were examined here, represent ones which 
are highly conserved across eukaryotes and which thus possibly have the most 
important regulatory roles. A more complete examination of the effects of chemicals 
on the liver miRNAome can be performed in the future when a larger proportion of 
the rat miRNAome would have been identified. 
 
At present considerable challenges exist in linking the expressions of miRNA with 
that of mRNA. For example, it is not possible to predict a priori whether a gene target 
of a miRNAs is regulated by mRNA degradation or repression of translation 
(Fillipowitz et al., 2008). In addition, the bioinformatic tools for predicting the genes 
which are regulated by miRNAs are currently imperfect (Bartel et al., 2009). It is 
expected that in the future as this and other issues are addressed, it will be possible to 
perform a much more robust integration of mRNA with miRNA data.  
 
An exciting possibility, if still somewhat controversial, is the use of circulating 
miRNAs found in bodyfluids as biomarkers of diseases (Gilad et al., 2008, Kosaka et 
al., 2010, Fabbri, 2010). Normally RNA species are rapidly degraded in biofluids due 
to the presence of ribonucleases, however circulating miRNAs are highly stable 
because they are located within lipid or lipoprotein complexes (Kosaka et al., 2010). 
Several studies have shown that levels of circulating miRNAs are altered in cancer 
(Mitchell et al., 2008, Taylor & Gercel-Taylor, 2008, Huang et al., 2010). A recent 
study has found that selected miRNAs which are often deregulated in HCC (miR-122, 
miR-21, and miR-223) are detectable in the plasma of patients with chronic hepatitis 
or HCC (Xu et al., 2011). Another study has found serum miRNA signatures that can 
identify Hepatitis B -infected and Hepatitis B -positive HCC (Li et al., 2010a). One 
preliminary study has also indicated that serum miRNA levels are altered from the 
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early stages of exposure of rats to hepatocarcinogens (Sukata et al., 2011). Circulating 
miRNA biomarkers have obvious benefits as biomarkers of disease in being more 
readily accessible and less invasive.  
 
Elucidating the importance of chemical-induced deregulation of the liver miRNAome 
is likely to be an area of intense future research. One powerful tool that can be utilised 
is that of genetically modified animals. For example, animals in which hepatic dicer1 
has been specifically knocked down, and hence lack miRNA expression in 
hepatocytes, have been already described (Sekine et al., 2009, Song et al., 2010). It 
will be very interesting to examine how animals with miRNA-depleted livers will 
respond to treatment with chemical carcinogens. The effects of selected miRNAs can 
also be investigated in vitro by targeted deletions or overexpression in hepatic cells.  It 
is also possible, as a few ambitious studies have demonstrated, to manipulate hepatic 
miRNA levels in vivo (Hou et al., 2011, Kota et al., 2009).  
 
Another long term goal would be to examine whether chemical-mediated effects on 
the liver miRNAome are involved in species-specificity. Species-specific effects of 
miRNAs could result either from differential regulation of the miRNAs or in 
divergences in the proteins that are regulated by a given miRNA in a particular 
species. For instance, the large CpG island that is involved in regulation of the miR-
200a/200b/429 cluster is humans (Li et al., 2010), is not conserved in rodents (Table 
5.1), suggesting likely differences in their regulation. Various approaches could be 
taken to examine species-specific chemical effects emerging from different miRNA 
activities such as computational methods, comparisons of rodent and human 
hepatocytes, and use of humanised animal models.  
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6.4 Conclusions: Opening the black box 
The rodent bioassay has been developed in more or less its present form about sixty to 
seventy years ago (Weisburger & Williams, 1981, Weisburger, 1983). At its most 
basic, this assay can be considered as a typical “black box system”: there is a defined 
input (the chemical treatment) which is examined; a black box (the animal itself); and 
a measurable output (cancer incidence). Hence the rodent bioassay can measure the 
carcinogenicity of chemicals in rodents. Whether this relates to similar processes in 
humans continues to be a very controversial debate. Today in the post-genomic era, 
with the availability of powerful “omic” and molecular biology technologies, after 
decades of extensive research, the complexity of cancer is still baffling (Hanahan & 
Weinberg, 2011). Moreover, the assessment of chemical hepatocarcinogens is 
rendered even more difficult due to the fact that the liver is possibly the second most 
complex mammalian organ, after the brain (Section 1.3). Simplicity was, and to a 
large extent still is, the main advantage of the rodent lifetime assay. 
 
In the pursuit for replacements or refinements of the rodent lifetime bioassays, some 
approaches focus on measuring different “outputs” (e.g. histopathological effects of 
chemicals or indeed miRNAs signatures generated after short-term exposure), or even 
using a different “black box” (e.g. performing the assay on transgenic mice which 
respond faster to carcinogenic treatment) (Section 1.4.2). If these strategies prove 
successful they will allow considerable savings in time and costs, whilst largely side-
stepping the issue of how the chemicals induce liver tumours. Yet, there are 
considerable benefits to elucidating the mechanisms of chemical carcinogenesis 
(Blomme et al., 2009): the improved extrapolation of human health hazard from 
animal carcinogenicity data; the safer design of new drugs and compounds; 
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illumination of early stages of HCC development; and perhaps more information on 
the aetiologies of human HCC. 
 
At present the utilisation of mechanistic information to predict carcinogenicity is 
limited. Instead mechanistic examination is often used only after the detection of a 
positive in the lifetime bioassay, in order to discriminate false positives (Boobis et al., 
2009a). This state of affairs is not surprising given the gaps of knowledge regarding 
the process of chemical carcinogenesis. As a case in point, the effects of chemical 
carcinogens on miRNAomes have been barely examined up to this point. Evidence 
gathered by this project suggests that examination of the hepatic miRNAome will 
reveal important aspects of chemical hepatocarcinogenesis. Of course, while 
deregulation of hepatic miRNAs could be an important step in chemical 
carcinogenesis, it will not be the whole story. Deep mechanistic understanding of 
chemical carcinogenesis will ultimately require the examination and integration of 
multiple layers of information: conventional toxicological, transcriptomic, proteomic, 
and metabonomic data (Waters & Fostel, 2004, Bugrim et al., 2004, Plant, 2008). 
Recent decades have seen tremendous progress in the field of biomedical sciences and 
cancer research (Hanahan & Weinberg, 2011). It is noteworthy that miRNAs had not 
even been properly identified until ten years ago (Lagos-Quintana et al., 2001, Lau et 
al., 2001, Lee & Ambros, 2001). The rapid pace of progress of biomedical sciences 
underlies the optimism that the black box of chemical carcinogenesis will be 
eventually opened. 
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Appendix I 
Table S.1:Expression of all detected miRNAs in control male Fischer rats 
miRNA Log2 SD miRNA Log2 SD miRNA Log2 SD 
rno-miR-122 10.9 0.4 rno-miR-378 3.8 0.1 rno-miR-25 1.8 0.3 
rno-let-7f 7.3 0.4 rno-miR-30b-5p 3.6 0.4 rno-miR-199a-
3p 
1.8 0.2 
rno-miR-21 7.0 0.3 rno-miR-30c 3.5 0.2 rno-miR-22* 1.8 0.4 
rno-let-7a 6.9 0.4 rno-let-7i 3.4 0.2 rno-miR-223 1.7 0.3 
rno-miR-192 6.5 0.4 rno-miR-195 3.4 0.4 rno-let-7e 1.7 0.4 
rno-miR-29a 6.5 0.1 rno-miR-107 3.4 0.1 rno-miR-193 1.6 0.5 
rno-miR-22 6.5 0.2 rno-miR-143 3.4 0.1 rno-miR-196a 1.4 1.0 
rno-miR-26a 6.3 0.1 rno-miR-19b 3.3 0.4 rno-miR-30e 1.2 0.2 
rno-let-7c 5.9 0.4 rno-miR-146a 3.2 0.2 rno-miR-140* 1.1 0.3 
rno-miR-26b 5.7 0.4 rno-miR-30a 3.1 0.2 rno-miR-148b-
3p 
1.0 0.2 
rno-miR-23b 5.3 0.2 rno-miR-30d 3.0 0.3 rno-miR-126* 0.9 0.2 
rno-miR-125b-5p 5.3 0.4 rno-miR-15b 2.8 0.2 rno-miR-322 0.8 0.3 
rno-miR-29c 5.1 0.2 rno-miR-31 2.8 0.4 rno-miR-152 0.7 0.3 
rno-let-7b 5.1 0.3 rno-miR-10a-5p 2.7 0.4 rno-miR-150 0.7 0.3 
rno-miR-126 5.0 0.2 rno-miR-497 2.7 0.2 rno-miR-139-
3p 
0.6 0.9 
rno-miR-99a 5.0 0.1 rno-miR-324-3p 2.7 0.4 rno-miR-30e* 0.6 0.3 
rno-miR-194 4.9 0.1 rno-miR-29b 2.6 0.1 rno-miR-17 0.5 0.2 
rno-let-7d 4.9 0.3 rno-miR-20a 2.6 0.3 rno-miR-30a* 0.5 0.2 
rno-miR-16 4.8 0.3 rno-miR-98 2.5 0.2 rno-miR-203 0.5 0.2 
rno-miR-23a 4.6 0.2 rno-miR-103 2.4 0.2 rno-miR-196b 0.5 0.7 
rno-miR-451 4.4 0.3 rno-miR-130a 2.4 0.5 rno-miR-345-
5p 
0.4 0.1 
rno-miR-365 4.2 0.3 rno-miR-151 2.3 0.1 rno-miR-652 0.3 0.3 
rno-miR-494 4.2 0.6 rno-miR-352 2.3 0.2 rno-miR-93 0.3 0.2 
rno-miR-27b 4.1 0.3 rno-miR-196c 2.2 0.8 rno-miR-125a-
5p 
0.3 0.3 
rno-miR-24 4.1 0.2 rno-miR-27a 2.1 0.2 rno-miR-199a-
5p 
0.3 0.1 
rno-miR-101b 3.9 0.1 rno-miR-101a 2.1 0.1 rno-miR-28 0.3 0.2 
rno-miR-92a 3.9 0.3 rno-miR-100 1.9 0.3 rno-miR-743a 0.2 0.9 
Mean log2 normalised hybridisation signal in control animals from multicompound study for  
the 167 miRNAs detected in 50% of animals in any treatment group  (Chapter 3)
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Table S.1 (continued) :Expression of all detected miRNAs in control male Fischer rats 
Mean log2 normalised hybridisation signal in control animals from multicompound study for  
the 167 miRNAs detected in 50% of animals in any treatment group (Chapter 3) 
miRNA Log2 SD miRNA Log2 SD miRNA Log2 SD 
rno-miR-142-3p 0.2 0.4 rno-miR-664 -0.9 0.4 rno-miR-181d -1.9 1.5 
rno-miR-361 0.2 0.2 rno-miR-200a -0.9 0.3 rno-miR-483 -2.1 0.3 
rno-miR-145 0.1 0.1 rno-miR-409-3p -1.0 0.2 rno-miR-7a* -2.1 0.4 
rno-miR-878 0.1 0.8 rno-miR-128 -1.0 0.3 rno-miR-142-
5p 
-2.2 0.6 
rno-miR-
333_v11.0 
0.1 0.7 rno-miR-1* -1.0 0.3 rno-miR-429 -2.2 0.5 
rno-miR-221 0.0 0.5 rno-miR-505 -1.0 0.6 rno-miR-324-
5p 
-2.3 0.2 
rno-miR-106b 0.0 0.1 rno-miR-125a-
3p 
-1.1 0.6 rno-miR-340-
5p 
-2.3 0.6 
rno-miR-186 0.0 0.3 rno-let-7b* -1.1 0.3 rno-miR-874 -2.3 0.8 
rno-miR-140 0.0 0.2 rno-miR-200c -1.1 0.6 rno-miR-92b -2.4 0.4 
rno-miR-188 -0.1 1.0 rno-miR-872 -1.1 0.4 rno-miR-484 -2.4 0.3 
rno-miR-378* -0.1 0.3 rno-miR-338 -1.2 0.2 rno-miR-350 -2.5 0.2 
rno-miR-500 -0.2 0.2 rno-miR-99b -1.2 0.3 rno-miR-532-
3p 
-2.5 0.8 
rno-miR-10b -0.2 0.3 rno-miR-466b -1.3 0.3 rno-miR-374 -2.5 0.4 
rno-miR-7a -0.4 0.3 rno-miR-29c* -1.3 0.4 rno-miR-674-
3p 
-2.5 0.6 
rno-miR-96 -0.5 0.3 rno-miR-450a -1.5 0.3 rno-miR-340-
3p 
-2.6 0.5 
rno-miR-335 -0.5 0.5 rno-miR-331 -1.5 0.4 rno-let-7d* -2.7 0.5 
rno-miR-200b -0.5 0.4 rno-miR-532-5p -1.5 0.2 rno-miR-598-
3p 
-2.8 0.5 
rno-miR-34a -0.5 0.3 rno-miR-296* -1.7 0.3 rno-miR-347 -2.9 0.6 
rno-miR-342-3p -0.5 0.3 rno-miR-328 -1.7 0.3 rno-miR-99a* -2.9 0.9 
rno-miR-214 -0.6 0.4 rno-miR-144 -1.7 0.7 rno-miR-290 -3.0 0.4 
rno-miR-345-3p -0.6 1.0 rno-miR-193* -1.7 0.1 rno-miR-30c-
1* 
-3.1 0.7 
rno-miR-425 -0.6 0.2 rno-miR-185 -1.7 0.4 rno-miR-146b -3.1 0.8 
rno-miR-210 -0.6 0.3 rno-miR-139-5p -1.8 0.6 rno-miR-322* -3.2 1.0 
rno-miR-181a -0.6 0.3 rno-miR-298 -1.9 0.1 rno-miR-99b* -3.2 0.9 
rno-miR-212 -0.7 0.6 rno-miR-129* -1.9 0.4 rno-miR-877 -3.3 0.8 
rno-miR-19a -0.7 0.3 rno-miR-375 -1.9 0.6 rno-miR-326 -3.3 0.6 
rno-miR-320 -0.9 0.6 rno-miR-30c-2* -1.9 0.2    
Appendices 
 307 
 
Appendix II 
 
Table S.2: Differentially expressed microRNAs at 90 days treatment 
 
 
microRNA 
 
Corrected 
p.value 
 
DETU 
 
BP     
 
PB 
 
DEHP 
 
MON 
 
Chl. 
Ac. 
 
MP 
HCL 
 
2-AAF 
miR-34a >0.01 -1.1 -1.3 1 -1.2 3.9 2.3 1.7 27.9 
miR-96 >0.01 1.3 2 3.6 1.6 1.6 -1.5 1 -1.3 
miR-221 >0.01 -1.5 -1.8 -1.1 3 -1.2 1.5 1 -1.1 
miR-200a >0.01 -1.2 2 3.7 1.7 1.1 2 1.7 2 
miR-107 >0.01 -1.1 1.1 -1.1 2.0 1 1.1 -1.2 -1.3 
miR-200b >0.01 -1 2.5 4.5 2.0 1.2 2.3 1.6 2 
miR-429 >0.01 -1.1 2.4 3.8 1.9 1.2 2.3 1.8 2.7 
miR-182 >0.01 2.4 4.3 6.3 3.1 3.3 1.1 1.3 1.4 
miR-375 >0.01 -2 -2.3 -2 1.8 2.2 1.7 -2.1 -1.5 
miR-193 >0.01 -1.3 -1.1 1.2 -1.7 -2.4 -4.9 -1.9 -1.3 
miR-17 >0.01 -1.1 1.1 -1.1 1.1 1 -1.6 -1.2 -1.2 
miR-497 >0.01 1 -1.1 -1.1 -1.2 -1.3 -1.7 -1.3 -1 
miR-203 >0.01 -1.2 -1.1 -1.4 -1.4 -1.2 -2 -1.2 -1.6 
miR-31 >0.01 1.1 1.1 -1 1.3 -1 1.3 -1.4 -1.5 
miR-29a >0.01 -1.1 -1 1.1 1.3 1 -1.2 -1.2 -1.2 
miR-29c >0.01 -1.1 1 1.2 1.3 -1 -1.3 -1.2 -1.2 
miR-99a >0.01 -1 -1.3 -1.3 -1.3 -1.5 -1.3 -1.5 -1.6 
miR-20a >0.01 -1 1 -1.1 1.1 -1 -1.6 -1.2 -1.3 
miR-139-5p >0.01 1.3 -1.1 1.1 1.3 1.3 3.2 1.3 -1.3 
miR-28 >0.01 1.1 1 1.1 -1.1 1 1.4 1 -1.3 
miR-505 >0.01 -1.1 1.1 1.5 1.5 1.1 2.8 1.2 -1.6 
miR-210 >0.01 -1 -1.1 1.1 -1.2 -1.3 -2.7 1.1 1.1 
miR-494 >0.01 -1.1 1.6 -1.6 -1.2 -1.7 -1.7 -1.5 3.7 
miR-199a-5p >0.01 1 -1.1 -1 -1.1 -1.1 -1 1.3 1.3 
miR-327 >0.01 2.1 1.9 -1.6 -1.2 -1.3 -2.6 -2.7 6.1 
miR-29b 0.01 1 1.2 1.1 1.3 -1.1 -1.8 -1.1 -1.1 
miR-126* 0.01 -1.4 -1.2 -1 -1.1 -1.1 -1.1 -1.2 -1.8 
miR-342-3p 0.01 1 -1.1 -1.5 -1.2 1 1.3 -1 1.1 
miR-101b 0.01 -1.1 -1 -1 -1.5 -1.2 -1.5 -1.3 -1.3 
miR-152 0.01 1 -1 1 1.2 1 1.2 -1.1 -1.2 
miR-146a 0.01 1.2 1 -1.2 -1 1.3 1.5 1.2 -1.1 
miR-30b-5p 0.01 -1.3 -1.2 -1.2 -1.2 -1.4 -1.9 -1.5 -1.5 
miR-345-5p 0.01 -1 1 1.1 -1.5 -1 -1.3 -1.1 -1.1 
miR-10a-5p 0.01 -1.2 -1.3 -1.2 -1.1 -1.1 -1 -1.2 -1.6 
miR-144 0.01 1.5 1.5 -1.4 -1.7 -1.2 -3.8 -1.1 1.8 
miR-186 0.01 1.1 1 1.1 1.1 1.1 1.5 1.1 -1.2 
miR-212 0.01 1.1 -1.1 -1.7 -1.5 -2 -7.6 -2.3 1.2 
MiRNAs were identified by one-way ANOVA with Benjamini-Hochbeg p<0.05. 
Shown is the mean fold change from control;; n=3-5 animals per treatment  
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Table S.2 (continued): Differentially expressed microRNAs at 90 days treatment 
 
 
 
microRNA 
 
Corrected 
p.value 
 
DETU 
 
BP     
 
PB 
 
DEHP 
 
MON 
 
Chl. 
Ac. 
 
MP 
HCL 
 
2-AAF 
miR-598-3p 0.01 1 1.2 1.2 1.5 1.1 1.6 -1.1 -1.7 
miR-130a 0.02 1.1 1.1 1.1 -1.3 1.1 -1.4 1.1 1.2 
miR-27a 0.02 1.1 -1.1 -1 -1.1 1.1 1.1 1 1.1 
miR-365 0.02 -1.1 -1 1 1.1 1.1 1.1 -1.2 -1.5 
miR-103 0.02 -1 1.2 -1 1.2 1.2 -1 -1.1 -1.2 
miR-142-3p 0.02 1.3 -1.1 -1.3 -1.3 -1.2 -1.6 1.2 1.4 
miR-451 0.02 -1 1.2 -1.3 -1.7 1.1 -1.3 -1.2 -1 
miR-352 0.02 -1 1.1 -1.1 1.2 1.2 1.2 -1.1 -1.4 
miR-338 0.02 1.1 1.1 1 -1.2 -1.5 -1.6 -1.1 -1 
miR-19a 0.02 1.1 -1 -1.1 -1.1 -1.2 -2.5 -1 -1.1 
miR-125b-5p 0.02 -1 -1.3 -1.3 -1.3 -1.3 -1.2 -1.5 -1.7 
miR-30b-3p 0.02 2 1.5 1.3 1.9 1.3 1.9 1.1 1.3 
miR-345-3p 0.02 -1.2 -1.6 -1.3 -1.7 -2.5 -10.3 -2.1 -1.3 
miR-324-3p 0.02 -1.1 -1.1 -1.2 -1.9 -1.5 -3.9 -1.6 -1.2 
miR-878 0.02 -1.1 -1.5 -1.5 -1.7 -2.9 -9.3 -2.1 -1.4 
miR-7a* 0.02 -1.1 -1.2 1.1 -1.3 -1.1 1.2 -1.3 -1.6 
miR-30c-1* 0.02 2.1 1.4 -1.3 -1.4 1.1 -1.6 -3.3 2.4 
miR-378* 0.02 -1 1.1 1 1.4 -1 1.3 -1.1 -1.3 
miR-100 0.03 1 -1.2 -1.2 -1.2 -1.3 -1.1 -1.3 -1.4 
miR-150 0.03 1.1 -1.1 -1.5 -1.1 1.1 1.3 -1.1 -1.1 
miR-101a 0.03 -1.1 -1.1 -1 -1.3 -1.3 -1.6 -1.3 -1.3 
miR-7a 0.03 -1.1 -1.1 -1 -1.2 -1.1 1.2 1.1 -1.4 
miR-331 0.03 1.2 1.2 1.1 1.6 1.3 1.9 1.2 1.2 
miR-425 0.03 -1 1.1 1.1 1.2 -1.1 1 1 -1.3 
miR-743a 0.03 -1.4 -1.5 -1.6 -2 -3 -9.7 -2.2 -1.6 
miR-128 0.04 1 1 -1 1.3 1 1.4 -1 -1.3 
miR-10b 0.04 -1.2 -1.3 -1.3 -1.1 -1.1 1 -1.1 -1.4 
miR-125a-5p 0.04 1 -1.1 -1.2 -1 1.1 1.5 1 -1 
miR-30d 0.04 1 1 -1 1.2 1.2 1.4 -1.1 -1.2 
miR-93 0.04 1.1 1.2 1.1 1.4 1.1 1 1.1 1 
let-7f 0.04 -1.1 -1.1 -1.1 1.1 1.1 1.2 -1.3 -1.5 
let-7i 0.04 -1 -1 -1.1 1.2 1 1.3 -1 -1.2 
miR-148b-3p 0.04 -1 -1.1 -1 1.1 -1 1.1 -1.1 -1.4 
MiRNAs were identified by one-way ANOVA with Benjamini-Hochbeg p<0.05. 
Shown is the mean fold change from control;; n=3-5 animals per treatment 
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Appendix III: Significantly over-represented pathways for 
“biomarker” miRNAs 
Table S.3: Significantly enriched pathways for rno-miR-200a 
Pathways Rat genome expected predicted p.value 
Insulin/IGF pathway-protein kinase B 
signaling cascade 
87 1.39 11 0.00 
PI3 kinase pathway 118 1.88 12 0.00 
TGF-beta signaling pathway 149 2.37 12 0.00 
EGF receptor signaling pathway 143 2.28 11 0.00 
Interleukin signaling pathway 161 2.56 11 0.00 
p53 pathway 158 2.52 10 0.00 
Parkinson disease 122 1.94 8 0.00 
FGF signaling pathway 129 2.05 8 0.00 
Wnt signaling pathway 338 5.38 14 0.00 
Insulin/IGF pathway-mitogen activated 
protein kinase kinase/MAP kinase cascade 
32 0.51 4 0.00 
Metabotropic glutamate receptor group I 
pathway 
34 0.54 4 0.00 
Synaptic_vesicle_trafficking 40 0.64 4 0.00 
Hedgehog signaling pathway 23 0.37 3 0.01 
Axon guidance mediated by Slit/Robo 23 0.37 3 0.01 
Metabotropic glutamate receptor group III 
pathway 
77 1.23 5 0.01 
Integrin signalling pathway 183 2.91 8 0.01 
Ionotropic glutamate receptor pathway 57 0.91 4 0.01 
p53 pathway feedback loops 2 58 0.92 4 0.01 
PDGF signaling pathway 162 2.58 7 0.02 
Muscarinic acetylcholine receptor 1 and 3 
signaling pathway 
68 1.08 4 0.02 
Axon guidance mediated by semaphorins 40 0.64 3 0.03 
Cadherin signaling pathway 155 2.47 6 0.04 
Inflammation mediated by chemokine and 
cytokine signaling pathway 
288 4.59 9 0.04 
Ras Pathway 84 1.34 4 0.05 
 
MiRNA targets for miR-200a were predicted using TargetScan V5.1 and allocated to 
pathways using the PANTHER database. The numbers shown in the table indicate the 
total number of known genes belonging to a pathway in the rat; the expected number 
of genes within the miRNA predicted targets that should belong to that pathway; the 
actual number of predicted miRNA-targets that belong to that pathway; and the 
calculated p.value. of enriched pathways using binomial statistics. Pathways shown 
are those with  p. values less than < 0.05 
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Table S.4: significantly enriched pathways for rno-miR-200b/429 
 
Pathways Rat 
genome 
expected predicted p.value 
PDGF signaling pathway 159 5.2 20 0.00 
Ras Pathway 79 2.58 14 0.00 
PI3 kinase pathway 115 3.76 16 0.00 
EGF receptor signaling pathway 135 4.41 16 0.00 
FGF signaling pathway 124 4.05 15 0.00 
Hedgehog signaling pathway 25 0.82 7 0.00 
Interleukin signaling pathway 161 5.26 17 0.00 
TGF-beta signaling pathway 145 4.74 16 0.00 
Angiogenesis 191 6.24 18 0.00 
Insulin/IGF pathway-protein kinase B signaling cascade 89 2.91 11 0.00 
Integrin signalling pathway 181 5.92 16 0.00 
GABA-B_receptor_II_signaling 40 1.31 7 0.00 
Axon guidance mediated by semaphorins 43 1.41 7 0.00 
Inflammation mediated by chemokine and cytokine signaling  283 9.25 20 0.00 
p53 pathway 113 3.69 11 0.00 
Metabotropic glutamate receptor group III pathway 73 2.39 8 0.00 
Beta2 adrenergic receptor signalling pathway 44 1.44 6 0.00 
Huntington disease 167 5.46 13 0.00 
Hypoxia response via HIF activation 32 1.05 5 0.00 
Wnt signaling pathway 317 10.4 20 0.00 
Cytoskeletal regulation by Rho GTPase 98 3.2 9 0.01 
Parkinson disease 100 3.27 9 0.01 
Metabotropic glutamate receptor group II pathway 51 1.67 6 0.01 
p53 pathway feedback loops 2 52 1.7 6 0.01 
Apoptosis signaling pathway 123 4.02 10 0.01 
Transcription regulation by bZIP transcription factor 53 1.73 6 0.01 
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs 
alpha mediated pathway 
166 5.43 12 0.01 
p53 pathway by glucose deprivation 25 0.82 4 0.01 
Endothelin signaling pathway 91 2.98 8 0.01 
VEGF signaling pathway 75 2.45 7 0.01 
Oxytocin receptor mediated signaling pathway 60 1.96 6 0.02 
Beta1 adrenergic receptor signaling pathway 44 1.44 5 0.02 
5HT1 type receptor mediated signaling pathway 44 1.44 5 0.02 
Interferon-gamma signaling pathway 29 0.95 4 0.02 
Muscarinic acetylcholine receptor 2 and 4 signaling pathway 62 2.03 6 0.02 
T cell activation 102 3.33 8 0.02 
5HT2 type receptor mediated signaling pathway 69 2.26 6 0.03 
Ubiquitin proteasome pathway 70 2.29 6 0.03 
Synaptic_vesicle_trafficking 38 1.24 4 0.04 
Histamine H2 receptor mediated signaling pathway 25 0.82 3 0.05 
Same methodology as for Table S.3 
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Table S.5 Significantly enriched pathways for rno-miR-96 
 
Pathways Rat 
genome 
expected predicted p.value 
PI3 kinase pathway 118 2.9 18 0.00 
EGF receptor signaling pathway 143 3.5 16 0.00 
Integrin signalling pathway 183 4.5 18 0.00 
Insulin/IGF pathway-protein kinase B signaling cascade 87 2.1 12 0.00 
FGF signaling pathway 129 3.2 14 0.00 
Interleukin signaling pathway 161 4 15 0.00 
5HT2 type receptor mediated signaling pathway 78 1.9 10 0.00 
Nicotinic acetylcholine receptor signaling pathway 98 2.4 11 0.00 
Oxytocin receptor mediated signaling pathway 68 1.7 9 0.00 
Metabotropic glutamate receptor group III pathway 77 1.9 9 0.00 
Alpha adrenergic receptor signaling pathway 32 0.8 6 0.00 
Insulin/IGF pathway-mitogen activated protein kinase 
kinase/MAP kinase  
32 0.8 6 0.00 
Endothelin signaling pathway 96 2.4 10 0.00 
Angiogenesis 200 4.9 15 0.00 
Metabotropic glutamate receptor group I pathway 34 0.8 6 0.00 
TGF-beta signaling pathway 149 3.7 12 0.00 
Thyrotropin-releasing hormone receptor signaling pathway 71 1.7 8 0.00 
Metabotropic glutamate receptor group II pathway 56 1.4 7 0.00 
PDGF signaling pathway 162 4 12 0.00 
Ras Pathway 84 2.1 8 0.00 
Muscarinic acetylcholine receptor 1 and 3 signaling pathway 68 1.7 7 0.00 
B cell activation 88 2.2 8 0.00 
T cell activation 135 3.3 10 0.00 
Heterotrimeric G-protein signaling pathway-Gq alpha and Go 
alpha mediated pathway 
137 3.4 10 0.00 
Axon guidance mediated by semaphorins 40 1 5 0.00 
Cadherin signaling pathway 155 3.8 10 0.01 
Muscarinic acetylcholine receptor 2 and 4 signaling pathway 70 1.7 6 0.01 
5HT3 type receptor mediated signaling pathway 17 0.4 3 0.01 
Gamma-aminobutyric acid synthesis 6 0.2 2 0.01 
Axon guidance mediated by netrin 34 0.8 4 0.01 
Beta2 adrenergic receptor signaling pathway 53 1.3 5 0.01 
Beta1 adrenergic receptor signaling pathway 53 1.3 5 0.01 
Histamine H1 receptor mediated signaling pathway 54 1.3 5 0.01 
Parkinson disease 122 3 8 0.01 
Cytoskeletal regulation by Rho GTPase 100 2.5 7 0.01 
Wnt signaling pathway 338 8.3 15 0.02 
GABA-B_receptor_II_signaling 44 1.1 4 0.02 
Oxidative stress response 67 1.7 5 0.03 
Inflammation mediated by chemokine and cytokine signaling  288 7.1 13 0.03 
5HT1 type receptor mediated signaling pathway 49 1.2 4 0.03 
Same methodology as for Table S.3 
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Table S.6: enriched pathways for rno-miR-182 
 
Pathways Rat 
genome 
expected predicted p.value 
PI3 kinase pathway 118 2.87 15 0.00 
EGF receptor signaling pathway 143 3.48 16 0.00 
FGF signaling pathway 129 3.14 13 0.00 
TGF-beta signaling pathway 149 3.62 13 0.00 
Metabotropic glutamate receptor group III pathway 77 1.87 9 0.00 
Insulin/IGF pathway-mitogen activated protein 
kinase kinase/MAP kinase cascade 
32 0.78 6 0.00 
PDGF signaling pathway 162 3.94 13 0.00 
Insulin/IGF pathway-protein kinase B signaling  87 2.12 9 0.00 
Angiogenesis 200 4.86 14 0.00 
Endothelin signaling pathway 96 2.33 9 0.00 
Interleukin signaling pathway 161 3.92 12 0.00 
5HT2 type receptor mediated signaling pathway 78 1.9 8 0.00 
Oxytocin receptor mediated signaling pathway 68 1.65 7 0.00 
B cell activation 88 2.14 8 0.00 
Thyrotropin-releasing hormone receptor signaling  71 1.73 7 0.00 
Integrin signalling pathway 183 4.45 12 0.00 
Inflammation mediated by chemokine and 
cytokine  
288 7 16 0.00 
Ionotropic glutamate receptor pathway 57 1.39 6 0.00 
Ras Pathway 84 2.04 7 0.00 
T cell activation 135 3.28 9 0.01 
5HT1 type receptor mediated signaling pathway 49 1.19 5 0.01 
Alpha adrenergic receptor signaling pathway 32 0.78 4 0.01 
5HT3 type receptor mediated signaling pathway 17 0.41 3 0.01 
Metabotropic glutamate receptor group I pathway 34 0.83 4 0.01 
Axon guidance mediated by netrin 34 0.83 4 0.01 
Histamine H1 receptor mediated signaling 
pathway 
54 1.31 5 0.01 
Nicotinic acetylcholine receptor signaling pathway 98 2.38 7 0.01 
Cytoskeletal regulation by Rho GTPase 100 2.43 7 0.01 
Metabotropic glutamate receptor group II pathway 56 1.36 5 0.01 
5HT4 type receptor mediated signaling pathway 40 0.97 4 0.02 
GABA-B_receptor_II_signaling 44 1.07 4 0.02 
Muscarinic acetylcholine receptor 1 and 3 
signaling  
68 1.65 5 0.03 
Notch signaling pathway 46 1.12 4 0.03 
Heterotrimeric G-protein signaling pathway-Gi 
alpha and Gs alpha mediated pathway 
173 4.21 9 0.03 
Cadherin signaling pathway 155 3.77 8 0.04 
Wnt signaling pathway 338 8.22 14 0.04 
Leucine biosynthesis 2 0.05 1 0.05 
Alanine biosynthesis 2 0.05 1 0.05 
Same methodology as for Table S.3 
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Table S.7: enriched pathways for rno-miR-34a 
 
Pathways Rat 
genome 
expected predicted p.value 
TGF-beta signaling pathway 149 2.08 12 0.00 
PI3 kinase pathway 118 1.65 9 0.00 
Metabotropic glutamate receptor group 
III pathway 
77 1.07 7 0.00 
Metabotropic glutamate receptor group 
II pathway 
56 0.78 6 0.00 
Insulin/IGF pathway-protein kinase B 
signaling cascade 
87 1.21 7 0.00 
Synaptic_vesicle_trafficking 40 0.56 5 0.00 
Interleukin signaling pathway 161 2.24 9 0.00 
Nicotinic acetylcholine receptor 
signaling pathway 
98 1.37 7 0.00 
Notch signaling pathway 46 0.64 5 0.00 
Thyrotropin-releasing hormone receptor 
signaling pathway 
71 0.99 6 0.00 
5HT2 type receptor mediated signaling 
pathway 
78 1.09 6 0.00 
EGF receptor signaling pathway 143 1.99 8 0.00 
Oxytocin receptor mediated signaling 
pathway 
68 0.95 5 0.00 
Angiogenesis 200 2.79 8 0.01 
5HT3 type receptor mediated signaling 
pathway 
17 0.24 2 0.02 
Plasminogen activating cascade 18 0.25 2 0.03 
PDGF signaling pathway 162 2.26 6 0.03 
Parkinson disease 122 1.7 5 0.03 
5HT1 type receptor mediated signaling 
pathway 
49 0.68 3 0.03 
Alzheimer disease-presenilin pathway 129 1.8 5 0.04 
Beta2 adrenergic receptor signaling 
pathway 
53 0.74 3 0.04 
Beta1 adrenergic receptor signaling 
pathway 
53 0.74 3 0.04 
Blood coagulation 55 0.77 3 0.04 
Cell cycle 24 0.33 2 0.04 
Integrin signalling pathway 183 2.55 6 0.05 
Ionotropic glutamate receptor pathway 57 0.79 3 0.05 
Same methodology as for Table S.3 
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Table S.8: enriched pathways for rno-miR-193 
 
Pathways Rat 
genome 
expected predicted p.value 
EGF receptor signalling pathway 143 0.5 6 0.00 
FGF receptor signalling pathway 129 0.5 5 0.00 
Ras pathway 84 0.3 4 0.00 
PDGF signalling pathway 162 0.6 5 0.00 
Inflammation mediated by 
chemokine and cytokine signalling 
pathway 
288 1 5 0.00 
B cell activation 88 0.3 3 0.00 
Interferon-gamma signalling 
pathway 
31 0.1 2 0.01 
Angiogenesis 200 0.7 4 0.01 
Wnt signalling pathway 338 1.2 5 0.01 
PI3K kinase pathway 118 0.4 3 0.01 
Alzheimer disease-presenilin 
pathway 
129 0.5 3 0.01 
p53 pathway feedback loops 2 58 0.2 2 0.02 
Interleukin signalling pathway 161 0.6 3 0.02 
Integrin signalling pathway 183 0.7 3 0.03 
VEGF signalling pathway 82 0.3 2 0.04 
Cytoskeletal regulation by Rho 
GTPase 
100 0.4 2 0.05 
              Same methodology as for Table S.3 
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Table S.9: significantly enriched pathways for rno-miR-203 
 
Pathways Rat 
genome 
expected predicted p.value 
Integrin signalling pathway 183 2.74 12 0.00 
Angiogenesis 200 3 11 0.00 
p53 pathway feedback loops 2 58 0.87 6 0.00 
Insulin/IGF pathway-protein kinase 
B signaling cascade 
87 1.3 7 0.00 
PI3 kinase pathway 118 1.77 8 0.00 
Endothelin signaling pathway 96 1.44 7 0.00 
EGF receptor signaling pathway 143 2.14 8 0.00 
VEGF signaling pathway 82 1.23 6 0.00 
TGF-beta signaling pathway 149 2.23 8 0.00 
Wnt signaling pathway 338 5.07 12 0.01 
p53 pathway by glucose 
deprivation 
25 0.37 3 0.01 
Circadian clock system 9 0.13 2 0.01 
p53 pathway 158 2.37 7 0.01 
Interleukin signaling pathway 161 2.41 7 0.01 
Interferon-gamma signaling 
pathway 
31 0.46 3 0.01 
PDGF signaling pathway 162 2.43 7 0.01 
Inflammation mediated by 
chemokine and cytokine signaling 
pathway 
288 4.32 10 0.01 
Alpha adrenergic receptor 
signaling pathway 
32 0.48 3 0.01 
Methionine biosynthesis 1 0.01 1 0.01 
Ras Pathway 84 1.26 4 0.04 
B cell activation 88 1.32 4 0.04 
FGF signaling pathway 129 1.93 5 0.05 
Hedgehog signaling pathway 23 0.34 2 0.05 
Axon guidance mediated by 
Slit/Robo 
23 0.34 2 0.05 
Same methodology as for Table S.3 
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Table S.10: Significantly enriched pathways for rno-miR-99a 
 
Same methodology as for Table S.3 
Pathways Rat 
genome 
expected predicted p.value 
Wnt signalling pathway 338 0.44 4 0.00 
Angiogenesis 200 0.26 3 0.00 
Alzheimer disease-
presenilin pathway 
129 0.17 2 0.01 
Cadherin signaling pathway 155 0.2 2 0.02 
p53 pathway by glucose 
deprivation 
25 0.03 1 0.03 
Insulin/IGF pathway-
mitogen activated protein 
kinase kinase/MAP kinase 
cascade 
32 0.04 1 0.04 
Hypoxia response via HIF 
activation 
33 0.04 1 0.04 
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